[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fczKYj-pCJPGFZmkga170wiAvKe8yFLVpJrdc7OkkzpA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Celgene",[4,6],"Celgene Corporation",478,false,24,86,93192,50,33,[15,18,21,23,26,28,31,33],{"name":16,"count":17},"Multiple Myeloma",97,{"name":19,"count":20},"Healthy Volunteers",38,{"name":22,"count":13},"Myelodysplastic Syndromes",{"name":24,"count":25},"Lymphoma, Non-Hodgkin",16,{"name":27,"count":25},"Leukemia, Myeloid, Acute",{"name":29,"count":30},"Healthy Volunteer",12,{"name":32,"count":30},"Neoplasms",{"name":34,"count":35},"Myelodysplastic Syndrome",11,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02677922","A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","2018-08-02","AG-120",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03703375","Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma","2021-02-10","Azacitidine",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03682536","A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve","2023-03-31","Luspatercept",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT02773030","A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","2024-05-09","CC-220",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04717414","An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions","2025-05-26","ACE-536",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06045806","A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation","2025-08-11","idecabtagene vicleucel",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT07242781","A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants","2026-06-14","BMS-986365",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06425302","A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","2026-11-23","Golcadomide",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT03989414","A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)","2026-11-30","CC-92480",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05519085","A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","2027-01-10","mezigdomide",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,240,622,804,861,916,962,1001,1093,1129,1159,1608,1638,1668,1724,1759,1785,1820,2036,2212,2310,2409,2470,2502,2529,2551,2569,2587,2605,2623,2647,2665,2683,2830,2945,2979,3033,3078,3123,3169,3191,3209,3227,3245,3263,3281,3299,3344,3366,3440,3493,3615,3751,3838,3916,3986,4058,4126,4188,4218,4248,4298,4324,4346,4377,4399,4426,4444,4469,4487,4505,4523,4541,4559,4583,4601,4619,4637,4655,4679,4697,4723,4741,4759,4777,4795,4820,4844,4862,4880,4898,4916,4939,4957,4982,5000,5027,5045,5063,5081,5178,5254,5304,5397,5472,5517,5551,5602,5636,5680,5728,5772,5815,5841,5867,5901,5933,5962,5993,6021,6053,6079,6109,6133,6157,6175,6193,6218,6236,6260,6278,6304,6322,6345,6363,6381,6405,6429,6447,6465,6483,6501,6519,6537,6561,6584,6602,6627,6649,6667,6685,6709,6727,6745,6770,6788,6806,6828,6846,6864,6882,6904,6928,6961,6997,7027,7068,7094,7120,7146,7172,7200,7231,7253,7286,7308,7334,7356,7378,7396,7414,7432,7455,7473,7491,7509,7527,7550,7572,7590,7613,7631,7649,7667,7689,7707,7725,7748,7766,7791,7814,7832,7850,7872,7890,7912,7930,7948,7970,7992,8016,8038,8061,8079,8103,8121,8139,8165,8183,8201,8219,8237,8261,8279,8301,8324,8342,8360,8378,8396,8428,8451,8469,8487,8505,8523,8541,8565,8583,8601,8619,8643,8661,8679,8697,8721,8743,8761,8779,8797,8819,8843,8861,8879,8897,8915,8933,8951,8969,8987,9005,9029,9052,9076,9094,9120,9138,9156,9174,9314,9428,9516,9587,9638,9674,9723,9748,9776,9804,9829,9852,9876,9900,9922,9946,9967,9990,10013,10037],{"intervention":96,"totalTrials":35,"cells":97},"Cyclophosphamide",{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":147,"PHASE3":191,"PHASE4":236,"NA":238},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":146,"soonestReadout":137},[103,116,132],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT04196491","A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)","COMPLETED",[89],"2023-06-07","2020-05-27",13,[16],[113,114,96,115],"bb2121","Fludarabine","Lenalidomide",{"nctId":117,"briefTitle":118,"status":106,"phases":119,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":126},"NCT02343536","A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma",[89],"2020-01-29","2015-04-29",59,[124,125],"Lymphoma, Large B-Cell, Diffuse","Lymphoma, Follicular",[127,128,129,130,131],"Oral Azacitidine","Rituximab","cyclophosphamide","Vincristine","Prednisone",{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},"NCT04884035","Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","RECRUITING",[89],"2028-12-01","2021-09-15",224,[141],"Lymphoma, B-Cell",[56,128,96,143,130,131,144,145,128],"Doxorubicin","CC-99282","Polatuzumab vedotin",1,{"trials":148,"activeCount":190,"soonestReadout":75},[149,160,168,180],{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"NCT04245839","A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","ACTIVE_NOT_RECRUITING",[90],"2031-09-30","2020-07-14",276,[24],[114,96,159],"JCAR017",{"nctId":73,"briefTitle":74,"status":152,"phases":161,"primaryCompletion":75,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":166},[90],"2028-11-27","2024-08-30",90,[125],[76,128,96,143,130,131,167],"Bendamustine",{"nctId":169,"briefTitle":170,"status":171,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT03743246","A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed\u002FRefractory (r\u002Fr) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)","TERMINATED",[89,90],"2024-01-26","2018-10-17",21,[177,24],"Precursor Cell Lymphoblastic Leukemia-Lymphoma",[159,179,114,96],"Lymphodepleting",{"nctId":181,"briefTitle":182,"status":106,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":188},"NCT03003520","A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma",[90],"2022-04-24","2017-02-28",46,[124],[189,128,143,130,96,131,115],"Durvalumab",2,{"trials":192,"activeCount":235,"soonestReadout":65},[193,205,216,229],{"nctId":194,"briefTitle":195,"status":135,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":203},"NCT06911502","A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed\u002FRefractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)",[91],"2028-04-24","2030-07-31","2025-07-28",400,[202],"Follicular Lymphoma",[76,128,115,96,143,130,204,167],"Prednisone\u002FPrednisolone",{"nctId":206,"briefTitle":207,"status":152,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT06356129","Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma",[91],"2028-08-14","2029-11-20","2024-06-19",850,[214],"Large B-cell Lymphoma",[76,128,96,143,130,131],{"nctId":217,"briefTitle":218,"status":106,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":225},"NCT02285062","Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma",[91],"2019-03-15","2022-07-28","2015-02-17",570,[124],[226,128,96,143,227,228],"lenalidomide","prednisone","vincristine",{"nctId":63,"briefTitle":64,"status":152,"phases":230,"primaryCompletion":65,"completion":210,"start":231,"enrollment":232,"conditions":233,"interventions":234},[91],"2023-10-16",79,[16],[66,115,114,96],3,{"trials":237,"activeCount":100},[],{"trials":239,"activeCount":100},[],{"intervention":241,"totalTrials":242,"cells":243},"Dexamethasone",37,{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":321,"PHASE3":461,"PHASE4":590,"NA":592},{"trials":245,"activeCount":100},[],{"trials":247,"activeCount":100},[248,259,270,280,290,300,311],{"nctId":249,"briefTitle":250,"status":106,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT01497093","Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",[89],"2019-07-23","2012-02-15",34,[16],[257,258,241],"Pomalidomide","Bortezomib",{"nctId":260,"briefTitle":261,"status":106,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":10,"conditions":265,"interventions":267},"NCT00629473","Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies",[89],"2013-04","2007-07",[266],"Advanced Cancer",[268,269,241],"NPI-0052 on Days 1, 8, 15 every 28 days","NPI-0052 on Days 1, 4, 8, 11 every 21 days",{"nctId":271,"briefTitle":272,"status":106,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":279},"NCT02616640","A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma",[89],"2018-11-23","2024-07-30","2016-01-11",114,[16],[189,257,241],{"nctId":281,"briefTitle":282,"status":106,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":20,"conditions":287,"interventions":288},"NCT01583283","Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma",[89],"2021-03-15","2021-03-24","2012-07-12",[16],[289,226,241],"ACY-1215",{"nctId":291,"briefTitle":292,"status":106,"phases":293,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":298},"NCT00555100","Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma",[89],"2010-12-01","2007-07-01",15,[16],[226,299],"dexamethasone",{"nctId":301,"briefTitle":302,"status":171,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":308},"NCT06163898","A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and\u002For Refractory Multiple Myeloma",[89],"2025-06-03","2024-02-27",4,[16],[309,310,241],"Alnuctamab","Mezigdomide",{"nctId":312,"briefTitle":313,"status":171,"phases":314,"primaryCompletion":315,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":319},"NCT02400242","Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma",[89],"2024-06-03","2015-05-07",85,[16],[320,257,241],"ACY-241",{"trials":322,"activeCount":235,"soonestReadout":55},[323,333,342,353,363,373,382,391,400,411,420,433,443,452],{"nctId":324,"briefTitle":325,"status":106,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":332},"NCT01698801","A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma",[90],"2013-11-26","2018-06-26","2012-10-01",26,[16],[115,299],{"nctId":334,"briefTitle":335,"status":106,"phases":336,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":341},"NCT02348528","Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed\u002FRefractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year",[90],"2016-09-29","2012-09-11",65,[16],[115,241],{"nctId":343,"briefTitle":344,"status":106,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":351},"NCT00833833","MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma",[89,90],"2011-04","2015-09","2008-06",259,[16],[257,241,352],"Aspirin",{"nctId":354,"briefTitle":355,"status":171,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":362},"NCT03374085","A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)",[89,90],"2025-08-20","2025-10-23","2018-02-06",200,[16],[81,241],{"nctId":364,"briefTitle":365,"status":171,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":330,"conditions":369,"interventions":371},"NCT00474188","A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[90],"2008-12","2007-05",[370],"Diffuse Large B-cell Lymphoma",[372,299],"CC-5013",{"nctId":374,"briefTitle":375,"status":106,"phases":376,"primaryCompletion":377,"completion":347,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT02011113","Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma",[90],"2014-09","2013-12",36,[16],[257,241],{"nctId":383,"briefTitle":384,"status":171,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":242,"conditions":388,"interventions":389},"NCT02807454","A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma",[90],"2022-01-03","2016-07-07",[16],[390,189,257,241],"Daratumumab",{"nctId":78,"briefTitle":79,"status":152,"phases":392,"primaryCompletion":80,"completion":80,"start":393,"enrollment":394,"conditions":395,"interventions":396},[89,90],"2019-09-30",424,[16],[81,258,241,390,397,398,399,397],"Carfilzomib","Elotuzumab","Isatuximab",{"nctId":401,"briefTitle":402,"status":135,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":409},"NCT06988488","A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and\u002For Refractory Multiple Myeloma",[89,90],"2027-05-31","2027-06-03","2025-10-07",62,[16],[410,310,241],"Elranatamab",{"nctId":412,"briefTitle":413,"status":106,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":419},"NCT01593410","Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed\u002FRefractory Multiple Myeloma",[90],"2013-01-03","2010-08-01",194,[16],[115,241],{"nctId":421,"briefTitle":422,"status":423,"phases":424,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":428,"interventions":429},"NCT04882163","Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","WITHDRAWN",[89,90],"2026-04-08","2029-04-07","2021-10-10",[141],[56,145,128,430,431,432,241,167,115],"Tafasitamab","Gemcitabine","Cisplatin",{"nctId":434,"briefTitle":435,"status":106,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT02685826","A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma",[89,90],"2017-12-15","2022-09-06","2016-04-25",56,[16],[189,115,241],{"nctId":53,"briefTitle":54,"status":152,"phases":444,"primaryCompletion":55,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":449},[89,90],"2028-07-28","2016-10-14",466,[16],[56,241,390,258,397,450,258,451],"Daratumumab - 16mg\u002Fkg","Daratumumab- 1800mg",{"nctId":453,"briefTitle":454,"status":106,"phases":455,"primaryCompletion":456,"completion":60,"start":457,"enrollment":458,"conditions":459,"interventions":460},"NCT01946477","Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting",[90],"2025-04-30","2014-05-29",186,[16],[257,241,390],{"trials":462,"activeCount":235,"soonestReadout":85},[463,474,483,492,502,512,521,530,540,551,558,569,580],{"nctId":464,"briefTitle":465,"status":106,"phases":466,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":472},"NCT00452569","Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma",[91],"2008-12-01","2009-01-01","2006-02-01",499,[16],[473,241],"Thalidomide",{"nctId":475,"briefTitle":476,"status":106,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT01712789","Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma",[91],"2019-12-11","2012-11-06",682,[16],[257,241],{"nctId":484,"briefTitle":485,"status":423,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":100,"conditions":490,"interventions":491},"NCT06232707","A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",[91],"2025-11-16","2030-09-21","2024-05-03",[16],[309,257,390,398,397,241],{"nctId":493,"briefTitle":494,"status":106,"phases":495,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":501},"NCT00420849","A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma",[91],"2009-10","2009-11","2006-11",587,[16],[115,241],{"nctId":503,"briefTitle":504,"status":106,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":511},"NCT00056160","CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma",[91],"2005-11-01","2008-10-01","2003-01-01",353,[16],[372,241],{"nctId":513,"briefTitle":514,"status":106,"phases":515,"primaryCompletion":367,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":520},"NCT00179647","Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma",[91],"2009-04","2005-09",1913,[16],[226,299],{"nctId":522,"briefTitle":523,"status":106,"phases":524,"primaryCompletion":525,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":529},"NCT00928486","A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma",[91],"2010-09-10","2009-04-28",25,[16],[115,241],{"nctId":531,"briefTitle":532,"status":106,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":539},"NCT01734928","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",[91],"2022-05-09","2022-05-13","2013-01-07",559,[16],[257,258,241],{"nctId":541,"briefTitle":542,"status":106,"phases":543,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":550},"NCT00478777","A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma",[91],"2007-11","2009-08","2007-03",150,[549],"Relapsed or Refractory Multiple Myeloma",[115,299],{"nctId":83,"briefTitle":84,"status":135,"phases":552,"primaryCompletion":85,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":557},[91],"2033-11-30","2022-09-20",810,[549],[86,257,258,241],{"nctId":559,"briefTitle":560,"status":152,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT04975997","Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",[91],"2027-11-16","2032-06-25","2022-06-23",939,[16],[241,390,258,568,568,568,241,390],"Iberdomide",{"nctId":570,"briefTitle":571,"status":106,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":578},"NCT01311687","A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study",[91],"2013-03-01","2017-08-29","2011-03-11",455,[16],[579,241],"pomalidomide",{"nctId":581,"briefTitle":582,"status":152,"phases":583,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":588},"NCT03651128","Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)",[91],"2027-04-08","2019-04-16",381,[16],[113,390,257,241,258,589,115,397,398],"Ixazomib",{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":100},[594,603,613],{"nctId":595,"briefTitle":596,"status":106,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":602},"NCT02692339","Safety Study of Lenalidomide\u002FDexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma",[],"2018-12-12","2016-02-25",22,[16],[115,241],{"nctId":604,"briefTitle":605,"status":106,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":611},"NCT02556905","A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea",[],"2016-11-30","2011-03-09",624,[16],[612,241],"REVLIMID®",{"nctId":614,"briefTitle":615,"status":106,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":621},"NCT02555839","Treatment of Relapsed\u002FRefractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice",[],"2023-06-30","2015-02-20",127,[16],[257,241,257,241,258],{"intervention":128,"totalTrials":623,"cells":624},20,{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":705,"PHASE3":742,"PHASE4":800,"NA":802},{"trials":626,"activeCount":100},[],{"trials":628,"activeCount":146,"soonestReadout":137},[629,641,652,663,674,678,688,692],{"nctId":630,"briefTitle":631,"status":171,"phases":632,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":637},"NCT02031419","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma",[89],"2023-12-12","2013-12-18",174,[124],[638,639,128,638,640,128,639,640,128],"CC-122","CC-223","CC-292",{"nctId":642,"briefTitle":643,"status":171,"phases":644,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":649},"NCT03783403","A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers",[89],"2024-08-05","2019-03-01",206,[32],[650,128,651],"CC-95251","Cetuximab",{"nctId":653,"briefTitle":654,"status":171,"phases":655,"primaryCompletion":656,"completion":657,"start":658,"enrollment":407,"conditions":659,"interventions":661},"NCT04464798","A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas",[89],"2023-01-31","2025-01-09","2020-11-11",[660],"Lymphoma",[56,128,662],"Obinutuzumab",{"nctId":664,"briefTitle":665,"status":106,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT02367196","A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers",[89],"2020-12-24","2015-03-12",60,[671],"Hematologic Neoplasms",[673,128],"CC-90002",{"nctId":117,"briefTitle":118,"status":106,"phases":675,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":676,"interventions":677},[89],[124,125],[127,128,129,130,131],{"nctId":679,"briefTitle":680,"status":106,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":687},"NCT01744626","Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[89],"2015-12","2012-12",40,[686],"Leukemia Lymphocytic Chronic B-Cell",[640,128],{"nctId":133,"briefTitle":134,"status":135,"phases":689,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":690,"interventions":691},[89],[141],[56,128,96,143,130,131,144,145,128],{"nctId":693,"briefTitle":694,"status":106,"phases":695,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":702},"NCT03283202","Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors",[89],"2019-07-30","2020-12-16","2017-10-04",35,[701],"Diffuse B-Cell Lymphoma",[703,128,704,130,131],"Avadomide","Cyclophosphamide 750mg\u002Fm2 by IV",{"trials":706,"activeCount":190,"soonestReadout":75},[707,718,730,734,738],{"nctId":708,"briefTitle":709,"status":152,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":716},"NCT03930953","A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R\u002FR NHL)",[89,90],"2027-04-07","2028-02-09","2019-05-20",438,[24],[144,128,662,430,717],"Valemetostat",{"nctId":719,"briefTitle":720,"status":106,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":728},"NCT02733042","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",[89,90],"2019-03-06","2022-08-21","2016-05-11",106,[660,727],"Leukemia, Lymphocytic, Chronic, B-Cell",[189,115,128,729,167],"Ibrutinib",{"nctId":73,"briefTitle":74,"status":152,"phases":731,"primaryCompletion":75,"completion":162,"start":163,"enrollment":164,"conditions":732,"interventions":733},[90],[125],[76,128,96,143,130,131,167],{"nctId":181,"briefTitle":182,"status":106,"phases":735,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":736,"interventions":737},[90],[124],[189,128,143,130,96,131,115],{"nctId":421,"briefTitle":422,"status":423,"phases":739,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":740,"interventions":741},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"trials":743,"activeCount":190,"soonestReadout":197},[744,748,752,764,774,786,790],{"nctId":194,"briefTitle":195,"status":135,"phases":745,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":746,"interventions":747},[91],[202],[76,128,115,96,143,130,204,167],{"nctId":206,"briefTitle":207,"status":152,"phases":749,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":750,"interventions":751},[91],[214],[76,128,96,143,130,131],{"nctId":753,"briefTitle":754,"status":106,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT01476787","Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma",[91],"2024-04-30","2011-12-29",1030,[202],[128,115,761,762,763],"Rituximab-CHOP","Rituximab-CVP","Rituximab-Bendamustine",{"nctId":765,"briefTitle":766,"status":106,"phases":767,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":773},"NCT01996865","Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed\u002FRefractory Follicular, Marginal Zone or Mantle Cell Lymphoma.",[91],"2024-05-11","2024-09-17","2014-04-01",503,[24],[115,128],{"nctId":775,"briefTitle":776,"status":106,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":783},"NCT01197560","Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",[90,91],"2013-07-04","2018-04-05","2010-09-02",111,[370],[115,431,784,128,785],"Oxaliplatin","Etoposide",{"nctId":217,"briefTitle":218,"status":106,"phases":787,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":788,"interventions":789},[91],[124],[226,128,96,143,227,228],{"nctId":791,"briefTitle":792,"status":106,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":799},"NCT01938001","Rituximab Plus Lenalidomide for Patients With Relapsed \u002F Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)",[91],"2018-06-22","2022-01-26","2013-11-21",358,[24],[128,115],{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"intervention":258,"totalTrials":805,"cells":806},9,{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":815,"PHASE3":835,"PHASE4":853,"NA":855},{"trials":808,"activeCount":100},[],{"trials":810,"activeCount":100},[811],{"nctId":249,"briefTitle":250,"status":106,"phases":812,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":813,"interventions":814},[89],[16],[257,258,241],{"trials":816,"activeCount":190,"soonestReadout":55},[817,827,831],{"nctId":818,"briefTitle":819,"status":171,"phases":820,"primaryCompletion":821,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":825},"NCT00765102","Trial of Romidepsin and Bortezomib for Multiple Myeloma",[90],"2010-03-01","2008-09-01",32,[16],[258,826],"Romidepsin",{"nctId":78,"briefTitle":79,"status":152,"phases":828,"primaryCompletion":80,"completion":80,"start":393,"enrollment":394,"conditions":829,"interventions":830},[89,90],[16],[81,258,241,390,397,398,399,397],{"nctId":53,"briefTitle":54,"status":152,"phases":832,"primaryCompletion":55,"completion":445,"start":446,"enrollment":447,"conditions":833,"interventions":834},[89,90],[16],[56,241,390,258,397,450,258,451],{"trials":836,"activeCount":235,"soonestReadout":85},[837,841,845,849],{"nctId":531,"briefTitle":532,"status":106,"phases":838,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":839,"interventions":840},[91],[16],[257,258,241],{"nctId":83,"briefTitle":84,"status":135,"phases":842,"primaryCompletion":85,"completion":553,"start":554,"enrollment":555,"conditions":843,"interventions":844},[91],[549],[86,257,258,241],{"nctId":559,"briefTitle":560,"status":152,"phases":846,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":847,"interventions":848},[91],[16],[241,390,258,568,568,568,241,390],{"nctId":581,"briefTitle":582,"status":152,"phases":850,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":851,"interventions":852},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":100},[857],{"nctId":614,"briefTitle":615,"status":106,"phases":858,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":859,"interventions":860},[],[16],[257,241,257,241,258],{"intervention":390,"totalTrials":862,"cells":863},8,{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":898,"PHASE4":912,"NA":914},{"trials":865,"activeCount":100},[],{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":190,"soonestReadout":55},[870,882,886,890,894],{"nctId":871,"briefTitle":872,"status":106,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":879},"NCT03000452","A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)",[90],"2017-09-18","2017-12-04","2017-03-14",18,[16],[880,881],"DARATUMUMAB","DURVALUMAB",{"nctId":383,"briefTitle":384,"status":171,"phases":883,"primaryCompletion":386,"completion":386,"start":387,"enrollment":242,"conditions":884,"interventions":885},[90],[16],[390,189,257,241],{"nctId":78,"briefTitle":79,"status":152,"phases":887,"primaryCompletion":80,"completion":80,"start":393,"enrollment":394,"conditions":888,"interventions":889},[89,90],[16],[81,258,241,390,397,398,399,397],{"nctId":53,"briefTitle":54,"status":152,"phases":891,"primaryCompletion":55,"completion":445,"start":446,"enrollment":447,"conditions":892,"interventions":893},[89,90],[16],[56,241,390,258,397,450,258,451],{"nctId":453,"briefTitle":454,"status":106,"phases":895,"primaryCompletion":456,"completion":60,"start":457,"enrollment":458,"conditions":896,"interventions":897},[90],[16],[257,241,390],{"trials":899,"activeCount":190,"soonestReadout":584},[900,904,908],{"nctId":484,"briefTitle":485,"status":423,"phases":901,"primaryCompletion":487,"completion":488,"start":489,"enrollment":100,"conditions":902,"interventions":903},[91],[16],[309,257,390,398,397,241],{"nctId":559,"briefTitle":560,"status":152,"phases":905,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":906,"interventions":907},[91],[16],[241,390,258,568,568,568,241,390],{"nctId":581,"briefTitle":582,"status":152,"phases":909,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":910,"interventions":911},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"intervention":130,"totalTrials":862,"cells":917},{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":934,"PHASE3":944,"PHASE4":958,"NA":960},{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":146,"soonestReadout":137},[922,926,930],{"nctId":117,"briefTitle":118,"status":106,"phases":923,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":924,"interventions":925},[89],[124,125],[127,128,129,130,131],{"nctId":133,"briefTitle":134,"status":135,"phases":927,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":928,"interventions":929},[89],[141],[56,128,96,143,130,131,144,145,128],{"nctId":693,"briefTitle":694,"status":106,"phases":931,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":932,"interventions":933},[89],[701],[703,128,704,130,131],{"trials":935,"activeCount":146,"soonestReadout":75},[936,940],{"nctId":73,"briefTitle":74,"status":152,"phases":937,"primaryCompletion":75,"completion":162,"start":163,"enrollment":164,"conditions":938,"interventions":939},[90],[125],[76,128,96,143,130,131,167],{"nctId":181,"briefTitle":182,"status":106,"phases":941,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":942,"interventions":943},[90],[124],[189,128,143,130,96,131,115],{"trials":945,"activeCount":190,"soonestReadout":197},[946,950,954],{"nctId":194,"briefTitle":195,"status":135,"phases":947,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":948,"interventions":949},[91],[202],[76,128,115,96,143,130,204,167],{"nctId":206,"briefTitle":207,"status":152,"phases":951,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":952,"interventions":953},[91],[214],[76,128,96,143,130,131],{"nctId":217,"briefTitle":218,"status":106,"phases":955,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":956,"interventions":957},[91],[124],[226,128,96,143,227,228],{"trials":959,"activeCount":100},[],{"trials":961,"activeCount":100},[],{"intervention":143,"totalTrials":963,"cells":964},6,{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":973,"PHASE3":983,"PHASE4":997,"NA":999},{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":146,"soonestReadout":137},[969],{"nctId":133,"briefTitle":134,"status":135,"phases":970,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":971,"interventions":972},[89],[141],[56,128,96,143,130,131,144,145,128],{"trials":974,"activeCount":146,"soonestReadout":75},[975,979],{"nctId":73,"briefTitle":74,"status":152,"phases":976,"primaryCompletion":75,"completion":162,"start":163,"enrollment":164,"conditions":977,"interventions":978},[90],[125],[76,128,96,143,130,131,167],{"nctId":181,"briefTitle":182,"status":106,"phases":980,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":981,"interventions":982},[90],[124],[189,128,143,130,96,131,115],{"trials":984,"activeCount":190,"soonestReadout":197},[985,989,993],{"nctId":194,"briefTitle":195,"status":135,"phases":986,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":987,"interventions":988},[91],[202],[76,128,115,96,143,130,204,167],{"nctId":206,"briefTitle":207,"status":152,"phases":990,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":991,"interventions":992},[91],[214],[76,128,96,143,130,131],{"nctId":217,"briefTitle":218,"status":106,"phases":994,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":995,"interventions":996},[91],[124],[226,128,96,143,227,228],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"intervention":131,"totalTrials":35,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1030,"PHASE3":1053,"PHASE4":1089,"NA":1091},{"trials":1004,"activeCount":100},[],{"trials":1006,"activeCount":146,"soonestReadout":137},[1007,1011,1022,1026],{"nctId":117,"briefTitle":118,"status":106,"phases":1008,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":1009,"interventions":1010},[89],[124,125],[127,128,129,130,131],{"nctId":1012,"briefTitle":1013,"status":106,"phases":1014,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":963,"conditions":1017,"interventions":1019},"NCT04628988","A Study of CC-90011 and Comparators in Participants With Prostate Cancer",[89],"2023-05-26","2021-07-28",[1018],"Prostatic Neoplasms",[1020,1021,131],"CC-90011","Abiraterone",{"nctId":133,"briefTitle":134,"status":135,"phases":1023,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":1024,"interventions":1025},[89],[141],[56,128,96,143,130,131,144,145,128],{"nctId":693,"briefTitle":694,"status":106,"phases":1027,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":1028,"interventions":1029},[89],[701],[703,128,704,130,131],{"trials":1031,"activeCount":146,"soonestReadout":75},[1032,1036,1049],{"nctId":73,"briefTitle":74,"status":152,"phases":1033,"primaryCompletion":75,"completion":162,"start":163,"enrollment":164,"conditions":1034,"interventions":1035},[90],[125],[76,128,96,143,130,131,167],{"nctId":1037,"briefTitle":1038,"status":106,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1048},"NCT00463385","A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia",[90],"2009-05-01","2013-12-31","2007-04-01",88,[1045,1046,1047],"Myelofibrosis With Myeloid Metaplasia","Myeloid Metaplasia","Myelofibrosis",[257,131],{"nctId":181,"briefTitle":182,"status":106,"phases":1050,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":1051,"interventions":1052},[90],[124],[189,128,143,130,96,131,115],{"trials":1054,"activeCount":146,"soonestReadout":209},[1055,1069,1073,1085],{"nctId":1056,"briefTitle":1057,"status":106,"phases":1058,"primaryCompletion":497,"completion":1059,"start":1060,"enrollment":1061,"conditions":1062,"interventions":1064},"NCT00405756","A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.",[91],"2016-04","2007-01",459,[1063],"Newly Diagnosed Multiple Myeloma",[1065,1066,131,352,1067,1068],"Lenalidomide: Double-blind Induction","Melphalan","Lenalidomide: Double-blind Maintenance","Lenalidomide: Open-label",{"nctId":206,"briefTitle":207,"status":152,"phases":1070,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":1071,"interventions":1072},[91],[214],[76,128,96,143,130,131],{"nctId":1074,"briefTitle":1075,"status":106,"phases":1076,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},"NCT00988208","Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer",[91],"2012-01-13","2016-11-28","2009-11-11",1059,[1082],"Prostate Cancer",[115,1084,131],"Docetaxel",{"nctId":217,"briefTitle":218,"status":106,"phases":1086,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":1087,"interventions":1088},[91],[124],[226,128,96,143,227,228],{"trials":1090,"activeCount":100},[],{"trials":1092,"activeCount":100},[],{"intervention":76,"totalTrials":306,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1109,"PHASE3":1115,"PHASE4":1125,"NA":1127},{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[1099],{"nctId":1100,"briefTitle":1101,"status":106,"phases":1102,"primaryCompletion":1103,"completion":1103,"start":1104,"enrollment":699,"conditions":1105,"interventions":1106},"NCT06363630","A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants",[89],"2024-08-29","2024-04-23",[19],[1107,1108,76],"Itraconazole","Rifampin",{"trials":1110,"activeCount":146,"soonestReadout":75},[1111],{"nctId":73,"briefTitle":74,"status":152,"phases":1112,"primaryCompletion":75,"completion":162,"start":163,"enrollment":164,"conditions":1113,"interventions":1114},[90],[125],[76,128,96,143,130,131,167],{"trials":1116,"activeCount":190,"soonestReadout":197},[1117,1121],{"nctId":194,"briefTitle":195,"status":135,"phases":1118,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":1119,"interventions":1120},[91],[202],[76,128,115,96,143,130,204,167],{"nctId":206,"briefTitle":207,"status":152,"phases":1122,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":1123,"interventions":1124},[91],[214],[76,128,96,143,130,131],{"trials":1126,"activeCount":100},[],{"trials":1128,"activeCount":100},[],{"intervention":397,"totalTrials":306,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1145,"PHASE4":1155,"NA":1157},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":190,"soonestReadout":55},[1137,1141],{"nctId":78,"briefTitle":79,"status":152,"phases":1138,"primaryCompletion":80,"completion":80,"start":393,"enrollment":394,"conditions":1139,"interventions":1140},[89,90],[16],[81,258,241,390,397,398,399,397],{"nctId":53,"briefTitle":54,"status":152,"phases":1142,"primaryCompletion":55,"completion":445,"start":446,"enrollment":447,"conditions":1143,"interventions":1144},[89,90],[16],[56,241,390,258,397,450,258,451],{"trials":1146,"activeCount":146,"soonestReadout":584},[1147,1151],{"nctId":484,"briefTitle":485,"status":423,"phases":1148,"primaryCompletion":487,"completion":488,"start":489,"enrollment":100,"conditions":1149,"interventions":1150},[91],[16],[309,257,390,398,397,241],{"nctId":581,"briefTitle":582,"status":152,"phases":1152,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":1153,"interventions":1154},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"intervention":115,"totalTrials":1160,"cells":1161},58,{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1239,"PHASE3":1439,"PHASE4":1573,"NA":1575},{"trials":1163,"activeCount":100},[],{"trials":1165,"activeCount":100},[1166,1170,1182,1191,1200,1211,1215,1219,1231],{"nctId":104,"briefTitle":105,"status":106,"phases":1167,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":1168,"interventions":1169},[89],[16],[113,114,96,115],{"nctId":1171,"briefTitle":1172,"status":106,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1181},"NCT00419250","A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia",[89],"2010-02-01","2010-06-01","2006-12-01",52,[1179,1180],"Chronic Lymphocytic Leukemia","Leukemia, B-Cell, Chronic",[226,226,226,226,226],{"nctId":1183,"briefTitle":1184,"status":106,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":9,"conditions":1189,"interventions":1190},"NCT00046735","Phase 1 Study OF CDC-501 in Patients With Solid Tumors",[89],"2006-08-01","2006-09-28","2002-06-01",[32],[115],{"nctId":1192,"briefTitle":1193,"status":106,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT02521714","Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension",[89],"2015-09-23","2015-08-14",28,[19],[115],{"nctId":1201,"briefTitle":1202,"status":106,"phases":1203,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":110,"conditions":1207,"interventions":1210},"NCT01169298","A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma",[89],"2013-12-01","2013-12-20","2010-07-01",[1208,1209],"Adult T-cell Leukemia-Lymphoma","Peripheral T-cell Lymphoma",[115],{"nctId":281,"briefTitle":282,"status":106,"phases":1212,"primaryCompletion":284,"completion":285,"start":286,"enrollment":20,"conditions":1213,"interventions":1214},[89],[16],[289,226,241],{"nctId":291,"briefTitle":292,"status":106,"phases":1216,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":1217,"interventions":1218},[89],[16],[226,299],{"nctId":1220,"briefTitle":1221,"status":106,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":329,"enrollment":1224,"conditions":1225,"interventions":1227},"NCT01712828","Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males",[89],"2013-01-01",31,[1226],"Healthy",[115,1228,1229,1230],"Quinidine","Temsirolimus","Diphenhydramine",{"nctId":1232,"briefTitle":1233,"status":106,"phases":1234,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":623,"conditions":1237,"interventions":1238},"NCT01732861","Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia\u002F Small Lymphocytic Lymphoma",[89],"2019-01-23","2012-12-28",[686],[640,115],{"trials":1240,"activeCount":100},[1241,1252,1261,1272,1276,1280,1290,1300,1308,1320,1324,1334,1342,1352,1363,1373,1381,1392,1403,1407,1417,1427,1431,1435],{"nctId":1242,"briefTitle":1243,"status":106,"phases":1244,"primaryCompletion":1245,"completion":1246,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1251},"NCT00737529","A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The \"EMERGE\" Trial",[90],"2016-04-06","2017-11-08","2008-12-22",134,[1250],"Mantle Cell Lymphoma",[226],{"nctId":1253,"briefTitle":1254,"status":106,"phases":1255,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1260},"NCT00065156","Lenalidomide Safety\u002FEfficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality",[90],"2008-08-01","2003-06-01",148,[22],[226],{"nctId":1262,"briefTitle":1263,"status":106,"phases":1264,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":1043,"conditions":1268,"interventions":1271},"NCT01358734","A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia",[90],"2015-05-19","2018-05-15","2012-04-27",[1269,1270],"Acute Myeloid Leukemia","Acute Myelogenous Leukemia",[46,115],{"nctId":324,"briefTitle":325,"status":106,"phases":1273,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":1274,"interventions":1275},[90],[16],[115,299],{"nctId":334,"briefTitle":335,"status":106,"phases":1277,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":1278,"interventions":1279},[90],[16],[115,241],{"nctId":1281,"briefTitle":1282,"status":171,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1289},"NCT00109772","Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1",[90],"2008-04","2005-02",184,[1288],"Complex Regional Pain Syndrome, Type I",[226],{"nctId":1291,"briefTitle":1292,"status":171,"phases":1293,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":25,"conditions":1296,"interventions":1298},"NCT00975806","Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma",[89,90],"2011-10-01","2009-09-01",[1297],"Renal Cell Carcinoma",[115,1299],"Sunitinib",{"nctId":1301,"briefTitle":1302,"status":106,"phases":1303,"primaryCompletion":348,"completion":348,"start":1304,"enrollment":12,"conditions":1305,"interventions":1307},"NCT00179660","Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)",[90],"2005-08",[1306],"Non-Hodgkins Lymphoma",[115],{"nctId":1309,"briefTitle":1310,"status":106,"phases":1311,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},"NCT00875667","A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)",[90],"2018-06-28","2018-10-09","2009-04-30",254,[1250,1317],"Lymphoma, Mantle-Cell",[115,1319],"Investigators choice single agent",{"nctId":719,"briefTitle":720,"status":106,"phases":1321,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":1322,"interventions":1323},[89,90],[660,727],[189,115,128,729,167],{"nctId":1325,"briefTitle":1326,"status":106,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1333},"NCT00963105","Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",[90],"2017-09-05","2009-10-19",104,[1332],"Relapsed or Refractory Chronic Lymphocytic Leukemia",[226],{"nctId":1335,"briefTitle":1336,"status":106,"phases":1337,"primaryCompletion":1338,"completion":1338,"start":1339,"enrollment":35,"conditions":1340,"interventions":1341},"NCT00812968","Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.",[90],"2010-09-01","2007-09-01",[22],[115],{"nctId":1343,"briefTitle":1344,"status":106,"phases":1345,"primaryCompletion":1346,"completion":1347,"start":1348,"enrollment":330,"conditions":1349,"interventions":1351},"NCT01724177","A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma",[90],"2014-11-20","2017-03-21","2012-11-12",[1350],"Adult T-Cell Leukemia-Lymphoma",[115],{"nctId":1353,"briefTitle":1354,"status":106,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":684,"conditions":1359,"interventions":1361},"NCT00910858","A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes",[89,90],"2006-04","2009-05","2005-01",[1360],"Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)",[115,1362],"Recombinant human erythropoietin",{"nctId":1364,"briefTitle":1365,"status":106,"phases":1366,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":684,"conditions":1370,"interventions":1372},"NCT00067743","A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)",[90],"2004-10","2007-08","2003-08",[1371],"Complex Regional Pain Syndrome (RSD)",[115],{"nctId":1374,"briefTitle":1375,"status":106,"phases":1376,"primaryCompletion":1284,"completion":1284,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1380},"NCT00179673","Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",[90],"2005-06",43,[1306],[115],{"nctId":1382,"briefTitle":1383,"status":171,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1390},"NCT01032291","A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer",[90],"2011-01","2009-12",51,[1389],"Colorectal Cancer",[1391,226],"cetuximab",{"nctId":1393,"briefTitle":1394,"status":106,"phases":1395,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":1399,"conditions":1400,"interventions":1402},"NCT02538965","A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia",[90],"2017-07-22","2019-01-11","2015-11-19",17,[1401],"Leukemia, Myeloid",[115],{"nctId":181,"briefTitle":182,"status":106,"phases":1404,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":1405,"interventions":1406},[90],[124],[189,128,143,130,96,131,115],{"nctId":1408,"briefTitle":1409,"status":171,"phases":1410,"primaryCompletion":821,"completion":1411,"start":1412,"enrollment":1413,"conditions":1414,"interventions":1416},"NCT00655668","A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma",[90],"2010-04-01","2008-03-01",54,[1415],"T-cell Non-Hodgkin's Lymphoma",[115],{"nctId":1418,"briefTitle":1419,"status":106,"phases":1420,"primaryCompletion":346,"completion":1421,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1426},"NCT00413036","A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma",[90],"2011-05","2006-06",217,[1425],"Lymphoma, Non-Hodgkin's",[226],{"nctId":412,"briefTitle":413,"status":106,"phases":1428,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":1429,"interventions":1430},[90],[16],[115,241],{"nctId":421,"briefTitle":422,"status":423,"phases":1432,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":1433,"interventions":1434},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"nctId":434,"briefTitle":435,"status":106,"phases":1436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":1437,"interventions":1438},[89,90],[16],[189,115,241],{"trials":1440,"activeCount":235,"soonestReadout":65},[1441,1445,1456,1460,1464,1473,1477,1481,1485,1489,1493,1507,1511,1522,1526,1530,1538,1547,1551,1559,1569],{"nctId":194,"briefTitle":195,"status":135,"phases":1442,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":1443,"interventions":1444},[91],[202],[76,128,115,96,143,130,204,167],{"nctId":1446,"briefTitle":1447,"status":106,"phases":1448,"primaryCompletion":1449,"completion":1450,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1455},"NCT01029262","A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q",[91],"2013-03-17","2018-05-09","2010-01-26",239,[1454],"Anemia",[115],{"nctId":493,"briefTitle":494,"status":106,"phases":1457,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":1458,"interventions":1459},[91],[16],[115,241],{"nctId":753,"briefTitle":754,"status":106,"phases":1461,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":1462,"interventions":1463},[91],[202],[128,115,761,762,763],{"nctId":1465,"briefTitle":1466,"status":106,"phases":1467,"primaryCompletion":1468,"completion":544,"start":1358,"enrollment":1469,"conditions":1470,"interventions":1472},"NCT00120120","Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy",[90,91],"2007-10",181,[1471],"Radiculopathy",[115],{"nctId":765,"briefTitle":766,"status":106,"phases":1474,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":1475,"interventions":1476},[91],[24],[115,128],{"nctId":1074,"briefTitle":1075,"status":106,"phases":1478,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1479,"interventions":1480},[91],[1082],[115,1084,131],{"nctId":775,"briefTitle":776,"status":106,"phases":1482,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":1483,"interventions":1484},[90,91],[370],[115,431,784,128,785],{"nctId":513,"briefTitle":514,"status":106,"phases":1486,"primaryCompletion":367,"completion":516,"start":517,"enrollment":518,"conditions":1487,"interventions":1488},[91],[16],[226,299],{"nctId":217,"briefTitle":218,"status":106,"phases":1490,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":1491,"interventions":1492},[91],[124],[226,128,96,143,227,228],{"nctId":1494,"briefTitle":1495,"status":423,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":100,"conditions":1500,"interventions":1506},"NCT02155634","Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma",[91],"2017-04","2021-03","2014-07",[16,32,1501,1502,1503,1504,1505],"Plasma Cells","Paraproteinemias","Blood Protein Disorders","Hematologic Diseases","Therapeutic Uses",[115],{"nctId":522,"briefTitle":523,"status":106,"phases":1508,"primaryCompletion":525,"completion":525,"start":526,"enrollment":527,"conditions":1509,"interventions":1510},[91],[16],[115,241],{"nctId":1512,"briefTitle":1513,"status":106,"phases":1514,"primaryCompletion":1515,"completion":1450,"start":1516,"enrollment":1517,"conditions":1518,"interventions":1520},"NCT00910910","Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)",[91],"2014-03-31","2009-10-13",450,[1519],"B-Cell Chronic Lymphocytic Leukemia",[115,1521],"Chlorambucil",{"nctId":541,"briefTitle":542,"status":106,"phases":1523,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":1524,"interventions":1525},[91],[549],[115,299],{"nctId":791,"briefTitle":792,"status":106,"phases":1527,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":1528,"interventions":1529},[91],[24],[128,115],{"nctId":1531,"briefTitle":1532,"status":106,"phases":1533,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":186,"conditions":1536,"interventions":1537},"NCT02112175","Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM",[91],"2020-10-12","2014-04-30",[16],[115],{"nctId":1539,"briefTitle":1540,"status":106,"phases":1541,"primaryCompletion":1542,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT00622336","A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma",[91],"2013-11-25","2003-04-01",330,[16],[372,115],{"nctId":63,"briefTitle":64,"status":152,"phases":1548,"primaryCompletion":65,"completion":210,"start":231,"enrollment":232,"conditions":1549,"interventions":1550},[91],[16],[66,115,114,96],{"nctId":1552,"briefTitle":1553,"status":171,"phases":1554,"primaryCompletion":1555,"completion":1555,"start":1411,"enrollment":805,"conditions":1556,"interventions":1558},"NCT01021423","A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).",[91],"2011-03-01",[1250,1557],"Non-Hodgkin's Lymphoma",[115],{"nctId":1560,"briefTitle":1561,"status":106,"phases":1562,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":1565,"conditions":1566,"interventions":1568},"NCT00774345","A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy",[91],"2020-10-27","2009-01-27",317,[1567],"B-cell Chronic Lymphocytic Leukemia",[115],{"nctId":581,"briefTitle":582,"status":152,"phases":1570,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":1571,"interventions":1572},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":1574,"activeCount":100},[],{"trials":1576,"activeCount":100},[1577,1581,1590,1599],{"nctId":595,"briefTitle":596,"status":106,"phases":1578,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":1579,"interventions":1580},[],[16],[115,241],{"nctId":1582,"briefTitle":1583,"status":106,"phases":1584,"primaryCompletion":1585,"completion":1585,"start":1586,"enrollment":1587,"conditions":1588,"interventions":1589},"NCT01347944","MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry",[],"2013-06-30","2011-01-01",149,[34],[226],{"nctId":1591,"briefTitle":1592,"status":106,"phases":1593,"primaryCompletion":1594,"completion":1594,"start":1595,"enrollment":1596,"conditions":1597,"interventions":1598},"NCT02279654","Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)",[],"2022-03-29","2014-12-17",389,[34],[115],{"nctId":1600,"briefTitle":1601,"status":106,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1607},"NCT03647124","A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma",[],"2024-01-10","2019-03-13",105,[1317],[115],{"intervention":114,"totalTrials":306,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1618,"PHASE3":1628,"PHASE4":1634,"NA":1636},{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":100},[1614],{"nctId":104,"briefTitle":105,"status":106,"phases":1615,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":1616,"interventions":1617},[89],[16],[113,114,96,115],{"trials":1619,"activeCount":146,"soonestReadout":154},[1620,1624],{"nctId":150,"briefTitle":151,"status":152,"phases":1621,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":1622,"interventions":1623},[90],[24],[114,96,159],{"nctId":169,"briefTitle":170,"status":171,"phases":1625,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":1626,"interventions":1627},[89,90],[177,24],[159,179,114,96],{"trials":1629,"activeCount":146,"soonestReadout":65},[1630],{"nctId":63,"briefTitle":64,"status":152,"phases":1631,"primaryCompletion":65,"completion":210,"start":231,"enrollment":232,"conditions":1632,"interventions":1633},[91],[16],[66,115,114,96],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":100},[],{"intervention":167,"totalTrials":306,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1658,"PHASE4":1664,"NA":1666},{"trials":1641,"activeCount":100},[],{"trials":1643,"activeCount":100},[],{"trials":1645,"activeCount":146,"soonestReadout":75},[1646,1650,1654],{"nctId":719,"briefTitle":720,"status":106,"phases":1647,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":1648,"interventions":1649},[89,90],[660,727],[189,115,128,729,167],{"nctId":73,"briefTitle":74,"status":152,"phases":1651,"primaryCompletion":75,"completion":162,"start":163,"enrollment":164,"conditions":1652,"interventions":1653},[90],[125],[76,128,96,143,130,131,167],{"nctId":421,"briefTitle":422,"status":423,"phases":1655,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":1656,"interventions":1657},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"trials":1659,"activeCount":146,"soonestReadout":197},[1660],{"nctId":194,"briefTitle":195,"status":135,"phases":1661,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":1662,"interventions":1663},[91],[202],[76,128,115,96,143,130,204,167],{"trials":1665,"activeCount":100},[],{"trials":1667,"activeCount":100},[],{"intervention":71,"totalTrials":306,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1703,"PHASE3":1705,"PHASE4":1720,"NA":1722},{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":146,"soonestReadout":70},[1674,1686,1692],{"nctId":1675,"briefTitle":1676,"status":106,"phases":1677,"primaryCompletion":1678,"completion":1679,"start":1680,"enrollment":9,"conditions":1681,"interventions":1682},"NCT06433505","A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants",[89],"2025-02-14","2025-02-28","2024-05-30",[19],[71,1683,1684,1685],"[14C] BMS-986365","[14C] BMS-986409 + BMS-986410","[14C] BMS-986410 + BMS-986409",{"nctId":68,"briefTitle":69,"status":135,"phases":1687,"primaryCompletion":70,"completion":70,"start":1688,"enrollment":1689,"conditions":1690,"interventions":1691},[89],"2025-12-15",42,[19],[71,1107,1108],{"nctId":1693,"briefTitle":1694,"status":106,"phases":1695,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1701},"NCT06417229","Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants",[89],"2025-02-19","2024-05-28",102,[1700],"Healthy Participants",[71,1702],"Rabeprazole",{"trials":1704,"activeCount":100},[],{"trials":1706,"activeCount":146,"soonestReadout":1711},[1707],{"nctId":1708,"briefTitle":1709,"status":135,"phases":1710,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1717},"NCT06764485","A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer",[91],"2027-09-12","2029-01-19","2025-03-13",960,[1716],"Metastatic Castration-resistant Prostate Cancer",[71,1718,1021,1084,1719],"Enzalutamide","Predinsone\u002FPrednisolone",{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[],{"intervention":310,"totalTrials":306,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1743,"PHASE3":1749,"PHASE4":1755,"NA":1757},{"trials":1727,"activeCount":100},[],{"trials":1729,"activeCount":100},[1730,1739],{"nctId":1731,"briefTitle":1732,"status":106,"phases":1733,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":330,"conditions":1736,"interventions":1738},"NCT06318676","A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment",[89],"2024-11-15","2024-03-21",[1737],"Renal Impairment",[310],{"nctId":301,"briefTitle":302,"status":171,"phases":1740,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":1741,"interventions":1742},[89],[16],[309,310,241],{"trials":1744,"activeCount":146,"soonestReadout":404},[1745],{"nctId":401,"briefTitle":402,"status":135,"phases":1746,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":1747,"interventions":1748},[89,90],[16],[410,310,241],{"trials":1750,"activeCount":146,"soonestReadout":85},[1751],{"nctId":83,"briefTitle":84,"status":135,"phases":1752,"primaryCompletion":85,"completion":553,"start":554,"enrollment":555,"conditions":1753,"interventions":1754},[91],[549],[86,257,258,241],{"trials":1756,"activeCount":100},[],{"trials":1758,"activeCount":100},[],{"intervention":398,"totalTrials":235,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1771,"PHASE4":1781,"NA":1783},{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":146,"soonestReadout":80},[1767],{"nctId":78,"briefTitle":79,"status":152,"phases":1768,"primaryCompletion":80,"completion":80,"start":393,"enrollment":394,"conditions":1769,"interventions":1770},[89,90],[16],[81,258,241,390,397,398,399,397],{"trials":1772,"activeCount":146,"soonestReadout":584},[1773,1777],{"nctId":484,"briefTitle":485,"status":423,"phases":1774,"primaryCompletion":487,"completion":488,"start":489,"enrollment":100,"conditions":1775,"interventions":1776},[91],[16],[309,257,390,398,397,241],{"nctId":581,"briefTitle":582,"status":152,"phases":1778,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":1779,"interventions":1780},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"intervention":61,"totalTrials":190,"cells":1786},{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1791,"PHASE3":1804,"PHASE4":1816,"NA":1818},{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":100},[],{"trials":1792,"activeCount":146,"soonestReadout":1797},[1793],{"nctId":1794,"briefTitle":1795,"status":135,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1803},"NCT04143724","Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia",[90],"2027-07-02","2035-06-11","2019-11-07",99,[1802],"Beta-Thalassemia",[61],{"trials":1805,"activeCount":146,"soonestReadout":60},[1806],{"nctId":58,"briefTitle":59,"status":152,"phases":1807,"primaryCompletion":60,"completion":1808,"start":1809,"enrollment":1810,"conditions":1811,"interventions":1815},[91],"2032-08-18","2021-02-25",313,[1812,1047,1813,1814,1454],"Myeloproliferative Disorders","Primary Myelofibrosis","Post-Polycythemia Vera Myelofibrosis",[61],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[],{"intervention":257,"totalTrials":1821,"cells":1822},30,{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1914,"PHASE3":1977,"PHASE4":2021,"NA":2023},{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[1827,1839,1843,1852,1863,1867,1875,1883,1895,1903,1910],{"nctId":1828,"briefTitle":1829,"status":106,"phases":1830,"primaryCompletion":1831,"completion":607,"start":1832,"enrollment":20,"conditions":1833,"interventions":1836},"NCT02103335","Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma",[89],"2016-10-03","2014-06-05",[1834,1835,16],"Multiple Myeloma in Relapse","Refractory Multiple Myeloma",[579,1837,1838],"marizomib","low-dose dexamethasone",{"nctId":249,"briefTitle":250,"status":106,"phases":1840,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":1841,"interventions":1842},[89],[16],[257,258,241],{"nctId":1844,"briefTitle":1845,"status":106,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1851},"NCT02168205","Food Effect and CYP1A2 Induction Study in Healthy Subjects",[89],"2014-09-19","2014-05-30",55,[19],[257],{"nctId":1853,"briefTitle":1854,"status":106,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1861},"NCT01986894","A Phase 1 QT Study in Healthy Male Subjects",[89],"2013-12-02","2013-10-18",72,[1860],"Clinical Pharmacology, Healthy Volunteer Study",[257,257,1862],"Moxifloxacin",{"nctId":271,"briefTitle":272,"status":106,"phases":1864,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":1865,"interventions":1866},[89],[16],[189,257,241],{"nctId":1868,"briefTitle":1869,"status":106,"phases":1870,"primaryCompletion":329,"completion":1204,"start":1871,"enrollment":30,"conditions":1872,"interventions":1874},"NCT01522547","Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease",[89],"2007-08-01",[1873],"Anemia, Sickle Cell",[579],{"nctId":1876,"briefTitle":1877,"status":106,"phases":1878,"primaryCompletion":1879,"completion":1880,"start":573,"enrollment":823,"conditions":1881,"interventions":1882},"NCT01835561","Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males",[89],"2014-08-16","2014-08-21",[1860],[257,257],{"nctId":1884,"briefTitle":1885,"status":106,"phases":1886,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":823,"conditions":1889,"interventions":1891},"NCT01707407","A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects",[89],"2012-11-01","2012-09-01",[1890,1226],"Pharmacology, Clinical",[257,1892,1893,1894],"Ketoconazole","Fluvoxamine","Carbamazepine",{"nctId":1896,"briefTitle":1897,"status":106,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":30,"conditions":1901,"interventions":1902},"NCT01568294","Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma",[89],"2015-07-08","2012-04-01",[16],[579],{"nctId":1904,"briefTitle":1905,"status":106,"phases":1906,"primaryCompletion":1294,"completion":1294,"start":1907,"enrollment":13,"conditions":1908,"interventions":1909},"NCT01474330","A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects",[89],"2011-08-01",[1226],[257],{"nctId":312,"briefTitle":313,"status":171,"phases":1911,"primaryCompletion":315,"completion":315,"start":316,"enrollment":317,"conditions":1912,"interventions":1913},[89],[16],[320,257,241],{"trials":1915,"activeCount":100},[1916,1925,1935,1949,1957,1961,1965,1969,1973],{"nctId":1917,"briefTitle":1918,"status":171,"phases":1919,"primaryCompletion":1920,"completion":294,"start":1921,"enrollment":600,"conditions":1922,"interventions":1924},"NCT00537511","A Phase I\u002FII Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide",[89,90],"2010-11-01","2008-02-01",[1923],"Carcinoma, Small Cell",[257,432,785],{"nctId":1926,"briefTitle":1927,"status":106,"phases":1928,"primaryCompletion":1929,"completion":1929,"start":874,"enrollment":1930,"conditions":1931,"interventions":1934},"NCT03257631","A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors",[90],"2023-09-14",53,[1932,1933],"Central Nervous System Neoplasms","Medulloblastoma",[257,257],{"nctId":1936,"briefTitle":1937,"status":171,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":1942,"interventions":1948},"NCT01559129","Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease",[90],"2016-11-03","2012-08-09",23,[1943,1944,1945,1946,1947],"Scleroderma, Systemic","Sclerosis, Systemic","Systemic Scleroderma","Systemic Sclerosis","Interstitial Lung Disease",[257],{"nctId":1950,"briefTitle":1951,"status":171,"phases":1952,"primaryCompletion":468,"completion":468,"start":1256,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT00717522","Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma",[90],7,[1955],"Soft Tissue Sarcoma",[257],{"nctId":343,"briefTitle":344,"status":106,"phases":1958,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":1959,"interventions":1960},[89,90],[16],[257,241,352],{"nctId":374,"briefTitle":375,"status":106,"phases":1962,"primaryCompletion":377,"completion":347,"start":378,"enrollment":379,"conditions":1963,"interventions":1964},[90],[16],[257,241],{"nctId":383,"briefTitle":384,"status":171,"phases":1966,"primaryCompletion":386,"completion":386,"start":387,"enrollment":242,"conditions":1967,"interventions":1968},[90],[16],[390,189,257,241],{"nctId":1037,"briefTitle":1038,"status":106,"phases":1970,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1971,"interventions":1972},[90],[1045,1046,1047],[257,131],{"nctId":453,"briefTitle":454,"status":106,"phases":1974,"primaryCompletion":456,"completion":60,"start":457,"enrollment":458,"conditions":1975,"interventions":1976},[90],[16],[257,241,390],{"trials":1978,"activeCount":190,"soonestReadout":85},[1979,1983,1987,1991,1995,2005,2009,2017],{"nctId":475,"briefTitle":476,"status":106,"phases":1980,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":1981,"interventions":1982},[91],[16],[257,241],{"nctId":484,"briefTitle":485,"status":423,"phases":1984,"primaryCompletion":487,"completion":488,"start":489,"enrollment":100,"conditions":1985,"interventions":1986},[91],[16],[309,257,390,398,397,241],{"nctId":531,"briefTitle":532,"status":106,"phases":1988,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":1989,"interventions":1990},[91],[16],[257,258,241],{"nctId":83,"briefTitle":84,"status":135,"phases":1992,"primaryCompletion":85,"completion":553,"start":554,"enrollment":555,"conditions":1993,"interventions":1994},[91],[549],[86,257,258,241],{"nctId":1996,"briefTitle":1997,"status":106,"phases":1998,"primaryCompletion":1223,"completion":1266,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2003},"NCT01178281","Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence",[91],"2010-09-08",267,[1813,2002],"MPN-associated Myelofibrosis",[2004,257],"Pomalidomide 0.5 mg",{"nctId":570,"briefTitle":571,"status":106,"phases":2006,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":2007,"interventions":2008},[91],[16],[579,241],{"nctId":2010,"briefTitle":2011,"status":106,"phases":2012,"primaryCompletion":2013,"completion":2013,"start":1555,"enrollment":2014,"conditions":2015,"interventions":2016},"NCT01324947","Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma",[91],"2014-07-31",74,[16],[579],{"nctId":581,"briefTitle":582,"status":152,"phases":2018,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":2019,"interventions":2020},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":2022,"activeCount":100},[],{"trials":2024,"activeCount":100},[2025,2032],{"nctId":2026,"briefTitle":2027,"status":2028,"phases":2029,"conditions":2030,"interventions":2031},"NCT01632826","Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma","APPROVED_FOR_MARKETING",[],[16],[257],{"nctId":614,"briefTitle":615,"status":106,"phases":2033,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":2034,"interventions":2035},[],[16],[257,241,257,241,258],{"intervention":46,"totalTrials":877,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2084,"PHASE3":2144,"PHASE4":2190,"NA":2201},{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[2042,2054,2064,2072],{"nctId":2043,"briefTitle":2044,"status":171,"phases":2045,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":600,"conditions":2049,"interventions":2050},"NCT04336982","A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia",[89],"2023-10-25","2024-04-05","2020-08-05",[27],[2051,2052,46,2053],"CC-90009","Venetoclax","Gilteritinib",{"nctId":2055,"briefTitle":2056,"status":106,"phases":2057,"primaryCompletion":1245,"completion":2058,"start":2059,"enrollment":1224,"conditions":2060,"interventions":2062},"NCT00761722","Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma",[89],"2016-04-07","2008-08-12",[1269,22,660,16,2061],"Leukemia, Myelomonocytic, Chronic",[2063],"azacitidine",{"nctId":2065,"briefTitle":2066,"status":171,"phases":2067,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":146,"conditions":2070,"interventions":2071},"NCT04748848","A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R\u002FR Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy",[89],"2022-03-09","2021-10-14",[1401],[1020,2052,46,2052,1020],{"nctId":2073,"briefTitle":2074,"status":106,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":1224,"conditions":2078,"interventions":2083},"NCT00652626","Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function",[89],"2012-07-01","2008-11-01",[2079,2080,2081,16,1557,2082],"MDS","AML","Solid Tumors","Hodgkin's Disease",[2063],{"trials":2085,"activeCount":146,"soonestReadout":40},[2086,2090,2098,2108,2116,2125,2135],{"nctId":1262,"briefTitle":1263,"status":106,"phases":2087,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":1043,"conditions":2088,"interventions":2089},[90],[1269,1270],[46,115],{"nctId":2091,"briefTitle":2092,"status":106,"phases":2093,"primaryCompletion":1256,"completion":1256,"start":2094,"enrollment":2095,"conditions":2096,"interventions":2097},"NCT00102687","Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes",[90],"2005-01-01",151,[22],[2063],{"nctId":2099,"briefTitle":2100,"status":106,"phases":2101,"primaryCompletion":2102,"completion":2103,"start":2104,"enrollment":1858,"conditions":2105,"interventions":2107},"NCT01599325","Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome",[90],"2015-01-29","2018-03-13","2012-07-24",[2106],"Myelodysplastic Syndrome (MDS)",[46],{"nctId":38,"briefTitle":39,"status":152,"phases":2109,"primaryCompletion":40,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2114},[89,90],"2026-09-30","2016-06-03",130,[27],[41,46,2115],"AG-221",{"nctId":2117,"briefTitle":2118,"status":106,"phases":2119,"primaryCompletion":2120,"completion":2121,"start":2111,"enrollment":2122,"conditions":2123,"interventions":2124},"NCT02775903","An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)",[90],"2018-12-31","2021-12-27",213,[27,22],[46,189],{"nctId":2126,"briefTitle":2127,"status":106,"phases":2128,"primaryCompletion":2129,"completion":2130,"start":2131,"enrollment":1197,"conditions":2132,"interventions":2134},"NCT02447666","Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)",[90],"2018-02-28","2019-05-24","2015-09-15",[34,2133],"Leukemia, Myelomonocytic, Juvenile",[46],{"nctId":2136,"briefTitle":2137,"status":106,"phases":2138,"primaryCompletion":2139,"completion":2140,"start":2141,"enrollment":1953,"conditions":2142,"interventions":2143},"NCT02450877","A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.",[90],"2018-10-10","2019-10-08","2015-08-12",[27],[46],{"trials":2145,"activeCount":146,"soonestReadout":45},[2146,2154,2160,2167,2180],{"nctId":43,"briefTitle":44,"status":152,"phases":2147,"primaryCompletion":45,"completion":2148,"start":2149,"enrollment":2150,"conditions":2151,"interventions":2153},[91],"2026-03-31","2018-11-06",93,[2152],"Lymphoma, T-Cell",[46,826,431],{"nctId":2155,"briefTitle":2156,"status":106,"phases":2157,"primaryCompletion":1295,"completion":1295,"start":1042,"enrollment":684,"conditions":2158,"interventions":2159},"NCT01186939","An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)",[91],[22],[46],{"nctId":2161,"briefTitle":2162,"status":106,"phases":2163,"primaryCompletion":295,"completion":295,"start":2164,"enrollment":797,"conditions":2165,"interventions":2166},"NCT00071799","A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care",[91],"2003-11-01",[22],[46],{"nctId":2168,"briefTitle":2169,"status":106,"phases":2170,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":2175,"interventions":2177},"NCT02577406","An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation",[91],"2020-03-17","2024-03-25","2015-12-30",319,[1401,2176],"Isocitrate Dehydrogenase",[2115,46,2178,2179],"Low-dose cytarabine","Intermediate-dose cytarabine",{"nctId":2181,"briefTitle":2182,"status":106,"phases":2183,"primaryCompletion":2184,"completion":2185,"start":1175,"enrollment":2186,"conditions":2187,"interventions":2188},"NCT01074047","Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)",[91],"2014-01-22","2016-07-25",488,[1269],[46,2189],"Conventional Care Regimen",{"trials":2191,"activeCount":100},[2192],{"nctId":2193,"briefTitle":2194,"status":106,"phases":2195,"primaryCompletion":2196,"completion":2196,"start":2197,"enrollment":2198,"conditions":2199,"interventions":2200},"NCT01201811","Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)",[92],"2013-05-01","2010-10-01",44,[22],[46],{"trials":2202,"activeCount":100},[2203],{"nctId":2204,"briefTitle":2205,"status":106,"phases":2206,"primaryCompletion":2207,"completion":2207,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2211},"NCT00481273","AVIDA The Vidaza® (Azacitidine) Patient Registry",[],"2010-08-31","2006-10-31",479,[22],[46],{"intervention":51,"totalTrials":805,"cells":2213},{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2218,"PHASE3":2255,"PHASE4":2297,"NA":2299},{"trials":2215,"activeCount":100},[],{"trials":2217,"activeCount":100},[],{"trials":2219,"activeCount":100},[2220,2228,2236,2246],{"nctId":2221,"briefTitle":2222,"status":106,"phases":2223,"primaryCompletion":2224,"completion":425,"start":2225,"enrollment":1821,"conditions":2226,"interventions":2227},"NCT04477850","A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions",[90],"2023-09-29","2020-11-30",[22],[51],{"nctId":2229,"briefTitle":2230,"status":106,"phases":2231,"primaryCompletion":2232,"completion":2233,"start":713,"enrollment":175,"conditions":2234,"interventions":2235},"NCT03900715","An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion",[90],"2022-07-01","2023-03-01",[22],[51],{"nctId":2237,"briefTitle":2238,"status":106,"phases":2239,"primaryCompletion":2240,"completion":2240,"start":2241,"enrollment":2242,"conditions":2243,"interventions":2245},"NCT03342404","A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia",[90],"2022-11-28","2018-02-05",145,[2244],"Thalassemia",[51],{"nctId":2247,"briefTitle":2248,"status":106,"phases":2249,"primaryCompletion":2250,"completion":2250,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2254},"NCT03194542","A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence",[90],"2022-07-18","2017-11-15",95,[1813,1454],[51],{"trials":2256,"activeCount":190,"soonestReadout":50},[2257,2269,2279,2287],{"nctId":2258,"briefTitle":2259,"status":135,"phases":2260,"primaryCompletion":2261,"completion":2261,"start":2262,"enrollment":2263,"conditions":2264,"interventions":2268},"NCT04064060","A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials",[91],"2028-05-12","2019-08-12",665,[2265,2266,2267],"Myelodysplastic Syndromes (MDS)","Beta-thalassemia","Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis",[51],{"nctId":2270,"briefTitle":2271,"status":106,"phases":2272,"primaryCompletion":2273,"completion":2273,"start":2274,"enrollment":2275,"conditions":2276,"interventions":2278},"NCT02604433","An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia",[91],"2021-01-05","2016-05-02",336,[2277,1802],"Erythrocyte Transfusion",[51],{"nctId":48,"briefTitle":49,"status":152,"phases":2280,"primaryCompletion":50,"completion":2281,"start":2282,"enrollment":2283,"conditions":2284,"interventions":2285},[91],"2027-09-28","2019-01-02",363,[22],[51,2286],"Epoetin alfa",{"nctId":2288,"briefTitle":2289,"status":106,"phases":2290,"primaryCompletion":2291,"completion":2292,"start":2293,"enrollment":2294,"conditions":2295,"interventions":2296},"NCT02631070","A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",[91],"2019-06-18","2020-11-26","2016-02-09",229,[22],[51],{"trials":2298,"activeCount":100},[],{"trials":2300,"activeCount":100},[2301],{"nctId":2302,"briefTitle":2303,"status":171,"phases":2304,"primaryCompletion":2305,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2309},"NCT01688011","Connect® Myeloid Disease Registry",[],"2024-10-18","2013-12-12",2013,[1813,22,27],[51],{"intervention":826,"totalTrials":2311,"cells":2312},10,{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2345,"PHASE3":2399,"PHASE4":2405,"NA":2407},{"trials":2314,"activeCount":100},[],{"trials":2316,"activeCount":100},[2317,2327,2336],{"nctId":2318,"briefTitle":2319,"status":106,"phases":2320,"primaryCompletion":2321,"completion":2321,"start":2322,"enrollment":296,"conditions":2323,"interventions":2326},"NCT01324310","Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer",[89],"2012-01-01","2011-04-01",[2324,2325],"Hematologic Malignancy","Malignant Lymphoma",[826,1892],{"nctId":2328,"briefTitle":2329,"status":106,"phases":2330,"primaryCompletion":2331,"completion":2332,"start":2322,"enrollment":2333,"conditions":2334,"interventions":2335},"NCT01324323","Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer",[89],"2012-02-01","2012-03-01",14,[2324,2325],[826,1108],{"nctId":2337,"briefTitle":2338,"status":106,"phases":2339,"primaryCompletion":2340,"completion":2340,"start":2341,"enrollment":379,"conditions":2342,"interventions":2344},"NCT00379639","A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors",[89],"2008-07-01","2006-07-01",[2343],"Pancreatic Cancer",[826,431],{"trials":2346,"activeCount":100},[2347,2356,2365,2369,2379,2389],{"nctId":2348,"briefTitle":2349,"status":106,"phases":2350,"primaryCompletion":2351,"completion":467,"start":2094,"enrollment":1698,"conditions":2352,"interventions":2354},"NCT00106431","A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)",[90],"2008-06-01",[2353],"Cutaneous T-cell Lymphoma",[2355],"romidepsin",{"nctId":2357,"briefTitle":2358,"status":106,"phases":2359,"primaryCompletion":2360,"completion":2360,"start":2361,"enrollment":699,"conditions":2362,"interventions":2364},"NCT00106418","A Research Study for Patients With Prostate Cancer",[90],"2006-09-01","2003-05-07",[1082,2363],"Metastases",[826],{"nctId":818,"briefTitle":819,"status":171,"phases":2366,"primaryCompletion":821,"completion":821,"start":822,"enrollment":823,"conditions":2367,"interventions":2368},[90],[16],[258,826],{"nctId":2370,"briefTitle":2371,"status":106,"phases":2372,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":2376,"interventions":2378},"NCT01353664","A Rollover Study for Patients Who Participated in Other Romidepsin Protocols",[90],"2012-09-05","2011-05-01",19,[660,2377],"Cancer",[826],{"nctId":2380,"briefTitle":2381,"status":106,"phases":2382,"primaryCompletion":2383,"completion":2384,"start":2385,"enrollment":2386,"conditions":2387,"interventions":2388},"NCT00426764","A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma",[90],"2010-11-11","2018-05-17","2007-06-19",131,[1209],[826],{"nctId":2390,"briefTitle":2391,"status":106,"phases":2392,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":1387,"conditions":2396,"interventions":2398},"NCT01456039","A Japanese Phase 1\u002F2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)",[89,90],"2015-07-28","2018-12-14","2011-12-01",[2397],"Lymphoma, T-cell, Peripheral",[826],{"trials":2400,"activeCount":146,"soonestReadout":45},[2401],{"nctId":43,"briefTitle":44,"status":152,"phases":2402,"primaryCompletion":45,"completion":2148,"start":2149,"enrollment":2150,"conditions":2403,"interventions":2404},[91],[2152],[46,826,431],{"trials":2406,"activeCount":100},[],{"trials":2408,"activeCount":100},[],{"intervention":113,"totalTrials":963,"cells":2410},{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2429,"PHASE3":2460,"PHASE4":2466,"NA":2468},{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":100},[2415,2419],{"nctId":104,"briefTitle":105,"status":106,"phases":2416,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":2417,"interventions":2418},[89],[16],[113,114,96,115],{"nctId":2420,"briefTitle":2421,"status":106,"phases":2422,"primaryCompletion":2423,"completion":2424,"start":2425,"enrollment":2426,"conditions":2427,"interventions":2428},"NCT02658929","Study of bb2121 in Multiple Myeloma",[89],"2019-07-22","2022-09-22","2015-12-22",67,[16],[113],{"trials":2430,"activeCount":100},[2431,2442,2450],{"nctId":2432,"briefTitle":2433,"status":106,"phases":2434,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":2437,"conditions":2438,"interventions":2439},"NCT03601078","An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma",[90],"2026-01-15","2018-12-13",312,[16],[113,2440,2441],"Lenalomide","Talquetamab",{"nctId":2443,"briefTitle":2444,"status":106,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":1587,"conditions":2448,"interventions":2449},"NCT03361748","Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma",[90],"2023-12-20","2017-12-13",[16],[113],{"nctId":2451,"briefTitle":2452,"status":171,"phases":2453,"primaryCompletion":2454,"completion":2454,"start":2455,"enrollment":175,"conditions":2456,"interventions":2457},"NCT04855136","Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma",[89,90],"2025-04-25","2021-06-01",[16],[2458,56,2459],"BB2121","BMS-986405",{"trials":2461,"activeCount":146,"soonestReadout":584},[2462],{"nctId":581,"briefTitle":582,"status":152,"phases":2463,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":2464,"interventions":2465},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"intervention":1084,"totalTrials":235,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2488,"PHASE4":2498,"NA":2500},{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[2478],{"nctId":2479,"briefTitle":2480,"status":106,"phases":2481,"primaryCompletion":1412,"completion":2482,"start":506,"enrollment":2483,"conditions":2484,"interventions":2486},"NCT00274456","Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer",[90],"2011-07-01",302,[2485],"Metastatic Breast Cancer",[2487,1084],"ABI-007",{"trials":2489,"activeCount":146,"soonestReadout":1711},[2490,2494],{"nctId":1708,"briefTitle":1709,"status":135,"phases":2491,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":2492,"interventions":2493},[91],[1716],[71,1718,1021,1084,1719],{"nctId":1074,"briefTitle":1075,"status":106,"phases":2495,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":2496,"interventions":2497},[91],[1082],[115,1084,131],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[],{"intervention":568,"totalTrials":190,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2517,"PHASE3":2519,"PHASE4":2525,"NA":2527},{"trials":2505,"activeCount":100},[],{"trials":2507,"activeCount":100},[2508],{"nctId":2509,"briefTitle":2510,"status":106,"phases":2511,"primaryCompletion":2512,"completion":2512,"start":2513,"enrollment":330,"conditions":2514,"interventions":2516},"NCT04933747","Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function",[89],"2023-01-23","2021-08-12",[2515],"Renal Insufficiency",[568,568],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":146,"soonestReadout":562},[2521],{"nctId":559,"briefTitle":560,"status":152,"phases":2522,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":2523,"interventions":2524},[91],[16],[241,390,258,568,568,568,241,390],{"trials":2526,"activeCount":100},[],{"trials":2528,"activeCount":100},[],{"intervention":1021,"totalTrials":190,"cells":2530},{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2539,"PHASE3":2541,"PHASE4":2547,"NA":2549},{"trials":2532,"activeCount":100},[],{"trials":2534,"activeCount":100},[2535],{"nctId":1012,"briefTitle":1013,"status":106,"phases":2536,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":963,"conditions":2537,"interventions":2538},[89],[1018],[1020,1021,131],{"trials":2540,"activeCount":100},[],{"trials":2542,"activeCount":146,"soonestReadout":1711},[2543],{"nctId":1708,"briefTitle":1709,"status":135,"phases":2544,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":2545,"interventions":2546},[91],[1716],[71,1718,1021,1084,1719],{"trials":2548,"activeCount":100},[],{"trials":2550,"activeCount":100},[],{"intervention":204,"totalTrials":146,"cells":2552},{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2565,"NA":2567},{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":146,"soonestReadout":197},[2561],{"nctId":194,"briefTitle":195,"status":135,"phases":2562,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":2563,"interventions":2564},[91],[202],[76,128,115,96,143,130,204,167],{"trials":2566,"activeCount":100},[],{"trials":2568,"activeCount":100},[],{"intervention":1718,"totalTrials":146,"cells":2570},{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2583,"NA":2585},{"trials":2572,"activeCount":100},[],{"trials":2574,"activeCount":100},[],{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":146,"soonestReadout":1711},[2579],{"nctId":1708,"briefTitle":1709,"status":135,"phases":2580,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":2581,"interventions":2582},[91],[1716],[71,1718,1021,1084,1719],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[],{"intervention":1719,"totalTrials":146,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2601,"NA":2603},{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[],{"trials":2596,"activeCount":146,"soonestReadout":1711},[2597],{"nctId":1708,"briefTitle":1709,"status":135,"phases":2598,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":2599,"interventions":2600},[91],[1716],[71,1718,1021,1084,1719],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[],{"intervention":2286,"totalTrials":146,"cells":2606},{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2613,"PHASE4":2619,"NA":2621},{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[],{"trials":2614,"activeCount":146,"soonestReadout":50},[2615],{"nctId":48,"briefTitle":49,"status":152,"phases":2616,"primaryCompletion":50,"completion":2281,"start":2282,"enrollment":2283,"conditions":2617,"interventions":2618},[91],[22],[51,2286],{"trials":2620,"activeCount":100},[],{"trials":2622,"activeCount":100},[],{"intervention":2624,"totalTrials":146,"cells":2625},"Gene-modified (GM) T cell therapy",{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2632,"PHASE4":2643,"NA":2645},{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":146,"soonestReadout":2638},[2634],{"nctId":2635,"briefTitle":2636,"status":135,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2642},"NCT03435796","Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells",[90,91],"2036-11-30","2018-07-19",1541,[32],[2624],{"trials":2644,"activeCount":100},[],{"trials":2646,"activeCount":100},[],{"intervention":66,"totalTrials":146,"cells":2648},{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2655,"PHASE4":2661,"NA":2663},{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[],{"trials":2656,"activeCount":146,"soonestReadout":65},[2657],{"nctId":63,"briefTitle":64,"status":152,"phases":2658,"primaryCompletion":65,"completion":210,"start":231,"enrollment":232,"conditions":2659,"interventions":2660},[91],[16],[66,115,114,96],{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[],{"intervention":589,"totalTrials":146,"cells":2666},{"EARLY_PHASE1":2667,"PHASE1":2669,"PHASE2":2671,"PHASE3":2673,"PHASE4":2679,"NA":2681},{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":146,"soonestReadout":584},[2675],{"nctId":581,"briefTitle":582,"status":152,"phases":2676,"primaryCompletion":584,"completion":584,"start":585,"enrollment":586,"conditions":2677,"interventions":2678},[91],[16],[113,390,257,241,258,589,115,397,398],{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[],{"intervention":431,"totalTrials":2333,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2716,"PHASE3":2762,"PHASE4":2817,"NA":2819},{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[2689,2702,2706],{"nctId":2690,"briefTitle":2691,"status":106,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":277,"conditions":2695,"interventions":2698},"NCT02309177","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel \u002F Carboplatin in Stage IIIB\u002FIV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",[89],"2018-09-12","2015-01-12",[2696,2697],"Breast Neoplasms","Pancreatic Neoplasms",[2699,2700,431,2701],"nab-Paclitaxel","Nivolumab","Carboplatin",{"nctId":2337,"briefTitle":2338,"status":106,"phases":2703,"primaryCompletion":2340,"completion":2340,"start":2341,"enrollment":379,"conditions":2704,"interventions":2705},[89],[2343],[826,431],{"nctId":2707,"briefTitle":2708,"status":171,"phases":2709,"primaryCompletion":2710,"completion":2710,"start":2711,"enrollment":146,"conditions":2712,"interventions":2714},"NCT02267707","Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia",[89],"2016-02-10","2015-05-27",[2697,2713],"Cholestasis",[2715,431],"nab-paclitaxel",{"trials":2717,"activeCount":100},[2718,2728,2737,2746,2758],{"nctId":2719,"briefTitle":2720,"status":106,"phases":2721,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":2725,"conditions":2726,"interventions":2727},"NCT02017015","Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer",[90],"2015-06-01","2016-08-03","2013-12-24",83,[2697],[2715,431],{"nctId":2729,"briefTitle":2730,"status":171,"phases":2731,"completion":2732,"start":2733,"enrollment":12,"conditions":2734,"interventions":2735},"NCT00179751","A Phase I\u002FII Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas",[89,90],"2006-08","2005-04",[2343],[372,2736],"gemcitabine",{"nctId":2738,"briefTitle":2739,"status":106,"phases":2740,"primaryCompletion":822,"completion":294,"start":2741,"enrollment":2426,"conditions":2742,"interventions":2744},"NCT00398086","Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer",[89,90],"2006-11-01",[2743],"Metastatic Pancreatic Cancer",[431,2745],"Albumin-bound paclitaxel",{"nctId":2747,"briefTitle":2748,"status":106,"phases":2749,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":2754,"interventions":2755},"NCT02301143","Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)",[90],"2017-11-21","2018-04-26","2015-04-21",107,[2697],[2699,431,2756,2757],"Chemoradiation","Capecitabine",{"nctId":421,"briefTitle":422,"status":423,"phases":2759,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":2760,"interventions":2761},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"trials":2763,"activeCount":146,"soonestReadout":45},[2764,2783,2793,2797,2801],{"nctId":2765,"briefTitle":2766,"status":106,"phases":2767,"primaryCompletion":2768,"completion":2768,"start":2769,"enrollment":2770,"conditions":2771,"interventions":2782},"NCT01881230","Evaluate Risk\u002FBenefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)",[90,91],"2016-10-28","2013-09-26",191,[2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2485],"Breast Tumor","Breast Cancer","Cancer of the Breast","Estrogen Receptor- Negative Breast Cancer","HER2- Negative Breast Cancer","Progesterone Receptor- Negative Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer","Triple-negative Breast Cancer","Triple-negative Metastatic Breast Cancer",[2699,2701,431],{"nctId":2784,"briefTitle":2785,"status":106,"phases":2786,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":2790,"conditions":2791,"interventions":2792},"NCT00844649","Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas",[91],"2012-09-17","2013-04-09","2009-03-01",861,[2743],[2745,431],{"nctId":775,"briefTitle":776,"status":106,"phases":2794,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":2795,"interventions":2796},[90,91],[370],[115,431,784,128,785],{"nctId":43,"briefTitle":44,"status":152,"phases":2798,"primaryCompletion":45,"completion":2148,"start":2149,"enrollment":2150,"conditions":2799,"interventions":2800},[91],[2152],[46,826,431],{"nctId":2802,"briefTitle":2803,"status":106,"phases":2804,"primaryCompletion":2805,"completion":2805,"start":2806,"enrollment":2807,"conditions":2808,"interventions":2816},"NCT01964430","Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the \"Apact\" Study)",[91],"2022-06-30","2014-03-28",866,[2697,2809,2810,32,2811,2812,2813,2814,431,2815],"Digestive System Neoplasms","Neoplasms by Site","Endocrine Gland Neoplasms","Pancreatic Diseases","Digestive System Diseases","Endocrine System Diseases","Antimetabolites, Antineoplastic",[2699,431],{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[2821],{"nctId":2822,"briefTitle":2823,"status":106,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":1565,"conditions":2827,"interventions":2828},"NCT02555813","Treatment of Pancreatic Cancer With Abraxane",[],"2020-09-07","2015-05-08",[2743],[2829,431],"Abraxane",{"intervention":56,"totalTrials":2333,"cells":2831},{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2897,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":146,"soonestReadout":137},[2836,2845,2849,2857,2865,2873,2881,2885],{"nctId":2837,"briefTitle":2838,"status":106,"phases":2839,"primaryCompletion":2840,"completion":2840,"start":2841,"enrollment":379,"conditions":2842,"interventions":2844},"NCT02820935","Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects",[89],"2016-09","2016-07",[2843],"Pharmacokinetics",[56,1108,1107],{"nctId":653,"briefTitle":654,"status":171,"phases":2846,"primaryCompletion":656,"completion":657,"start":658,"enrollment":407,"conditions":2847,"interventions":2848},[89],[660],[56,128,662],{"nctId":2850,"briefTitle":2851,"status":106,"phases":2852,"primaryCompletion":2291,"completion":2291,"start":2853,"enrollment":684,"conditions":2854,"interventions":2856},"NCT03824678","Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects",[89],"2019-02-13",[2855,19],"Hepatic Impairment",[56],{"nctId":2858,"briefTitle":2859,"status":106,"phases":2860,"primaryCompletion":378,"completion":378,"start":2861,"enrollment":2862,"conditions":2863,"interventions":2864},"NCT02034773","3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule",[89],"2013-05",64,[19],[56,56,56,56,56,56,56],{"nctId":2866,"briefTitle":2867,"status":106,"phases":2868,"primaryCompletion":2869,"completion":2869,"start":2870,"enrollment":963,"conditions":2871,"interventions":2872},"NCT03294603","Radiolabeled Study of CC-220 in Healthy Male Subjects",[89],"2017-10-16","2017-09-11",[29],[56],{"nctId":2874,"briefTitle":2875,"status":106,"phases":2876,"primaryCompletion":2877,"completion":2877,"start":2878,"enrollment":25,"conditions":2879,"interventions":2880},"NCT03135509","A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects",[89],"2017-06-28","2017-05-24",[19],[56],{"nctId":133,"briefTitle":134,"status":135,"phases":2882,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":2883,"interventions":2884},[89],[141],[56,128,96,143,130,131,144,145,128],{"nctId":2886,"briefTitle":2887,"status":106,"phases":2888,"primaryCompletion":2889,"completion":2889,"start":1887,"enrollment":339,"conditions":2890,"interventions":2891},"NCT01733875","2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects",[89],"2013-10-09",[1226],[2892,2893,2894,2895,2896,56,56,56],"CC-220 0.03 mg","CC-220 0.1 mg","CC-220 0.3 mg","CC-220 1 mg","CC-220 2 mg",{"trials":2898,"activeCount":146,"soonestReadout":55},[2899,2909,2918,2922,2931,2935],{"nctId":2900,"briefTitle":2901,"status":106,"phases":2902,"primaryCompletion":2903,"completion":2903,"start":2904,"enrollment":2905,"conditions":2906,"interventions":2908},"NCT03161483","A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus",[90],"2021-08-03","2017-08-31",289,[2907],"Lupus Erythematosus, Systemic",[56],{"nctId":2910,"briefTitle":2911,"status":106,"phases":2912,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":2915,"interventions":2916},"NCT03310619","A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed\u002FRefractory B-cell Malignancies",[89,90],"2023-02-15","2017-12-20",[24,124,125],[159,189,638,729,56,2917,2700,144],"Relatlimab",{"nctId":2451,"briefTitle":2452,"status":171,"phases":2919,"primaryCompletion":2454,"completion":2454,"start":2455,"enrollment":175,"conditions":2920,"interventions":2921},[89,90],[16],[2458,56,2459],{"nctId":2923,"briefTitle":2924,"status":106,"phases":2925,"primaryCompletion":2926,"completion":2926,"start":2927,"enrollment":1689,"conditions":2928,"interventions":2930},"NCT02185040","A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.",[90],"2018-09-25","2014-09-16",[2929],"Systemic Lupus Erythematosus",[56,56,56,56],{"nctId":421,"briefTitle":422,"status":423,"phases":2932,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":2933,"interventions":2934},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"nctId":53,"briefTitle":54,"status":152,"phases":2936,"primaryCompletion":55,"completion":445,"start":446,"enrollment":447,"conditions":2937,"interventions":2938},[89,90],[16],[56,241,390,258,397,450,258,451],{"trials":2940,"activeCount":100},[],{"trials":2942,"activeCount":100},[],{"trials":2944,"activeCount":100},[],{"intervention":144,"totalTrials":306,"cells":2946},{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2963,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":146,"soonestReadout":137},[2951,2959],{"nctId":2952,"briefTitle":2953,"status":106,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":25,"conditions":2957,"interventions":2958},"NCT04434196","A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[89],"2024-05-21","2020-12-21",[24],[144,662],{"nctId":133,"briefTitle":134,"status":135,"phases":2960,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":2961,"interventions":2962},[89],[141],[56,128,96,143,130,131,144,145,128],{"trials":2964,"activeCount":146,"soonestReadout":711},[2965,2969],{"nctId":708,"briefTitle":709,"status":152,"phases":2966,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":2967,"interventions":2968},[89,90],[24],[144,128,662,430,717],{"nctId":2910,"briefTitle":2911,"status":106,"phases":2970,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":2971,"interventions":2972},[89,90],[24,124,125],[159,189,638,729,56,2917,2700,144],{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":100},[],{"trials":2978,"activeCount":100},[],{"intervention":2980,"totalTrials":306,"cells":2981},"BMS-986368",{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":3003,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":2983,"activeCount":100},[],{"trials":2985,"activeCount":100},[2986,2995],{"nctId":2987,"briefTitle":2988,"status":106,"phases":2989,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":823,"conditions":2992,"interventions":2993},"NCT06170723","A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants",[89],"2024-05-25","2024-03-18",[1700],[2980,1107,2994],"Famotidine",{"nctId":2996,"briefTitle":2997,"status":106,"phases":2998,"primaryCompletion":2999,"completion":2999,"start":3000,"enrollment":440,"conditions":3001,"interventions":3002},"NCT06411730","A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity",[89],"2024-10-28","2024-05-31",[1700],[2980],{"trials":3004,"activeCount":190,"soonestReadout":3021},[3005,3017],{"nctId":3006,"briefTitle":3007,"status":135,"phases":3008,"primaryCompletion":3009,"completion":3010,"start":3011,"enrollment":3012,"conditions":3013,"interventions":3016},"NCT06808984","Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease",[90],"2027-11-26","2028-01-07","2025-06-09",120,[3014,3015],"Agitation","Alzheimer Disease",[2980],{"nctId":3018,"briefTitle":3019,"status":135,"phases":3020,"primaryCompletion":3021,"completion":3022,"start":3023,"enrollment":360,"conditions":3024,"interventions":3026},"NCT06782490","A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity",[90],"2027-05-26","2027-06-09","2025-06-05",[3025],"Multiple Sclerosis Spasticity",[2980],{"trials":3028,"activeCount":100},[],{"trials":3030,"activeCount":100},[],{"trials":3032,"activeCount":100},[],{"intervention":159,"totalTrials":3034,"cells":3035},5,{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3063,"PHASE4":3074,"NA":3076},{"trials":3037,"activeCount":100},[],{"trials":3039,"activeCount":100},[],{"trials":3041,"activeCount":146,"soonestReadout":154},[3042,3046,3050,3054],{"nctId":150,"briefTitle":151,"status":152,"phases":3043,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":3044,"interventions":3045},[90],[24],[114,96,159],{"nctId":169,"briefTitle":170,"status":171,"phases":3047,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":3048,"interventions":3049},[89,90],[177,24],[159,179,114,96],{"nctId":2910,"briefTitle":2911,"status":106,"phases":3051,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":3052,"interventions":3053},[89,90],[24,124,125],[159,189,638,729,56,2917,2700,144],{"nctId":3055,"briefTitle":3056,"status":106,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":3060,"conditions":3061,"interventions":3062},"NCT03484702","Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma",[90],"2023-12-15","2018-06-05",113,[24],[159],{"trials":3064,"activeCount":100},[3065],{"nctId":3066,"briefTitle":3067,"status":106,"phases":3068,"primaryCompletion":3069,"completion":3069,"start":3070,"enrollment":1286,"conditions":3071,"interventions":3072},"NCT03575351","A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas",[91],"2023-10-23","2018-10-23",[24],[3073,159],"Standard of Care",{"trials":3075,"activeCount":100},[],{"trials":3077,"activeCount":100},[],{"intervention":662,"totalTrials":3034,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3102,"PHASE3":3117,"PHASE4":3119,"NA":3121},{"trials":3081,"activeCount":100},[],{"trials":3083,"activeCount":100},[3084,3088,3092],{"nctId":653,"briefTitle":654,"status":171,"phases":3085,"primaryCompletion":656,"completion":657,"start":658,"enrollment":407,"conditions":3086,"interventions":3087},[89],[660],[56,128,662],{"nctId":2952,"briefTitle":2953,"status":106,"phases":3089,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":25,"conditions":3090,"interventions":3091},[89],[24],[144,662],{"nctId":3093,"briefTitle":3094,"status":106,"phases":3095,"primaryCompletion":3096,"completion":3097,"start":3098,"enrollment":3099,"conditions":3100,"interventions":3101},"NCT02417285","A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed\u002FRefractory DLBCL and iNHL.",[89],"2019-05-27","2023-09-28","2015-05-22",75,[124,24],[662,638],{"trials":3103,"activeCount":146,"soonestReadout":711},[3104,3113],{"nctId":3105,"briefTitle":3106,"status":106,"phases":3107,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3111,"interventions":3112},"NCT02406742","A Phase 1\u002F2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[89,90],"2020-07-07","2015-07-27",47,[727],[638,729,662],{"nctId":708,"briefTitle":709,"status":152,"phases":3114,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3115,"interventions":3116},[89,90],[24],[144,128,662,430,717],{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"intervention":81,"totalTrials":3034,"cells":3124},{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3153,"PHASE3":3163,"PHASE4":3165,"NA":3167},{"trials":3126,"activeCount":100},[],{"trials":3128,"activeCount":100},[3129,3137,3145],{"nctId":3130,"briefTitle":3131,"status":106,"phases":3132,"primaryCompletion":3133,"completion":3133,"start":3134,"enrollment":440,"conditions":3135,"interventions":3136},"NCT03803644","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects",[89],"2019-05-28","2018-12-21",[29],[81,81],{"nctId":3138,"briefTitle":3139,"status":106,"phases":3140,"primaryCompletion":3141,"completion":3141,"start":3142,"enrollment":684,"conditions":3143,"interventions":3144},"NCT04839809","A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants",[89],"2021-10-08","2021-01-19",[19],[81],{"nctId":3146,"briefTitle":3147,"status":106,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":9,"conditions":3151,"interventions":3152},"NCT04211545","Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects",[89],"2019-12-26","2019-10-21",[29],[1702,81],{"trials":3154,"activeCount":146,"soonestReadout":80},[3155,3159],{"nctId":354,"briefTitle":355,"status":171,"phases":3156,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":3157,"interventions":3158},[89,90],[16],[81,241],{"nctId":78,"briefTitle":79,"status":152,"phases":3160,"primaryCompletion":80,"completion":80,"start":393,"enrollment":394,"conditions":3161,"interventions":3162},[89,90],[16],[81,258,241,390,397,398,399,397],{"trials":3164,"activeCount":100},[],{"trials":3166,"activeCount":100},[],{"trials":3168,"activeCount":100},[],{"intervention":430,"totalTrials":190,"cells":3170},{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3172,"activeCount":100},[],{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":146,"soonestReadout":711},[3177,3181],{"nctId":708,"briefTitle":709,"status":152,"phases":3178,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3179,"interventions":3180},[89,90],[24],[144,128,662,430,717],{"nctId":421,"briefTitle":422,"status":423,"phases":3182,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":3183,"interventions":3184},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"intervention":717,"totalTrials":146,"cells":3192},{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3197,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":146,"soonestReadout":711},[3199],{"nctId":708,"briefTitle":709,"status":152,"phases":3200,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":3201,"interventions":3202},[89,90],[24],[144,128,662,430,717],{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[],{"trials":3208,"activeCount":100},[],{"intervention":41,"totalTrials":146,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3221,"PHASE4":3223,"NA":3225},{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":146,"soonestReadout":40},[3217],{"nctId":38,"briefTitle":39,"status":152,"phases":3218,"primaryCompletion":40,"completion":2110,"start":2111,"enrollment":2112,"conditions":3219,"interventions":3220},[89,90],[27],[41,46,2115],{"trials":3222,"activeCount":100},[],{"trials":3224,"activeCount":100},[],{"trials":3226,"activeCount":100},[],{"intervention":399,"totalTrials":146,"cells":3228},{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3239,"PHASE4":3241,"NA":3243},{"trials":3230,"activeCount":100},[],{"trials":3232,"activeCount":100},[],{"trials":3234,"activeCount":146,"soonestReadout":80},[3235],{"nctId":78,"briefTitle":79,"status":152,"phases":3236,"primaryCompletion":80,"completion":80,"start":393,"enrollment":394,"conditions":3237,"interventions":3238},[89,90],[16],[81,258,241,390,397,398,399,397],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"trials":3244,"activeCount":100},[],{"intervention":410,"totalTrials":146,"cells":3246},{"EARLY_PHASE1":3247,"PHASE1":3249,"PHASE2":3251,"PHASE3":3257,"PHASE4":3259,"NA":3261},{"trials":3248,"activeCount":100},[],{"trials":3250,"activeCount":100},[],{"trials":3252,"activeCount":146,"soonestReadout":404},[3253],{"nctId":401,"briefTitle":402,"status":135,"phases":3254,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":3255,"interventions":3256},[89,90],[16],[410,310,241],{"trials":3258,"activeCount":100},[],{"trials":3260,"activeCount":100},[],{"trials":3262,"activeCount":100},[],{"intervention":450,"totalTrials":146,"cells":3264},{"EARLY_PHASE1":3265,"PHASE1":3267,"PHASE2":3269,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":146,"soonestReadout":55},[3271],{"nctId":53,"briefTitle":54,"status":152,"phases":3272,"primaryCompletion":55,"completion":445,"start":446,"enrollment":447,"conditions":3273,"interventions":3274},[89,90],[16],[56,241,390,258,397,450,258,451],{"trials":3276,"activeCount":100},[],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"intervention":451,"totalTrials":146,"cells":3282},{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3287,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3284,"activeCount":100},[],{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":146,"soonestReadout":55},[3289],{"nctId":53,"briefTitle":54,"status":152,"phases":3290,"primaryCompletion":55,"completion":445,"start":446,"enrollment":447,"conditions":3291,"interventions":3292},[89,90],[16],[56,241,390,258,397,450,258,451],{"trials":3294,"activeCount":100},[],{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[],{"intervention":2115,"totalTrials":3034,"cells":3300},{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3321,"PHASE3":3327,"PHASE4":3333,"NA":3335},{"trials":3302,"activeCount":100},[],{"trials":3304,"activeCount":100},[3305,3313],{"nctId":3306,"briefTitle":3307,"status":106,"phases":3308,"primaryCompletion":3309,"completion":3309,"start":3310,"enrollment":862,"conditions":3311,"interventions":3312},"NCT02443168","Radiolabeled Study of AG-221 in Healthy Male Subjects.",[89],"2015-07-21","2015-05-14",[19],[2115],{"nctId":3314,"briefTitle":3315,"status":106,"phases":3316,"primaryCompletion":3317,"completion":3109,"start":3318,"enrollment":407,"conditions":3319,"interventions":3320},"NCT02387866","PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects",[89],"2015-05-21","2015-03-02",[1226],[2115],{"trials":3322,"activeCount":146,"soonestReadout":40},[3323],{"nctId":38,"briefTitle":39,"status":152,"phases":3324,"primaryCompletion":40,"completion":2110,"start":2111,"enrollment":2112,"conditions":3325,"interventions":3326},[89,90],[27],[41,46,2115],{"trials":3328,"activeCount":100},[3329],{"nctId":2168,"briefTitle":2169,"status":106,"phases":3330,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":3331,"interventions":3332},[91],[1401,2176],[2115,46,2178,2179],{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[3337],{"nctId":3338,"briefTitle":3339,"status":3340,"phases":3341,"conditions":3342,"interventions":3343},"NCT03723057","Expanded Access for AG-221","NO_LONGER_AVAILABLE",[],[1269],[2115],{"intervention":145,"totalTrials":190,"cells":3345},{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3354,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3347,"activeCount":100},[],{"trials":3349,"activeCount":146,"soonestReadout":137},[3350],{"nctId":133,"briefTitle":134,"status":135,"phases":3351,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":3352,"interventions":3353},[89],[141],[56,128,96,143,130,131,144,145,128],{"trials":3355,"activeCount":100},[3356],{"nctId":421,"briefTitle":422,"status":423,"phases":3357,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":3358,"interventions":3359},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"trials":3361,"activeCount":100},[],{"trials":3363,"activeCount":100},[],{"trials":3365,"activeCount":100},[],{"intervention":1107,"totalTrials":862,"cells":3367},{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3369,"activeCount":100},[],{"trials":3371,"activeCount":146,"soonestReadout":70},[3372,3376,3380,3389,3397,3401,3412,3416],{"nctId":1100,"briefTitle":1101,"status":106,"phases":3373,"primaryCompletion":1103,"completion":1103,"start":1104,"enrollment":699,"conditions":3374,"interventions":3375},[89],[19],[1107,1108,76],{"nctId":2837,"briefTitle":2838,"status":106,"phases":3377,"primaryCompletion":2840,"completion":2840,"start":2841,"enrollment":379,"conditions":3378,"interventions":3379},[89],[2843],[56,1108,1107],{"nctId":3381,"briefTitle":3382,"status":106,"phases":3383,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":3386,"conditions":3387,"interventions":3388},"NCT03340662","Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122",[89],"2018-01-27","2017-11-09",81,[29],[638,1107,1893,1108],{"nctId":3390,"briefTitle":3391,"status":171,"phases":3392,"primaryCompletion":2172,"completion":2172,"start":3393,"enrollment":3099,"conditions":3394,"interventions":3395},"NCT02875223","A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and\u002For Refractory Solid Tumors and Non-Hodgkin's Lymphomas",[89],"2016-08-31",[24,32],[1020,3396,1107],"Rifampicin",{"nctId":2987,"briefTitle":2988,"status":106,"phases":3398,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":823,"conditions":3399,"interventions":3400},[89],[1700],[2980,1107,2994],{"nctId":3402,"briefTitle":3403,"status":106,"phases":3404,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":3408,"interventions":3409},"NCT03624959","Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and\u002For CYP3A",[89],"2018-08-10","2018-06-20",100,[29],[3410,3411,1107,1108],"Ozanimod","Gemfibrozil",{"nctId":68,"briefTitle":69,"status":135,"phases":3413,"primaryCompletion":70,"completion":70,"start":1688,"enrollment":1689,"conditions":3414,"interventions":3415},[89],[19],[71,1107,1108],{"nctId":3417,"briefTitle":3418,"status":106,"phases":3419,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":3423,"interventions":3424},"NCT04268394","A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677",[89],"2021-06-02","2020-03-13",48,[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],"CC-99677","Methotrexate","Sulfasalazine","Midazolam","Digoxin","Metformin","Rosuvastatin",{"trials":3433,"activeCount":100},[],{"trials":3435,"activeCount":100},[],{"trials":3437,"activeCount":100},[],{"trials":3439,"activeCount":100},[],{"intervention":1108,"totalTrials":862,"cells":3441},{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3485,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3443,"activeCount":100},[],{"trials":3445,"activeCount":146,"soonestReadout":70},[3446,3450,3454,3458,3462,3466,3470,3481],{"nctId":1100,"briefTitle":1101,"status":106,"phases":3447,"primaryCompletion":1103,"completion":1103,"start":1104,"enrollment":699,"conditions":3448,"interventions":3449},[89],[19],[1107,1108,76],{"nctId":2837,"briefTitle":2838,"status":106,"phases":3451,"primaryCompletion":2840,"completion":2840,"start":2841,"enrollment":379,"conditions":3452,"interventions":3453},[89],[2843],[56,1108,1107],{"nctId":3381,"briefTitle":3382,"status":106,"phases":3455,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":3386,"conditions":3456,"interventions":3457},[89],[29],[638,1107,1893,1108],{"nctId":3402,"briefTitle":3403,"status":106,"phases":3459,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":3460,"interventions":3461},[89],[29],[3410,3411,1107,1108],{"nctId":2328,"briefTitle":2329,"status":106,"phases":3463,"primaryCompletion":2331,"completion":2332,"start":2322,"enrollment":2333,"conditions":3464,"interventions":3465},[89],[2324,2325],[826,1108],{"nctId":68,"briefTitle":69,"status":135,"phases":3467,"primaryCompletion":70,"completion":70,"start":1688,"enrollment":1689,"conditions":3468,"interventions":3469},[89],[19],[71,1107,1108],{"nctId":3471,"briefTitle":3472,"status":106,"phases":3473,"primaryCompletion":3474,"completion":3475,"start":3476,"enrollment":823,"conditions":3477,"interventions":3478},"NCT03983239","Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects",[89],"2019-11-02","2019-11-06","2019-06-21",[19],[3479,1108,3480],"Fedratinib","Efavirenz",{"nctId":3417,"briefTitle":3418,"status":106,"phases":3482,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":3483,"interventions":3484},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"trials":3486,"activeCount":100},[],{"trials":3488,"activeCount":100},[],{"trials":3490,"activeCount":100},[],{"trials":3492,"activeCount":100},[],{"intervention":2701,"totalTrials":35,"cells":3494},{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3536,"PHASE3":3567,"PHASE4":3596,"NA":3613},{"trials":3496,"activeCount":100},[],{"trials":3498,"activeCount":100},[3499,3517,3521,3530],{"nctId":3500,"briefTitle":3501,"status":106,"phases":3502,"primaryCompletion":3503,"completion":3503,"start":3504,"enrollment":3505,"conditions":3506,"interventions":3515},"NCT01478685","A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors",[89],"2015-11-17","2011-11-29",169,[3507,3508,3509,3510,3511,3512,3513,3514],"Urinary Bladder Neoplasms","Carcinoma, Transitional Cell","Ovarian Neoplasms","Fallopian Tube Neoplasms","Peritoneal Neoplasms","Carcinoma, Non-Small-Cell Lung","Carcinoma, Pancreatic Ductal","Tumor Virus Infections",[3516,2701,2487],"CC-486",{"nctId":2690,"briefTitle":2691,"status":106,"phases":3518,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":277,"conditions":3519,"interventions":3520},[89],[2696,2697],[2699,2700,431,2701],{"nctId":3522,"briefTitle":3523,"status":106,"phases":3524,"primaryCompletion":3525,"completion":3525,"start":3526,"enrollment":164,"conditions":3527,"interventions":3529},"NCT03850067","A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer",[89],"2024-07-16","2019-03-12",[3528],"Small Cell Lung Carcinoma",[1020,432,2701,785,2700],{"nctId":3531,"briefTitle":3532,"status":171,"phases":3533,"primaryCompletion":1921,"completion":1921,"start":2741,"enrollment":963,"conditions":3534,"interventions":3535},"NCT00407407","ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma",[89],[3510,3511,3509],[2487,2701],{"trials":3537,"activeCount":100},[3538,3546,3554],{"nctId":3539,"briefTitle":3540,"status":106,"phases":3541,"primaryCompletion":507,"completion":507,"start":3542,"enrollment":823,"conditions":3543,"interventions":3544},"NCT00093145","Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer",[90],"2004-06-01",[2773],[2745,2701,3545],"Herceptin®",{"nctId":3547,"briefTitle":3548,"status":106,"phases":3549,"primaryCompletion":3550,"completion":3550,"start":3551,"enrollment":684,"conditions":3552,"interventions":3553},"NCT02289456","Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2",[90],"2017-02-22","2015-04-28",[3512],[2699,2701],{"nctId":3555,"briefTitle":3556,"status":106,"phases":3557,"primaryCompletion":3558,"completion":3559,"start":3560,"enrollment":3561,"conditions":3562,"interventions":3564},"NCT01836029","Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[90],"2016-04-13","2016-09-19","2013-10-14",195,[3563],"Carcinoma, Squamous Cell of Head and Neck",[3565,2701,432,3566],"VTX-2337","5-fluorouracil",{"trials":3568,"activeCount":100},[3569,3580,3584],{"nctId":3570,"briefTitle":3571,"status":106,"phases":3572,"primaryCompletion":3573,"completion":3574,"start":3575,"enrollment":3576,"conditions":3577,"interventions":3579},"NCT02027428","Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB \u002F IV Squamous Cell Non-small Cell Lung Cancer",[91],"2017-09-15","2019-08-01","2014-02-11",427,[3578],"Squamous Cell Carcinoma, Non-Small-Cell Lung",[2829,2701,2829,2829,2701],{"nctId":2765,"briefTitle":2766,"status":106,"phases":3581,"primaryCompletion":2768,"completion":2768,"start":2769,"enrollment":2770,"conditions":3582,"interventions":3583},[90,91],[2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2485],[2699,2701,431],{"nctId":3585,"briefTitle":3586,"status":106,"phases":3587,"primaryCompletion":3588,"completion":3589,"start":3590,"enrollment":3591,"conditions":3592,"interventions":3594},"NCT00540514","Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer",[91],"2009-10-01","2013-02-01","2007-11-01",1052,[3593],"Non-Small Cell Lung Carcinoma",[2745,3595,2701],"Paclitaxel",{"trials":3597,"activeCount":100},[3598],{"nctId":3599,"briefTitle":3600,"status":106,"phases":3601,"primaryCompletion":3602,"completion":3602,"start":3603,"enrollment":3604,"conditions":3605,"interventions":3612},"NCT02151149","Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly",[92],"2017-07-14","2014-06-09",143,[3606,3607,3608,3609,3610,3611],"Non-Small Cell Lung Cancer","Carcinoma","Squamous Cell Carcinoma","Adenocarcinoma","Carcinoma, Large Cell","Lung Neoplasm",[2715,2701],{"trials":3614,"activeCount":100},[],{"intervention":372,"totalTrials":25,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3646,"PHASE3":3726,"PHASE4":3747,"NA":3749},{"trials":3618,"activeCount":100},[],{"trials":3620,"activeCount":100},[3621,3628,3637],{"nctId":3622,"briefTitle":3623,"status":171,"phases":3624,"completion":498,"start":517,"enrollment":684,"conditions":3625,"interventions":3626},"NCT00179699","Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer",[89],[3606],[372,3627],"pemetrexed",{"nctId":3629,"briefTitle":3630,"status":106,"phases":3631,"primaryCompletion":3632,"completion":3632,"start":3633,"enrollment":1197,"conditions":3634,"interventions":3636},"NCT00179608","Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy",[89],"2007-06-01","2005-09-01",[3635],"Malignant Melanoma",[372],{"nctId":3638,"briefTitle":3639,"status":106,"phases":3640,"primaryCompletion":3641,"completion":3641,"start":3642,"enrollment":3643,"conditions":3644,"interventions":3645},"NCT00091624","A Study of Doxil, Vincristine and Decadron (DVd) +\u002F CC-5013 in Relapsed Refractory Multiple Myeloma (MM)",[89],"2007-09","2003-03",77,[16],[372],{"trials":3647,"activeCount":100},[3648,3657,3667,3675,3679,3687,3696,3700,3709,3718],{"nctId":3649,"briefTitle":3650,"status":106,"phases":3651,"primaryCompletion":3652,"completion":3653,"start":3654,"enrollment":527,"conditions":3655,"interventions":3656},"NCT00044382","Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome",[90],"2007-01-01","2007-01-30","2002-02-01",[34],[372],{"nctId":3658,"briefTitle":3659,"status":106,"phases":3660,"primaryCompletion":3661,"completion":3662,"start":3663,"enrollment":3664,"conditions":3665,"interventions":3666},"NCT00065351","Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma",[90],"2006-10-01","2007-03-01","2003-07-01",222,[16],[372],{"nctId":3668,"briefTitle":3669,"status":106,"phases":3670,"completion":3671,"start":3672,"enrollment":684,"conditions":3673,"interventions":3674},"NCT00179686","A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer",[90],"2006-07","2005-03",[3606],[372],{"nctId":364,"briefTitle":365,"status":171,"phases":3676,"primaryCompletion":367,"completion":367,"start":368,"enrollment":330,"conditions":3677,"interventions":3678},[90],[370],[372,299],{"nctId":3680,"briefTitle":3681,"status":106,"phases":3682,"completion":498,"start":2733,"enrollment":669,"conditions":3683,"interventions":3685},"NCT00179712","Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma",[89,90],[3684],"Ovarian Cancer",[372,3686],"topotecan",{"nctId":3688,"briefTitle":3689,"status":106,"phases":3690,"primaryCompletion":1060,"completion":3691,"start":3692,"enrollment":3693,"conditions":3694,"interventions":3695},"NCT00064974","Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes",[90],"2007-02","2003-06",215,[22],[372],{"nctId":2729,"briefTitle":2730,"status":171,"phases":3697,"completion":2732,"start":2733,"enrollment":12,"conditions":3698,"interventions":3699},[89,90],[2343],[372,2736],{"nctId":3701,"briefTitle":3702,"status":171,"phases":3703,"completion":3704,"start":3705,"enrollment":669,"conditions":3706,"interventions":3707},"NCT00179725","Phase I\u002FII Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma",[89,90],"2007-06","2005-11",[3684],[372,3708],"liposomal doxorubicin",{"nctId":3710,"briefTitle":3711,"status":106,"phases":3712,"completion":3713,"start":3714,"enrollment":164,"conditions":3715,"interventions":3717},"NCT00446433","A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease",[90],"2003-12","2002-03",[3716],"Crohn's Disease",[372],{"nctId":3719,"briefTitle":3720,"status":106,"phases":3721,"primaryCompletion":3722,"completion":3722,"start":3723,"enrollment":3407,"conditions":3724,"interventions":3725},"NCT00051116","A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma",[90],"2006-10","2002-05",[16],[372],{"trials":3727,"activeCount":100},[3728,3732,3736],{"nctId":503,"briefTitle":504,"status":106,"phases":3729,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":3730,"interventions":3731},[91],[16],[372,241],{"nctId":1539,"briefTitle":1540,"status":106,"phases":3733,"primaryCompletion":1542,"completion":1542,"start":1543,"enrollment":1544,"conditions":3734,"interventions":3735},[91],[16],[372,115],{"nctId":3737,"briefTitle":3738,"status":106,"phases":3739,"completion":3740,"start":3741,"enrollment":3742,"conditions":3743,"interventions":3746},"NCT00057616","Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.",[91],"2005-07-15","2002-10-01",274,[3744,3745],"Melanoma","Neoplasm Metastasis",[372],{"trials":3748,"activeCount":100},[],{"trials":3750,"activeCount":100},[],{"intervention":127,"totalTrials":862,"cells":3752},{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3802,"PHASE3":3812,"PHASE4":3834,"NA":3836},{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[3757,3767,3771,3778,3789],{"nctId":3758,"briefTitle":3759,"status":106,"phases":3760,"primaryCompletion":3761,"completion":3762,"start":3763,"enrollment":254,"conditions":3764,"interventions":3765},"NCT01519011","Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine",[89],"2012-12-31","2015-05-12","2012-02-07",[22,2061,27],[3766,3766],"oral azacitidine",{"nctId":117,"briefTitle":118,"status":106,"phases":3768,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":3769,"interventions":3770},[89],[124,125],[127,128,129,130,131],{"nctId":3772,"briefTitle":3773,"status":106,"phases":3774,"primaryCompletion":1223,"completion":1223,"start":1900,"enrollment":3034,"conditions":3775,"interventions":3776},"NCT01571648","A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes",[89],[22],[3777],"Oral azacitidine",{"nctId":3779,"briefTitle":3780,"status":171,"phases":3781,"primaryCompletion":3782,"completion":3782,"start":3783,"enrollment":190,"conditions":3784,"interventions":3788},"NCT01908387","Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms",[89],"2015-07","2013-07",[22,3785,1269,16,3786,3787],"Chronic Myelomonocytic Leukemia","Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[3777],{"nctId":3790,"briefTitle":3791,"status":106,"phases":3792,"primaryCompletion":3793,"completion":3794,"start":3795,"enrollment":3796,"conditions":3797,"interventions":3800},"NCT00528983","Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia",[89],"2013-07-31","2016-04-05","2007-09-11",133,[2265,3798,3799],"Chronic Myelomonocytic Leukemia (CMML)","Acute Myelogenous Leukemia (AML)",[3801,127,127],"Subcutaneous (SC) Azacitidine",{"trials":3803,"activeCount":100},[3804],{"nctId":3805,"briefTitle":3806,"status":106,"phases":3807,"primaryCompletion":3808,"completion":1929,"start":3809,"enrollment":339,"conditions":3810,"interventions":3811},"NCT02281084","Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes",[90],"2019-06-19","2015-07-06",[22],[127,189],{"trials":3813,"activeCount":100},[3814,3824],{"nctId":3815,"briefTitle":3816,"status":106,"phases":3817,"primaryCompletion":3818,"completion":3819,"start":3820,"enrollment":3821,"conditions":3822,"interventions":3823},"NCT01566695","The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)",[91],"2019-01-25","2023-12-21","2013-04-26",216,[34],[127],{"nctId":3825,"briefTitle":3826,"status":106,"phases":3827,"primaryCompletion":3828,"completion":3829,"start":3830,"enrollment":3831,"conditions":3832,"interventions":3833},"NCT01757535","Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission",[91],"2019-07-15","2024-06-18","2013-04-24",472,[27],[127],{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":100},[],{"intervention":3839,"totalTrials":1953,"cells":3840},"GED-0301",{"EARLY_PHASE1":3841,"PHASE1":3843,"PHASE2":3864,"PHASE3":3884,"PHASE4":3912,"NA":3914},{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[3845,3855],{"nctId":3846,"briefTitle":3847,"status":106,"phases":3848,"primaryCompletion":3849,"completion":3850,"start":3851,"enrollment":2862,"conditions":3852,"interventions":3854},"NCT02367183","A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease",[89],"2016-09-06","2017-12-14","2015-04-08",[3853],"Crohn Disease",[3839],{"nctId":3856,"briefTitle":3857,"status":106,"phases":3858,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":877,"conditions":3861,"interventions":3862},"NCT02957474","A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects",[89],"2016-12","2016-11",[19],[3839,3863],"Omeprazole",{"trials":3865,"activeCount":100},[3866,3876],{"nctId":3867,"briefTitle":3868,"status":106,"phases":3869,"primaryCompletion":3849,"completion":3870,"start":3871,"enrollment":3872,"conditions":3873,"interventions":3875},"NCT02601300","An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis",[90],"2017-08-08","2015-12-14",41,[3874],"Colitis, Ulcerative",[3839],{"nctId":3877,"briefTitle":3878,"status":171,"phases":3879,"primaryCompletion":3880,"completion":3385,"start":3881,"enrollment":877,"conditions":3882,"interventions":3883},"NCT02685683","Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease",[90],"2017-09-25","2016-04-04",[3716],[3839],{"trials":3885,"activeCount":100},[3886,3894,3903],{"nctId":3887,"briefTitle":3888,"status":171,"phases":3889,"primaryCompletion":3890,"completion":3890,"start":2185,"enrollment":3891,"conditions":3892,"interventions":3893},"NCT02641392","A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease",[91],"2018-01-04",310,[3716],[3839],{"nctId":3895,"briefTitle":3896,"status":423,"phases":3897,"primaryCompletion":3898,"completion":3899,"start":3900,"enrollment":100,"conditions":3901,"interventions":3902},"NCT02974322","A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease",[91],"2018-11-17","2018-12-24","2017-12-01",[3853],[3839],{"nctId":3904,"briefTitle":3905,"status":171,"phases":3906,"primaryCompletion":3907,"completion":3907,"start":3908,"enrollment":3909,"conditions":3910,"interventions":3911},"NCT02596893","Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease",[91],"2018-01-05","2015-12-08",701,[3853],[3839],{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":100},[],{"intervention":3917,"totalTrials":963,"cells":3918},"RPC1063",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3939,"PHASE3":3951,"PHASE4":3982,"NA":3984},{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[3923,3932],{"nctId":3924,"briefTitle":3925,"status":106,"phases":3926,"primaryCompletion":3927,"completion":3927,"start":3928,"enrollment":600,"conditions":3929,"interventions":3931},"NCT02797015","Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS",[89],"2017-10-20","2016-06-23",[3930],"Multiple Sclerosis",[3917],{"nctId":3933,"briefTitle":3934,"status":106,"phases":3935,"primaryCompletion":3860,"completion":3860,"start":3936,"enrollment":963,"conditions":3937,"interventions":3938},"NCT02994381","A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults",[89],"2016-10",[19],[3917],{"trials":3940,"activeCount":100},[3941],{"nctId":3942,"briefTitle":3943,"status":106,"phases":3944,"primaryCompletion":3945,"completion":3946,"start":3947,"enrollment":3948,"conditions":3949,"interventions":3950},"NCT02531113","Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease",[90],"2019-09-12","2019-11-28","2015-10-09",69,[3716],[3917],{"trials":3952,"activeCount":100},[3953,3964,3973],{"nctId":3954,"briefTitle":3955,"status":106,"phases":3956,"primaryCompletion":3957,"completion":3958,"start":3959,"enrollment":3960,"conditions":3961,"interventions":3963},"NCT02435992","Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis",[91],"2020-03-27","2020-06-17","2015-06-17",1012,[3962],"Ulcerative Colitis",[3917],{"nctId":3965,"briefTitle":3966,"status":106,"phases":3967,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":3970,"conditions":3971,"interventions":3972},"NCT02531126","An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis",[91],"2024-12-19","2015-12-02",877,[3962],[3917],{"nctId":3974,"briefTitle":3975,"status":106,"phases":3976,"primaryCompletion":3977,"completion":3977,"start":3978,"enrollment":3979,"conditions":3980,"interventions":3981},"NCT02576717","A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis",[91],"2023-01-05","2015-10-16",2494,[3930],[3917],{"trials":3983,"activeCount":100},[],{"trials":3985,"activeCount":100},[],{"intervention":3987,"totalTrials":963,"cells":3988},"CC-93538",{"EARLY_PHASE1":3989,"PHASE1":3991,"PHASE2":4009,"PHASE3":4023,"PHASE4":4054,"NA":4056},{"trials":3990,"activeCount":100},[],{"trials":3992,"activeCount":100},[3993,4001],{"nctId":3994,"briefTitle":3995,"status":106,"phases":3996,"primaryCompletion":120,"completion":3997,"start":3998,"enrollment":3422,"conditions":3999,"interventions":4000},"NCT04096105","Japanese Pharmacokinetic Bridging Study for CC-93538",[89],"2020-01-30","2019-10-14",[19],[3987],{"nctId":4002,"briefTitle":4003,"status":106,"phases":4004,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":1177,"conditions":4007,"interventions":4008},"NCT04373187","Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects",[89],"2021-05-26","2020-06-22",[19],[3987,3987],{"trials":4010,"activeCount":100},[4011],{"nctId":4012,"briefTitle":4013,"status":106,"phases":4014,"primaryCompletion":4015,"completion":4016,"start":4017,"enrollment":4018,"conditions":4019,"interventions":4022},"NCT04800315","A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis",[90],"2022-07-20","2022-11-09","2021-05-14",221,[4020,4021],"Dermatitis, Atopic","Eczema",[3987],{"trials":4024,"activeCount":100},[4025,4035,4045],{"nctId":4026,"briefTitle":4027,"status":106,"phases":4028,"primaryCompletion":4029,"completion":4030,"start":4031,"enrollment":3422,"conditions":4032,"interventions":4034},"NCT05214768","A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis",[91],"2024-07-02","2025-08-22","2022-03-04",[4033],"Eosinophilic Gastroenteritis",[3987],{"nctId":4036,"briefTitle":4037,"status":106,"phases":4038,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":4041,"conditions":4042,"interventions":4044},"NCT04991935","Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis",[91],"2025-08-14","2022-08-09",367,[4043],"Eosinophilic Esophagitis",[3987],{"nctId":4046,"briefTitle":4047,"status":106,"phases":4048,"primaryCompletion":4049,"completion":1103,"start":4050,"enrollment":4051,"conditions":4052,"interventions":4053},"NCT04753697","A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis",[91],"2024-01-11","2021-02-22",430,[4043],[3987],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"intervention":3479,"totalTrials":963,"cells":4059},{"EARLY_PHASE1":4060,"PHASE1":4062,"PHASE2":4096,"PHASE3":4098,"PHASE4":4122,"NA":4124},{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[4064,4072,4083,4087],{"nctId":4065,"briefTitle":4066,"status":106,"phases":4067,"primaryCompletion":3977,"completion":3977,"start":4068,"enrollment":4069,"conditions":4070,"interventions":4071},"NCT03983161","A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment",[89],"2019-09-04",39,[19,2855],[3479],{"nctId":4073,"briefTitle":4074,"status":106,"phases":4075,"primaryCompletion":4076,"completion":4077,"start":4078,"enrollment":4079,"conditions":4080,"interventions":4081},"NCT04702464","A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects",[89],"2021-05-09","2021-05-13","2021-01-12",29,[19],[3479,4082],"Fluconazole",{"nctId":3471,"briefTitle":3472,"status":106,"phases":4084,"primaryCompletion":3474,"completion":3475,"start":3476,"enrollment":823,"conditions":4085,"interventions":4086},[89],[19],[3479,1108,3480],{"nctId":4088,"briefTitle":4089,"status":106,"phases":4090,"primaryCompletion":4091,"completion":4092,"start":4093,"enrollment":9,"conditions":4094,"interventions":4095},"NCT04231435","Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin",[89],"2020-02-19","2020-02-21","2019-12-18",[19],[3479,3429,3431,3430],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[4100,4112],{"nctId":4101,"briefTitle":4102,"status":106,"phases":4103,"primaryCompletion":4104,"completion":199,"start":4105,"enrollment":4106,"conditions":4107,"interventions":4109},"NCT03952039","An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",[91],"2022-12-15","2019-09-09",202,[1813,4108,1047],"Post-Polycythemia Vera",[4110,4111],"FEDRATINIB","Best Available Therapy",{"nctId":4113,"briefTitle":4114,"status":171,"phases":4115,"primaryCompletion":4116,"completion":4117,"start":4118,"enrollment":20,"conditions":4119,"interventions":4121},"NCT03755518","A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",[91],"2021-11-26","2023-11-08","2019-03-27",[1813,1814,1047,4120],"Post-essential Thrombocythemia Myelofibrosis",[4110],{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[],{"intervention":4127,"totalTrials":963,"cells":4128},"Amrubicin",{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4141,"PHASE3":4175,"PHASE4":4184,"NA":4186},{"trials":4130,"activeCount":100},[],{"trials":4132,"activeCount":100},[4133],{"nctId":4134,"briefTitle":4135,"status":106,"phases":4136,"primaryCompletion":2374,"completion":2374,"start":4137,"enrollment":9,"conditions":4138,"interventions":4140},"NCT00915083","A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT\u002FQTc Interval in Cancer Patients With Advanced Solid Tumors.",[89],"2009-06-01",[4139],"Advanced Solid Tumors",[4127],{"trials":4142,"activeCount":100},[4143,4151,4157,4165],{"nctId":4144,"briefTitle":4145,"status":106,"phases":4146,"primaryCompletion":4147,"completion":2789,"start":2741,"enrollment":3099,"conditions":4148,"interventions":4150},"NCT00375193","Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy",[90],"2008-05-01",[4149],"Small Cell Lung Cancer",[4127],{"nctId":4152,"briefTitle":4153,"status":106,"phases":4154,"primaryCompletion":1411,"completion":294,"start":2741,"enrollment":1800,"conditions":4155,"interventions":4156},"NCT00388960","Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer",[90],[4149],[4127,432,785],{"nctId":4158,"briefTitle":4159,"status":423,"phases":4160,"completion":4161,"enrollment":4162,"conditions":4163,"interventions":4164},"NCT00380835","Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer",[90],"2007-12",66,[2485],[4127],{"nctId":4166,"briefTitle":4167,"status":106,"phases":4168,"primaryCompletion":4169,"completion":4170,"start":1356,"enrollment":4171,"conditions":4172,"interventions":4173},"NCT00319969","Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.",[90],"2008-07","2009-01",76,[4149],[4127,4174],"Topotecan",{"trials":4176,"activeCount":100},[4177],{"nctId":4178,"briefTitle":4179,"status":106,"phases":4180,"primaryCompletion":2374,"completion":2374,"start":1339,"enrollment":4181,"conditions":4182,"interventions":4183},"NCT00547651","AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy",[91],637,[4149],[4127,4174],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"intervention":785,"totalTrials":306,"cells":4189},{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4198,"PHASE3":4208,"PHASE4":4214,"NA":4216},{"trials":4191,"activeCount":100},[],{"trials":4193,"activeCount":100},[4194],{"nctId":3522,"briefTitle":3523,"status":106,"phases":4195,"primaryCompletion":3525,"completion":3525,"start":3526,"enrollment":164,"conditions":4196,"interventions":4197},[89],[3528],[1020,432,2701,785,2700],{"trials":4199,"activeCount":100},[4200,4204],{"nctId":1917,"briefTitle":1918,"status":171,"phases":4201,"primaryCompletion":1920,"completion":294,"start":1921,"enrollment":600,"conditions":4202,"interventions":4203},[89,90],[1923],[257,432,785],{"nctId":4152,"briefTitle":4153,"status":106,"phases":4205,"primaryCompletion":1411,"completion":294,"start":2741,"enrollment":1800,"conditions":4206,"interventions":4207},[90],[4149],[4127,432,785],{"trials":4209,"activeCount":100},[4210],{"nctId":775,"briefTitle":776,"status":106,"phases":4211,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":4212,"interventions":4213},[90,91],[370],[115,431,784,128,785],{"trials":4215,"activeCount":100},[],{"trials":4217,"activeCount":100},[],{"intervention":2745,"totalTrials":306,"cells":4219},{"EARLY_PHASE1":4220,"PHASE1":4222,"PHASE2":4224,"PHASE3":4234,"PHASE4":4244,"NA":4246},{"trials":4221,"activeCount":100},[],{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[4226,4230],{"nctId":3539,"briefTitle":3540,"status":106,"phases":4227,"primaryCompletion":507,"completion":507,"start":3542,"enrollment":823,"conditions":4228,"interventions":4229},[90],[2773],[2745,2701,3545],{"nctId":2738,"briefTitle":2739,"status":106,"phases":4231,"primaryCompletion":822,"completion":294,"start":2741,"enrollment":2426,"conditions":4232,"interventions":4233},[89,90],[2743],[431,2745],{"trials":4235,"activeCount":100},[4236,4240],{"nctId":2784,"briefTitle":2785,"status":106,"phases":4237,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":2790,"conditions":4238,"interventions":4239},[91],[2743],[2745,431],{"nctId":3585,"briefTitle":3586,"status":106,"phases":4241,"primaryCompletion":3588,"completion":3589,"start":3590,"enrollment":3591,"conditions":4242,"interventions":4243},[91],[3593],[2745,3595,2701],{"trials":4245,"activeCount":100},[],{"trials":4247,"activeCount":100},[],{"intervention":4249,"totalTrials":235,"cells":4250},"ozanimod placebo",{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4276,"PHASE3":4278,"PHASE4":4294,"NA":4296},{"trials":4252,"activeCount":100},[],{"trials":4254,"activeCount":100},[4255,4268],{"nctId":4256,"briefTitle":4257,"status":106,"phases":4258,"primaryCompletion":4259,"completion":4259,"start":4260,"enrollment":4261,"conditions":4262,"interventions":4263},"NCT03694119","Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response",[89],"2019-01-08","2018-07-24",92,[29],[4264,4265,4266,4249,4267],"Phenelzine","Tyramine","Phenelzine placebo","ozanimod",{"nctId":4269,"briefTitle":4270,"status":106,"phases":4271,"primaryCompletion":2693,"completion":2693,"start":4272,"enrollment":1413,"conditions":4273,"interventions":4274},"NCT03644576","Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate",[89],"2018-07-11",[19],[4267,4275,4249],"Pseudoephedrine",{"trials":4277,"activeCount":100},[],{"trials":4279,"activeCount":100},[4280],{"nctId":4281,"briefTitle":4282,"status":106,"phases":4283,"primaryCompletion":4284,"completion":4285,"start":4286,"enrollment":4287,"conditions":4288,"interventions":4290},"NCT02047734","Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis",[91],"2017-03-27","2017-04-13","2013-12-03",1320,[4289],"Relapsing Multiple Sclerosis",[3410,4291,4292,4293],"Ozanimod placebo","Interferon beta-1a","Interferon beta-1a placebo",{"trials":4295,"activeCount":100},[],{"trials":4297,"activeCount":100},[],{"intervention":4174,"totalTrials":235,"cells":4299},{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4304,"PHASE3":4314,"PHASE4":4320,"NA":4322},{"trials":4301,"activeCount":100},[],{"trials":4303,"activeCount":100},[],{"trials":4305,"activeCount":100},[4306,4310],{"nctId":3680,"briefTitle":3681,"status":106,"phases":4307,"completion":498,"start":2733,"enrollment":669,"conditions":4308,"interventions":4309},[89,90],[3684],[372,3686],{"nctId":4166,"briefTitle":4167,"status":106,"phases":4311,"primaryCompletion":4169,"completion":4170,"start":1356,"enrollment":4171,"conditions":4312,"interventions":4313},[90],[4149],[4127,4174],{"trials":4315,"activeCount":100},[4316],{"nctId":4178,"briefTitle":4179,"status":106,"phases":4317,"primaryCompletion":2374,"completion":2374,"start":1339,"enrollment":4181,"conditions":4318,"interventions":4319},[91],[4149],[4127,4174],{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"intervention":352,"totalTrials":190,"cells":4325},{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4336,"PHASE4":4342,"NA":4344},{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[4332],{"nctId":343,"briefTitle":344,"status":106,"phases":4333,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":4334,"interventions":4335},[89,90],[16],[257,241,352],{"trials":4337,"activeCount":100},[4338],{"nctId":1056,"briefTitle":1057,"status":106,"phases":4339,"primaryCompletion":497,"completion":1059,"start":1060,"enrollment":1061,"conditions":4340,"interventions":4341},[91],[1063],[1065,1066,131,352,1067,1068],{"trials":4343,"activeCount":100},[],{"trials":4345,"activeCount":100},[],{"intervention":4347,"totalTrials":190,"cells":4348},"oxaliplatin",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4365,"PHASE3":4367,"PHASE4":4373,"NA":4375},{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[4353],{"nctId":4354,"briefTitle":4355,"status":106,"phases":4356,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":30,"conditions":4359,"interventions":4361},"NCT02620800","Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",[89],"2018-10-29","2016-01-18",[4360],"Metastatic Pancreas Adenocarcinoma",[4362,2715,4363,4364,4347],"5FU","bevacizumab","calcium leucovorin",{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":100},[4369],{"nctId":775,"briefTitle":776,"status":106,"phases":4370,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":4371,"interventions":4372},[90,91],[370],[115,431,784,128,785],{"trials":4374,"activeCount":100},[],{"trials":4376,"activeCount":100},[],{"intervention":309,"totalTrials":190,"cells":4378},{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4387,"PHASE3":4389,"PHASE4":4395,"NA":4397},{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[4383],{"nctId":301,"briefTitle":302,"status":171,"phases":4384,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":4385,"interventions":4386},[89],[16],[309,310,241],{"trials":4388,"activeCount":100},[],{"trials":4390,"activeCount":100},[4391],{"nctId":484,"briefTitle":485,"status":423,"phases":4392,"primaryCompletion":487,"completion":488,"start":489,"enrollment":100,"conditions":4393,"interventions":4394},[91],[16],[309,257,390,398,397,241],{"trials":4396,"activeCount":100},[],{"trials":4398,"activeCount":100},[],{"intervention":4292,"totalTrials":190,"cells":4400},{"EARLY_PHASE1":4401,"PHASE1":4403,"PHASE2":4405,"PHASE3":4407,"PHASE4":4422,"NA":4424},{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[],{"trials":4406,"activeCount":100},[],{"trials":4408,"activeCount":100},[4409,4418],{"nctId":4410,"briefTitle":4411,"status":106,"phases":4412,"primaryCompletion":4413,"completion":4413,"start":4414,"enrollment":4415,"conditions":4416,"interventions":4417},"NCT02294058","Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)",[91],"2016-12-22","2014-12-03",1346,[3930],[3410,4292],{"nctId":4281,"briefTitle":4282,"status":106,"phases":4419,"primaryCompletion":4284,"completion":4285,"start":4286,"enrollment":4287,"conditions":4420,"interventions":4421},[91],[4289],[3410,4291,4292,4293],{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[],{"intervention":3073,"totalTrials":146,"cells":4427},{"EARLY_PHASE1":4428,"PHASE1":4430,"PHASE2":4432,"PHASE3":4434,"PHASE4":4440,"NA":4442},{"trials":4429,"activeCount":100},[],{"trials":4431,"activeCount":100},[],{"trials":4433,"activeCount":100},[],{"trials":4435,"activeCount":100},[4436],{"nctId":3066,"briefTitle":3067,"status":106,"phases":4437,"primaryCompletion":3069,"completion":3069,"start":3070,"enrollment":1286,"conditions":4438,"interventions":4439},[91],[24],[3073,159],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[],{"intervention":4445,"totalTrials":146,"cells":4446},"A",{"EARLY_PHASE1":4447,"PHASE1":4449,"PHASE2":4451,"PHASE3":4453,"PHASE4":4465,"NA":4467},{"trials":4448,"activeCount":100},[],{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[],{"trials":4454,"activeCount":100},[4455],{"nctId":4456,"briefTitle":4457,"status":106,"phases":4458,"primaryCompletion":1356,"completion":4459,"start":4460,"enrollment":4461,"conditions":4462,"interventions":4463},"NCT00057564","A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma",[91],"2013-08","2003-02",470,[16],[4445,4464],"B",{"trials":4466,"activeCount":100},[],{"trials":4468,"activeCount":100},[],{"intervention":4464,"totalTrials":146,"cells":4470},{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4475,"PHASE3":4477,"PHASE4":4483,"NA":4485},{"trials":4472,"activeCount":100},[],{"trials":4474,"activeCount":100},[],{"trials":4476,"activeCount":100},[],{"trials":4478,"activeCount":100},[4479],{"nctId":4456,"briefTitle":4457,"status":106,"phases":4480,"primaryCompletion":1356,"completion":4459,"start":4460,"enrollment":4461,"conditions":4481,"interventions":4482},[91],[16],[4445,4464],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"intervention":1065,"totalTrials":146,"cells":4488},{"EARLY_PHASE1":4489,"PHASE1":4491,"PHASE2":4493,"PHASE3":4495,"PHASE4":4501,"NA":4503},{"trials":4490,"activeCount":100},[],{"trials":4492,"activeCount":100},[],{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[4497],{"nctId":1056,"briefTitle":1057,"status":106,"phases":4498,"primaryCompletion":497,"completion":1059,"start":1060,"enrollment":1061,"conditions":4499,"interventions":4500},[91],[1063],[1065,1066,131,352,1067,1068],{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"intervention":1066,"totalTrials":146,"cells":4506},{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4511,"PHASE3":4513,"PHASE4":4519,"NA":4521},{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":100},[],{"trials":4514,"activeCount":100},[4515],{"nctId":1056,"briefTitle":1057,"status":106,"phases":4516,"primaryCompletion":497,"completion":1059,"start":1060,"enrollment":1061,"conditions":4517,"interventions":4518},[91],[1063],[1065,1066,131,352,1067,1068],{"trials":4520,"activeCount":100},[],{"trials":4522,"activeCount":100},[],{"intervention":1067,"totalTrials":146,"cells":4524},{"EARLY_PHASE1":4525,"PHASE1":4527,"PHASE2":4529,"PHASE3":4531,"PHASE4":4537,"NA":4539},{"trials":4526,"activeCount":100},[],{"trials":4528,"activeCount":100},[],{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[4533],{"nctId":1056,"briefTitle":1057,"status":106,"phases":4534,"primaryCompletion":497,"completion":1059,"start":1060,"enrollment":1061,"conditions":4535,"interventions":4536},[91],[1063],[1065,1066,131,352,1067,1068],{"trials":4538,"activeCount":100},[],{"trials":4540,"activeCount":100},[],{"intervention":1068,"totalTrials":146,"cells":4542},{"EARLY_PHASE1":4543,"PHASE1":4545,"PHASE2":4547,"PHASE3":4549,"PHASE4":4555,"NA":4557},{"trials":4544,"activeCount":100},[],{"trials":4546,"activeCount":100},[],{"trials":4548,"activeCount":100},[],{"trials":4550,"activeCount":100},[4551],{"nctId":1056,"briefTitle":1057,"status":106,"phases":4552,"primaryCompletion":497,"completion":1059,"start":1060,"enrollment":1061,"conditions":4553,"interventions":4554},[91],[1063],[1065,1066,131,352,1067,1068],{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[],{"intervention":4560,"totalTrials":146,"cells":4561},"RPC-1063",{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4566,"PHASE3":4568,"PHASE4":4579,"NA":4581},{"trials":4563,"activeCount":100},[],{"trials":4565,"activeCount":100},[],{"trials":4567,"activeCount":100},[],{"trials":4569,"activeCount":100},[4570],{"nctId":4571,"briefTitle":4572,"status":171,"phases":4573,"primaryCompletion":4574,"completion":4574,"start":4575,"enrollment":4576,"conditions":4577,"interventions":4578},"NCT04140305","Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)",[91],"2025-05-15","2020-01-16",188,[3930],[4560],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"intervention":4111,"totalTrials":146,"cells":4584},{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4589,"PHASE3":4591,"PHASE4":4597,"NA":4599},{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[],{"trials":4590,"activeCount":100},[],{"trials":4592,"activeCount":100},[4593],{"nctId":4101,"briefTitle":4102,"status":106,"phases":4594,"primaryCompletion":4104,"completion":199,"start":4105,"enrollment":4106,"conditions":4595,"interventions":4596},[91],[1813,4108,1047],[4110,4111],{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[],{"intervention":761,"totalTrials":146,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4607,"PHASE3":4609,"PHASE4":4615,"NA":4617},{"trials":4604,"activeCount":100},[],{"trials":4606,"activeCount":100},[],{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[4611],{"nctId":753,"briefTitle":754,"status":106,"phases":4612,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":4613,"interventions":4614},[91],[202],[128,115,761,762,763],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"intervention":762,"totalTrials":146,"cells":4620},{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4627,"PHASE4":4633,"NA":4635},{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[],{"trials":4628,"activeCount":100},[4629],{"nctId":753,"briefTitle":754,"status":106,"phases":4630,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":4631,"interventions":4632},[91],[202],[128,115,761,762,763],{"trials":4634,"activeCount":100},[],{"trials":4636,"activeCount":100},[],{"intervention":763,"totalTrials":146,"cells":4638},{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4643,"PHASE3":4645,"PHASE4":4651,"NA":4653},{"trials":4640,"activeCount":100},[],{"trials":4642,"activeCount":100},[],{"trials":4644,"activeCount":100},[],{"trials":4646,"activeCount":100},[4647],{"nctId":753,"briefTitle":754,"status":106,"phases":4648,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":4649,"interventions":4650},[91],[202],[128,115,761,762,763],{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[],{"intervention":4656,"totalTrials":146,"cells":4657},"CC-5013 plus dexamethasone",{"EARLY_PHASE1":4658,"PHASE1":4660,"PHASE2":4662,"PHASE3":4664,"PHASE4":4675,"NA":4677},{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":100},[],{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[4666],{"nctId":4667,"briefTitle":4668,"status":106,"phases":4669,"primaryCompletion":506,"completion":4670,"start":508,"enrollment":4671,"conditions":4672,"interventions":4673},"NCT00424047","A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma",[91],"2013-11-12",351,[16],[4656,4674],"Dexamethasone plus Placebo",{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"intervention":4674,"totalTrials":146,"cells":4680},{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4685,"PHASE3":4687,"PHASE4":4693,"NA":4695},{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[],{"trials":4686,"activeCount":100},[],{"trials":4688,"activeCount":100},[4689],{"nctId":4667,"briefTitle":4668,"status":106,"phases":4690,"primaryCompletion":506,"completion":4670,"start":508,"enrollment":4671,"conditions":4691,"interventions":4692},[91],[16],[4656,4674],{"trials":4694,"activeCount":100},[],{"trials":4696,"activeCount":100},[],{"intervention":4698,"totalTrials":146,"cells":4699},"Lenalidomide and low-dose dexamethasone",{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4704,"PHASE3":4706,"PHASE4":4719,"NA":4721},{"trials":4701,"activeCount":100},[],{"trials":4703,"activeCount":100},[],{"trials":4705,"activeCount":100},[],{"trials":4707,"activeCount":100},[4708],{"nctId":4709,"briefTitle":4710,"status":106,"phases":4711,"primaryCompletion":4712,"completion":4712,"start":4713,"enrollment":4714,"conditions":4715,"interventions":4716},"NCT00689936","Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",[91],"2016-07-14","2008-08-21",1623,[16],[4698,4717,4718],"Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles","Melphalan, Prednisone and Thalidomide",{"trials":4720,"activeCount":100},[],{"trials":4722,"activeCount":100},[],{"intervention":4717,"totalTrials":146,"cells":4724},{"EARLY_PHASE1":4725,"PHASE1":4727,"PHASE2":4729,"PHASE3":4731,"PHASE4":4737,"NA":4739},{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"trials":4730,"activeCount":100},[],{"trials":4732,"activeCount":100},[4733],{"nctId":4709,"briefTitle":4710,"status":106,"phases":4734,"primaryCompletion":4712,"completion":4712,"start":4713,"enrollment":4714,"conditions":4735,"interventions":4736},[91],[16],[4698,4717,4718],{"trials":4738,"activeCount":100},[],{"trials":4740,"activeCount":100},[],{"intervention":4718,"totalTrials":146,"cells":4742},{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4747,"PHASE3":4749,"PHASE4":4755,"NA":4757},{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[],{"trials":4748,"activeCount":100},[],{"trials":4750,"activeCount":100},[4751],{"nctId":4709,"briefTitle":4710,"status":106,"phases":4752,"primaryCompletion":4712,"completion":4712,"start":4713,"enrollment":4714,"conditions":4753,"interventions":4754},[91],[16],[4698,4717,4718],{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[],{"intervention":1521,"totalTrials":146,"cells":4760},{"EARLY_PHASE1":4761,"PHASE1":4763,"PHASE2":4765,"PHASE3":4767,"PHASE4":4773,"NA":4775},{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[],{"trials":4766,"activeCount":100},[],{"trials":4768,"activeCount":100},[4769],{"nctId":1512,"briefTitle":1513,"status":106,"phases":4770,"primaryCompletion":1515,"completion":1450,"start":1516,"enrollment":1517,"conditions":4771,"interventions":4772},[91],[1519],[115,1521],{"trials":4774,"activeCount":100},[],{"trials":4776,"activeCount":100},[],{"intervention":3595,"totalTrials":146,"cells":4778},{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4783,"PHASE3":4785,"PHASE4":4791,"NA":4793},{"trials":4780,"activeCount":100},[],{"trials":4782,"activeCount":100},[],{"trials":4784,"activeCount":100},[],{"trials":4786,"activeCount":100},[4787],{"nctId":3585,"briefTitle":3586,"status":106,"phases":4788,"primaryCompletion":3588,"completion":3589,"start":3590,"enrollment":3591,"conditions":4789,"interventions":4790},[91],[3593],[2745,3595,2701],{"trials":4792,"activeCount":100},[],{"trials":4794,"activeCount":100},[],{"intervention":4796,"totalTrials":146,"cells":4797},"Dacarbazine",{"EARLY_PHASE1":4798,"PHASE1":4800,"PHASE2":4802,"PHASE3":4804,"PHASE4":4816,"NA":4818},{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[],{"trials":4805,"activeCount":100},[4806],{"nctId":4807,"briefTitle":4808,"status":106,"phases":4809,"primaryCompletion":4810,"completion":4811,"start":4812,"enrollment":4813,"conditions":4814,"interventions":4815},"NCT00864253","A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma",[91],"2012-06-01","2014-02-12","2009-04-23",529,[3635],[2487,4796],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"intervention":4821,"totalTrials":146,"cells":4822},"Tislelizumab",{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4827,"PHASE3":4829,"PHASE4":4840,"NA":4842},{"trials":4824,"activeCount":100},[],{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[],{"trials":4830,"activeCount":100},[4831],{"nctId":4832,"briefTitle":4833,"status":171,"phases":4834,"primaryCompletion":4835,"completion":4835,"start":4836,"enrollment":146,"conditions":4837,"interventions":4838},"NCT03745222","A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer",[91],"2019-06-26","2019-05-22",[3512],[4821,4839],"Concurrent chemoradiotherapy",{"trials":4841,"activeCount":100},[],{"trials":4843,"activeCount":100},[],{"intervention":4839,"totalTrials":146,"cells":4845},{"EARLY_PHASE1":4846,"PHASE1":4848,"PHASE2":4850,"PHASE3":4852,"PHASE4":4858,"NA":4860},{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[4854],{"nctId":4832,"briefTitle":4833,"status":171,"phases":4855,"primaryCompletion":4835,"completion":4835,"start":4836,"enrollment":146,"conditions":4856,"interventions":4857},[91],[3512],[4821,4839],{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":100},[],{"intervention":2004,"totalTrials":146,"cells":4863},{"EARLY_PHASE1":4864,"PHASE1":4866,"PHASE2":4868,"PHASE3":4870,"PHASE4":4876,"NA":4878},{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[4872],{"nctId":1996,"briefTitle":1997,"status":106,"phases":4873,"primaryCompletion":1223,"completion":1266,"start":1999,"enrollment":2000,"conditions":4874,"interventions":4875},[91],[1813,2002],[2004,257],{"trials":4877,"activeCount":100},[],{"trials":4879,"activeCount":100},[],{"intervention":2178,"totalTrials":146,"cells":4881},{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4886,"PHASE3":4888,"PHASE4":4894,"NA":4896},{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"trials":4889,"activeCount":100},[4890],{"nctId":2168,"briefTitle":2169,"status":106,"phases":4891,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":4892,"interventions":4893},[91],[1401,2176],[2115,46,2178,2179],{"trials":4895,"activeCount":100},[],{"trials":4897,"activeCount":100},[],{"intervention":2179,"totalTrials":146,"cells":4899},{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4906,"PHASE4":4912,"NA":4914},{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[],{"trials":4905,"activeCount":100},[],{"trials":4907,"activeCount":100},[4908],{"nctId":2168,"briefTitle":2169,"status":106,"phases":4909,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":4910,"interventions":4911},[91],[1401,2176],[2115,46,2178,2179],{"trials":4913,"activeCount":100},[],{"trials":4915,"activeCount":100},[],{"intervention":4917,"totalTrials":146,"cells":4918},"CC 5013",{"EARLY_PHASE1":4919,"PHASE1":4921,"PHASE2":4923,"PHASE3":4925,"PHASE4":4935,"NA":4937},{"trials":4920,"activeCount":100},[],{"trials":4922,"activeCount":100},[],{"trials":4924,"activeCount":100},[],{"trials":4926,"activeCount":100},[4927],{"nctId":4928,"briefTitle":4929,"status":106,"phases":4930,"completion":4931,"start":4932,"enrollment":3742,"conditions":4933,"interventions":4934},"NCT00055562","Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma",[90,91],"2004-12","2003-01",[3744,3745],[4917],{"trials":4936,"activeCount":100},[],{"trials":4938,"activeCount":100},[],{"intervention":4293,"totalTrials":146,"cells":4940},{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4945,"PHASE3":4947,"PHASE4":4953,"NA":4955},{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[],{"trials":4948,"activeCount":100},[4949],{"nctId":4281,"briefTitle":4282,"status":106,"phases":4950,"primaryCompletion":4284,"completion":4285,"start":4286,"enrollment":4287,"conditions":4951,"interventions":4952},[91],[4289],[3410,4291,4292,4293],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"intervention":4958,"totalTrials":146,"cells":4959},"Lenalidomide 5 mg",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4966,"PHASE4":4978,"NA":4980},{"trials":4961,"activeCount":100},[],{"trials":4963,"activeCount":100},[],{"trials":4965,"activeCount":100},[],{"trials":4967,"activeCount":100},[4968],{"nctId":4969,"briefTitle":4970,"status":106,"phases":4971,"primaryCompletion":348,"completion":4972,"start":4973,"enrollment":4974,"conditions":4975,"interventions":4976},"NCT00179621","Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality",[91],"2010-06","2005-07",205,[22],[4958,4977],"Lenalidomide 10 mg",{"trials":4979,"activeCount":100},[],{"trials":4981,"activeCount":100},[],{"intervention":4977,"totalTrials":146,"cells":4983},{"EARLY_PHASE1":4984,"PHASE1":4986,"PHASE2":4988,"PHASE3":4990,"PHASE4":4996,"NA":4998},{"trials":4985,"activeCount":100},[],{"trials":4987,"activeCount":100},[],{"trials":4989,"activeCount":100},[],{"trials":4991,"activeCount":100},[4992],{"nctId":4969,"briefTitle":4970,"status":106,"phases":4993,"primaryCompletion":348,"completion":4972,"start":4973,"enrollment":4974,"conditions":4994,"interventions":4995},[91],[22],[4958,4977],{"trials":4997,"activeCount":100},[],{"trials":4999,"activeCount":100},[],{"intervention":5001,"totalTrials":146,"cells":5002},"Tetanus, diphtheria, and acellular pertussis vaccine",{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5007,"PHASE3":5009,"PHASE4":5023,"NA":5025},{"trials":5004,"activeCount":100},[],{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[5011],{"nctId":5012,"briefTitle":5013,"status":106,"phases":5014,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":5018,"interventions":5020},"NCT05028634","Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy",[91],"2023-11-15","2021-11-11",63,[3930,5019],"Multiple Sclerosis, Relapsing-Remitting",[5001,5021,5022],"Pneumococcal polysaccharide vaccine","Seasonal influenza vaccine",{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"intervention":5021,"totalTrials":146,"cells":5028},{"EARLY_PHASE1":5029,"PHASE1":5031,"PHASE2":5033,"PHASE3":5035,"PHASE4":5041,"NA":5043},{"trials":5030,"activeCount":100},[],{"trials":5032,"activeCount":100},[],{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[5037],{"nctId":5012,"briefTitle":5013,"status":106,"phases":5038,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":5039,"interventions":5040},[91],[3930,5019],[5001,5021,5022],{"trials":5042,"activeCount":100},[],{"trials":5044,"activeCount":100},[],{"intervention":5022,"totalTrials":146,"cells":5046},{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5051,"PHASE3":5053,"PHASE4":5059,"NA":5061},{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[],{"trials":5052,"activeCount":100},[],{"trials":5054,"activeCount":100},[5055],{"nctId":5012,"briefTitle":5013,"status":106,"phases":5056,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":5057,"interventions":5058},[91],[3930,5019],[5001,5021,5022],{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[],{"intervention":2189,"totalTrials":146,"cells":5064},{"EARLY_PHASE1":5065,"PHASE1":5067,"PHASE2":5069,"PHASE3":5071,"PHASE4":5077,"NA":5079},{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[],{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[5073],{"nctId":2181,"briefTitle":2182,"status":106,"phases":5074,"primaryCompletion":2184,"completion":2185,"start":1175,"enrollment":2186,"conditions":5075,"interventions":5076},[91],[1269],[46,2189],{"trials":5078,"activeCount":100},[],{"trials":5080,"activeCount":100},[],{"intervention":638,"totalTrials":30,"cells":5082},{"EARLY_PHASE1":5083,"PHASE1":5085,"PHASE2":5155,"PHASE3":5172,"PHASE4":5174,"NA":5176},{"trials":5084,"activeCount":100},[],{"trials":5086,"activeCount":100},[5087,5091,5099,5111,5115,5125,5133,5143,5147],{"nctId":630,"briefTitle":631,"status":171,"phases":5088,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":5089,"interventions":5090},[89],[124],[638,639,128,638,640,128,639,640,128],{"nctId":5092,"briefTitle":5093,"status":106,"phases":5094,"primaryCompletion":5095,"completion":5095,"start":5096,"enrollment":963,"conditions":5097,"interventions":5098},"NCT02234999","Radiolabeled Study of CC-122 in Healthy Subjects",[89],"2014-10-08","2014-09-23",[19],[638],{"nctId":5100,"briefTitle":5101,"status":106,"phases":5102,"primaryCompletion":5103,"completion":5103,"start":5104,"enrollment":5105,"conditions":5106,"interventions":5110},"NCT01421524","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",[89],"2023-11-21","2011-09-12",271,[16,124,5107,5108,660,5109],"Pleiotropic Pathway Modifier","Glioblastoma","Primary Central Nervous System Lymphoma",[638,638,638,638],{"nctId":3381,"briefTitle":3382,"status":106,"phases":5112,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":3386,"conditions":5113,"interventions":5114},[89],[29],[638,1107,1893,1108],{"nctId":5116,"briefTitle":5117,"status":171,"phases":5118,"primaryCompletion":5119,"completion":5119,"start":5120,"enrollment":30,"conditions":5121,"interventions":5123},"NCT02323906","Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer",[89],"2016-12-21","2015-01-16",[5122],"Carcinoma, Hepatocellular",[638,5124],"Sorafenib",{"nctId":5126,"briefTitle":5127,"status":171,"phases":5128,"primaryCompletion":5129,"completion":5129,"start":5130,"enrollment":296,"conditions":5131,"interventions":5132},"NCT02509039","A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)",[89],"2023-05-09","2015-09-02",[24],[638],{"nctId":5134,"briefTitle":5135,"status":106,"phases":5136,"primaryCompletion":5137,"completion":5138,"start":5139,"enrollment":877,"conditions":5140,"interventions":5142},"NCT02049528","Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study",[89],"2014-02-02","2014-02-08","2014-01-16",[5141],"Clinical Pharmacology, Healthy Male Volunteer Study",[638,638,638],{"nctId":3093,"briefTitle":3094,"status":106,"phases":5144,"primaryCompletion":3096,"completion":3097,"start":3098,"enrollment":3099,"conditions":5145,"interventions":5146},[89],[124,24],[662,638],{"nctId":5148,"briefTitle":5149,"status":106,"phases":5150,"primaryCompletion":5151,"completion":5151,"start":5152,"enrollment":3422,"conditions":5153,"interventions":5154},"NCT03097016","A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment",[89],"2017-12-23","2017-03-30",[2515],[638],{"trials":5156,"activeCount":100},[5157,5161,5165],{"nctId":3105,"briefTitle":3106,"status":106,"phases":5158,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":5159,"interventions":5160},[89,90],[727],[638,729,662],{"nctId":2910,"briefTitle":2911,"status":106,"phases":5162,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":5163,"interventions":5164},[89,90],[24,124,125],[159,189,638,729,56,2917,2700,144],{"nctId":5166,"briefTitle":5167,"status":106,"phases":5168,"primaryCompletion":3957,"completion":3957,"start":5169,"enrollment":175,"conditions":5170,"interventions":5171},"NCT02859324","A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)",[89,90],"2016-09-20",[5122],[638,2700],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"intervention":2700,"totalTrials":805,"cells":5179},{"EARLY_PHASE1":5180,"PHASE1":5182,"PHASE2":5231,"PHASE3":5248,"PHASE4":5250,"NA":5252},{"trials":5181,"activeCount":100},[],{"trials":5183,"activeCount":100},[5184,5195,5205,5214,5218,5222],{"nctId":5185,"briefTitle":5186,"status":171,"phases":5187,"primaryCompletion":5188,"completion":5189,"start":5190,"enrollment":877,"conditions":5191,"interventions":5193},"NCT02124850","A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab",[89],"2016-08-11","2016-10-31","2014-10-28",[5192],"Squamous Cell Carcinoma of the Head and Neck",[5194,651,2700],"Motolimod",{"nctId":5196,"briefTitle":5197,"status":106,"phases":5198,"primaryCompletion":5199,"completion":5199,"start":5200,"enrollment":146,"conditions":5201,"interventions":5202},"NCT02935790","Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab",[89],"2017-04-07","2016-09-30",[3635],[320,5203,5204],"nivolumab","ipilimumab",{"nctId":5206,"briefTitle":5207,"status":171,"phases":5208,"primaryCompletion":5209,"completion":5209,"start":5210,"enrollment":296,"conditions":5211,"interventions":5213},"NCT03906526","A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer",[89],"2022-01-24","2019-07-03",[5212],"Carcinoma, Squamous Cell",[3565,2700],{"nctId":2690,"briefTitle":2691,"status":106,"phases":5215,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":277,"conditions":5216,"interventions":5217},[89],[2696,2697],[2699,2700,431,2701],{"nctId":3522,"briefTitle":3523,"status":106,"phases":5219,"primaryCompletion":3525,"completion":3525,"start":3526,"enrollment":164,"conditions":5220,"interventions":5221},[89],[3528],[1020,432,2701,785,2700],{"nctId":5223,"briefTitle":5224,"status":171,"phases":5225,"primaryCompletion":5226,"completion":5226,"start":5227,"enrollment":1399,"conditions":5228,"interventions":5230},"NCT02635061","Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer",[89],"2024-01-22","2016-08-25",[5229],"Non Small Cell Lung Cancer",[320,2700],{"trials":5232,"activeCount":100},[5233,5237,5244],{"nctId":2910,"briefTitle":2911,"status":106,"phases":5234,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":5235,"interventions":5236},[89,90],[24,124,125],[159,189,638,729,56,2917,2700,144],{"nctId":5238,"briefTitle":5239,"status":106,"phases":5240,"primaryCompletion":5241,"completion":5241,"start":155,"enrollment":4261,"conditions":5242,"interventions":5243},"NCT04350463","A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers",[90],"2023-12-19",[32],[1020,2700],{"nctId":5166,"briefTitle":5167,"status":106,"phases":5245,"primaryCompletion":3957,"completion":3957,"start":5169,"enrollment":175,"conditions":5246,"interventions":5247},[89,90],[5122],[638,2700],{"trials":5249,"activeCount":100},[],{"trials":5251,"activeCount":100},[],{"trials":5253,"activeCount":100},[],{"intervention":189,"totalTrials":805,"cells":5255},{"EARLY_PHASE1":5256,"PHASE1":5258,"PHASE2":5264,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5257,"activeCount":100},[],{"trials":5259,"activeCount":100},[5260],{"nctId":271,"briefTitle":272,"status":106,"phases":5261,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":5262,"interventions":5263},[89],[16],[189,257,241],{"trials":5265,"activeCount":100},[5266,5270,5274,5278,5282,5286,5290,5294],{"nctId":871,"briefTitle":872,"status":106,"phases":5267,"primaryCompletion":874,"completion":875,"start":876,"enrollment":877,"conditions":5268,"interventions":5269},[90],[16],[880,881],{"nctId":3805,"briefTitle":3806,"status":106,"phases":5271,"primaryCompletion":3808,"completion":1929,"start":3809,"enrollment":339,"conditions":5272,"interventions":5273},[90],[22],[127,189],{"nctId":719,"briefTitle":720,"status":106,"phases":5275,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":5276,"interventions":5277},[89,90],[660,727],[189,115,128,729,167],{"nctId":2117,"briefTitle":2118,"status":106,"phases":5279,"primaryCompletion":2120,"completion":2121,"start":2111,"enrollment":2122,"conditions":5280,"interventions":5281},[90],[27,22],[46,189],{"nctId":2910,"briefTitle":2911,"status":106,"phases":5283,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":5284,"interventions":5285},[89,90],[24,124,125],[159,189,638,729,56,2917,2700,144],{"nctId":383,"briefTitle":384,"status":171,"phases":5287,"primaryCompletion":386,"completion":386,"start":387,"enrollment":242,"conditions":5288,"interventions":5289},[90],[16],[390,189,257,241],{"nctId":181,"briefTitle":182,"status":106,"phases":5291,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":5292,"interventions":5293},[90],[124],[189,128,143,130,96,131,115],{"nctId":434,"briefTitle":435,"status":106,"phases":5295,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":5296,"interventions":5297},[89,90],[16],[189,115,241],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[],{"trials":5303,"activeCount":100},[],{"intervention":5305,"totalTrials":862,"cells":5306},"CC-90001",{"EARLY_PHASE1":5307,"PHASE1":5309,"PHASE2":5363,"PHASE3":5391,"PHASE4":5393,"NA":5395},{"trials":5308,"activeCount":100},[],{"trials":5310,"activeCount":100},[5311,5320,5328,5336,5346,5355],{"nctId":5312,"briefTitle":5313,"status":106,"phases":5314,"primaryCompletion":5315,"completion":5315,"start":5316,"enrollment":330,"conditions":5317,"interventions":5319},"NCT02321644","Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study",[89],"2015-02","2014-11",[5318],"Healthy Subjects",[5305],{"nctId":5321,"briefTitle":5322,"status":106,"phases":5323,"primaryCompletion":377,"completion":377,"start":5324,"enrollment":5325,"conditions":5326,"interventions":5327},"NCT02110420","First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001",[89],"2014-02",96,[19],[5305,5305,5305,5305,5305,5305,5305,5305,5305,5305,5305,5305,5305],{"nctId":5329,"briefTitle":5330,"status":106,"phases":5331,"primaryCompletion":5332,"completion":5332,"start":5333,"enrollment":669,"conditions":5334,"interventions":5335},"NCT03958864","A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects",[89],"2019-06-13","2019-04-04",[29],[5305],{"nctId":5337,"briefTitle":5338,"status":106,"phases":5339,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":5341,"interventions":5343},"NCT03363815","A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects",[89],"2018-07-29",[5342],"Heathy Volunteer",[5305,3863,3428,5344,3431,3430,3429,5345],"Warfarin","Nintedanib",{"nctId":5347,"briefTitle":5348,"status":106,"phases":5349,"primaryCompletion":5350,"completion":5350,"start":5351,"enrollment":25,"conditions":5352,"interventions":5354},"NCT02510937","Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis",[89],"2017-02-06","2015-08-05",[5353],"Pulmonary Fibrosis",[5305],{"nctId":5356,"briefTitle":5357,"status":106,"phases":5358,"primaryCompletion":5359,"completion":5359,"start":5360,"enrollment":684,"conditions":5361,"interventions":5362},"NCT03742882","A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects",[89],"2019-06-10","2018-12-06",[2855],[5305],{"trials":5364,"activeCount":100},[5365,5381],{"nctId":5366,"briefTitle":5367,"status":171,"phases":5368,"primaryCompletion":5369,"completion":5369,"start":5370,"enrollment":5371,"conditions":5372,"interventions":5380},"NCT03142191","A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis",[90],"2021-12-24","2017-07-26",138,[5373,5374,5375,5376,5377,5378,5379],"Idiopathic Pulmonary Fibrosis","Fibrosis","Idiopathic Interstitial Pneumonias","Pathologic Processes","Lung Diseases, Interstitial","Lung Diseases","Respiratory Tract Diseases",[5305],{"nctId":5382,"briefTitle":5383,"status":171,"phases":5384,"primaryCompletion":5385,"completion":5385,"start":5386,"enrollment":440,"conditions":5387,"interventions":5390},"NCT04048876","Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis",[90],"2021-09-28","2019-08-14",[5388,5389],"Non-alcoholic Fatty Liver Disease","Liver Cirrhosis",[5305],{"trials":5392,"activeCount":100},[],{"trials":5394,"activeCount":100},[],{"trials":5396,"activeCount":100},[],{"intervention":5398,"totalTrials":963,"cells":5399},"Enasidenib",{"EARLY_PHASE1":5400,"PHASE1":5402,"PHASE2":5442,"PHASE3":5466,"PHASE4":5468,"NA":5470},{"trials":5401,"activeCount":100},[],{"trials":5403,"activeCount":100},[5404,5412,5421,5434],{"nctId":5405,"briefTitle":5406,"status":106,"phases":5407,"primaryCompletion":5408,"completion":5408,"start":5409,"enrollment":684,"conditions":5410,"interventions":5411},"NCT04573582","Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment",[89],"2023-03-08","2020-11-13",[2855],[5398],{"nctId":5413,"briefTitle":5414,"status":106,"phases":5415,"primaryCompletion":5416,"completion":5417,"start":5418,"enrollment":1197,"conditions":5419,"interventions":5420},"NCT04310527","Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults",[89],"2019-11-27","2019-12-09","2019-10-09",[19],[5398],{"nctId":5422,"briefTitle":5423,"status":106,"phases":5424,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":684,"conditions":5428,"interventions":5429},"NCT03720366","A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients",[89],"2023-09-22","2023-12-22","2018-10-04",[27],[5430,5431,5432,5433],"enasidenib","Arm 1 probes","Arm 2 Probes","Arm 3 probes",{"nctId":5435,"briefTitle":5436,"status":106,"phases":5437,"primaryCompletion":5438,"completion":5438,"start":5439,"enrollment":1224,"conditions":5440,"interventions":5441},"NCT03290443","A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.",[89],"2018-10-26","2017-09-21",[2855],[5398],{"trials":5443,"activeCount":100},[5444,5454],{"nctId":5445,"briefTitle":5446,"status":106,"phases":5447,"primaryCompletion":5448,"completion":5449,"start":5450,"enrollment":5451,"conditions":5452,"interventions":5453},"NCT01915498","Phase 1\u002F2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation",[89,90],"2019-07-25","2023-10-31","2013-08-27",345,[671],[5398],{"nctId":5455,"briefTitle":5456,"status":106,"phases":5457,"primaryCompletion":2111,"completion":2111,"start":5458,"enrollment":175,"conditions":5459,"interventions":5465},"NCT02273739","Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",[89,90],"2014-12-08",[5460,5461,5462,5463,5464],"Solid Tumor","Glioma","Angioimmunoblastic T-cell Lymphoma","Intrahepatic Cholangiocarcinoma","Chondrosarcoma",[5398],{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[],{"intervention":640,"totalTrials":3034,"cells":5473},{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5499,"PHASE3":5511,"PHASE4":5513,"NA":5515},{"trials":5475,"activeCount":100},[],{"trials":5477,"activeCount":100},[5478,5482,5491,5495],{"nctId":630,"briefTitle":631,"status":171,"phases":5479,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":5480,"interventions":5481},[89],[124],[638,639,128,638,640,128,639,640,128],{"nctId":5483,"briefTitle":5484,"status":106,"phases":5485,"primaryCompletion":5486,"completion":5486,"start":5487,"enrollment":9,"conditions":5488,"interventions":5489},"NCT02433457","Relative Bioavailability Study of CC-292",[89],"2014-09-26","2014-05-26",[19],[640,5490],"Oral Omeprazole",{"nctId":679,"briefTitle":680,"status":106,"phases":5492,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":5493,"interventions":5494},[89],[686],[640,128],{"nctId":1232,"briefTitle":1233,"status":106,"phases":5496,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":623,"conditions":5497,"interventions":5498},[89],[686],[640,115],{"trials":5500,"activeCount":100},[5501],{"nctId":5502,"briefTitle":5503,"status":106,"phases":5504,"primaryCompletion":5505,"completion":5506,"start":5507,"enrollment":3110,"conditions":5508,"interventions":5510},"NCT01975610","Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis",[90],"2016-01","2016-02","2013-10",[5509],"Rheumatoid Arthritis",[640],{"trials":5512,"activeCount":100},[],{"trials":5514,"activeCount":100},[],{"trials":5516,"activeCount":100},[],{"intervention":432,"totalTrials":3034,"cells":5518},{"EARLY_PHASE1":5519,"PHASE1":5521,"PHASE2":5527,"PHASE3":5545,"PHASE4":5547,"NA":5549},{"trials":5520,"activeCount":100},[],{"trials":5522,"activeCount":100},[5523],{"nctId":3522,"briefTitle":3523,"status":106,"phases":5524,"primaryCompletion":3525,"completion":3525,"start":3526,"enrollment":164,"conditions":5525,"interventions":5526},[89],[3528],[1020,432,2701,785,2700],{"trials":5528,"activeCount":100},[5529,5533,5537,5541],{"nctId":1917,"briefTitle":1918,"status":171,"phases":5530,"primaryCompletion":1920,"completion":294,"start":1921,"enrollment":600,"conditions":5531,"interventions":5532},[89,90],[1923],[257,432,785],{"nctId":4152,"briefTitle":4153,"status":106,"phases":5534,"primaryCompletion":1411,"completion":294,"start":2741,"enrollment":1800,"conditions":5535,"interventions":5536},[90],[4149],[4127,432,785],{"nctId":421,"briefTitle":422,"status":423,"phases":5538,"primaryCompletion":425,"completion":426,"start":427,"enrollment":100,"conditions":5539,"interventions":5540},[89,90],[141],[56,145,128,430,431,432,241,167,115],{"nctId":3555,"briefTitle":3556,"status":106,"phases":5542,"primaryCompletion":3558,"completion":3559,"start":3560,"enrollment":3561,"conditions":5543,"interventions":5544},[90],[3563],[3565,2701,432,3566],{"trials":5546,"activeCount":100},[],{"trials":5548,"activeCount":100},[],{"trials":5550,"activeCount":100},[],{"intervention":3425,"totalTrials":3034,"cells":5552},{"EARLY_PHASE1":5553,"PHASE1":5555,"PHASE2":5584,"PHASE3":5596,"PHASE4":5598,"NA":5600},{"trials":5554,"activeCount":100},[],{"trials":5556,"activeCount":100},[5557,5565,5572,5576],{"nctId":5558,"briefTitle":5559,"status":106,"phases":5560,"primaryCompletion":2903,"completion":2903,"start":5561,"enrollment":1197,"conditions":5562,"interventions":5563},"NCT04718636","A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants",[89],"2020-09-30",[19],[5564,3425],"Oral Contraceptive",{"nctId":5566,"briefTitle":5567,"status":106,"phases":5568,"primaryCompletion":5210,"completion":5210,"start":5569,"enrollment":17,"conditions":5570,"interventions":5571},"NCT03554993","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects",[89],"2018-05-23",[29],[3425],{"nctId":3417,"briefTitle":3418,"status":106,"phases":5573,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":5574,"interventions":5575},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"nctId":5577,"briefTitle":5578,"status":106,"phases":5579,"primaryCompletion":5580,"completion":5581,"start":2903,"enrollment":527,"conditions":5582,"interventions":5583},"NCT04958291","Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.",[89],"2021-12-06","2021-12-07",[19],[3425],{"trials":5585,"activeCount":100},[5586],{"nctId":5587,"briefTitle":5588,"status":171,"phases":5589,"primaryCompletion":5590,"completion":5590,"start":5591,"enrollment":5592,"conditions":5593,"interventions":5595},"NCT04947579","A Study of CC-99677 in Participants With Active Ankylosing Spondylitis",[90],"2023-02-21","2021-08-25",167,[5594],"Spondylitis, Ankylosing",[3425],{"trials":5597,"activeCount":100},[],{"trials":5599,"activeCount":100},[],{"trials":5601,"activeCount":100},[],{"intervention":1020,"totalTrials":3034,"cells":5603},{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5624,"PHASE3":5630,"PHASE4":5632,"NA":5634},{"trials":5605,"activeCount":100},[],{"trials":5607,"activeCount":100},[5608,5612,5616,5620],{"nctId":3390,"briefTitle":3391,"status":171,"phases":5609,"primaryCompletion":2172,"completion":2172,"start":3393,"enrollment":3099,"conditions":5610,"interventions":5611},[89],[24,32],[1020,3396,1107],{"nctId":1012,"briefTitle":1013,"status":106,"phases":5613,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":963,"conditions":5614,"interventions":5615},[89],[1018],[1020,1021,131],{"nctId":2065,"briefTitle":2066,"status":171,"phases":5617,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":146,"conditions":5618,"interventions":5619},[89],[1401],[1020,2052,46,2052,1020],{"nctId":3522,"briefTitle":3523,"status":106,"phases":5621,"primaryCompletion":3525,"completion":3525,"start":3526,"enrollment":164,"conditions":5622,"interventions":5623},[89],[3528],[1020,432,2701,785,2700],{"trials":5625,"activeCount":100},[5626],{"nctId":5238,"briefTitle":5239,"status":106,"phases":5627,"primaryCompletion":5241,"completion":5241,"start":155,"enrollment":4261,"conditions":5628,"interventions":5629},[90],[32],[1020,2700],{"trials":5631,"activeCount":100},[],{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":100},[],{"intervention":4363,"totalTrials":306,"cells":5637},{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5646,"PHASE3":5674,"PHASE4":5676,"NA":5678},{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[5642],{"nctId":4354,"briefTitle":4355,"status":106,"phases":5643,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":30,"conditions":5644,"interventions":5645},[89],[4360],[4362,2715,4363,4364,4347],{"trials":5647,"activeCount":100},[5648,5659,5667],{"nctId":5649,"briefTitle":5650,"status":106,"phases":5651,"primaryCompletion":3662,"completion":1921,"start":1186,"enrollment":5652,"conditions":5653,"interventions":5654},"NCT00394251","Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer",[90],197,[2773],[5655,2487,5656,5657,5658],"Adriamycin and Cytoxan","Taxol","Bevacizumab","pegfilgrastim",{"nctId":5660,"briefTitle":5661,"status":106,"phases":5662,"primaryCompletion":1295,"completion":5663,"start":5664,"enrollment":12,"conditions":5665,"interventions":5666},"NCT00394082","ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer",[90],"2011-02-01","2006-06-01",[2485],[2487,5657],{"nctId":5668,"briefTitle":5669,"status":171,"phases":5670,"primaryCompletion":1206,"completion":1555,"start":469,"enrollment":5671,"conditions":5672,"interventions":5673},"NCT00281528","Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)\u002FBevacizumab Combination in Metastatic Breast Cancer",[90],208,[2696,3745],[2487,4363],{"trials":5675,"activeCount":100},[],{"trials":5677,"activeCount":100},[],{"trials":5679,"activeCount":100},[],{"intervention":639,"totalTrials":306,"cells":5681},{"EARLY_PHASE1":5682,"PHASE1":5684,"PHASE2":5705,"PHASE3":5722,"PHASE4":5724,"NA":5726},{"trials":5683,"activeCount":100},[],{"trials":5685,"activeCount":100},[5686,5690,5698],{"nctId":630,"briefTitle":631,"status":171,"phases":5687,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":5688,"interventions":5689},[89],[124],[638,639,128,638,640,128,639,640,128],{"nctId":5691,"briefTitle":5692,"status":106,"phases":5693,"primaryCompletion":5694,"completion":5694,"start":5695,"enrollment":2333,"conditions":5696,"interventions":5697},"NCT01896323","CC-223 and Ketoconazole Drug-Drug Interaction Study",[89],"2013-08-01","2013-07-01",[19],[639,1892],{"nctId":5699,"briefTitle":5700,"status":106,"phases":5701,"primaryCompletion":2076,"completion":2076,"start":4810,"enrollment":877,"conditions":5702,"interventions":5704},"NCT01611467","A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects",[89],[5703],"Safety and Pharmacokinetics in Healthy Volunteer Subjects",[639,639],{"trials":5706,"activeCount":100},[5707],{"nctId":5708,"briefTitle":5709,"status":106,"phases":5710,"primaryCompletion":5711,"completion":5712,"start":5713,"enrollment":5714,"conditions":5715,"interventions":5721},"NCT01177397","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",[89,90],"2016-11-15","2016-12-09","2010-07-20",226,[16,5716,5717,5718,3606,5719,5720],"Diffuse Large B-Cell Lymphoma","Glioblastoma Multiforme","Hepatocellular Carcinoma","Neuroendocrine Tumors of Non-Pancreatic Origin","Hormone Receptor-Positive Breast Cancer",[639],{"trials":5723,"activeCount":100},[],{"trials":5725,"activeCount":100},[],{"trials":5727,"activeCount":100},[],{"intervention":3565,"totalTrials":306,"cells":5729},{"EARLY_PHASE1":5730,"PHASE1":5732,"PHASE2":5747,"PHASE3":5766,"PHASE4":5768,"NA":5770},{"trials":5731,"activeCount":100},[],{"trials":5733,"activeCount":100},[5734,5738],{"nctId":5206,"briefTitle":5207,"status":171,"phases":5735,"primaryCompletion":5209,"completion":5209,"start":5210,"enrollment":296,"conditions":5736,"interventions":5737},[89],[5212],[3565,2700],{"nctId":5739,"briefTitle":5740,"status":106,"phases":5741,"primaryCompletion":5742,"completion":5743,"start":5744,"enrollment":13,"conditions":5745,"interventions":5746},"NCT00688415","Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer",[89],"2010-08","2010-11","2008-11-07",[4139,660],[3565],{"trials":5748,"activeCount":100},[5749,5762],{"nctId":5750,"briefTitle":5751,"status":106,"phases":5752,"primaryCompletion":5753,"completion":5753,"start":5754,"enrollment":5755,"conditions":5756,"interventions":5760},"NCT01666444","VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[90],"2016-07-31","2012-10-31",297,[5757,5758,5759],"Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer",[5761,3565],"pegylated liposomal doxorubicin",{"nctId":3555,"briefTitle":3556,"status":106,"phases":5763,"primaryCompletion":3558,"completion":3559,"start":3560,"enrollment":3561,"conditions":5764,"interventions":5765},[90],[3563],[3565,2701,432,3566],{"trials":5767,"activeCount":100},[],{"trials":5769,"activeCount":100},[],{"trials":5771,"activeCount":100},[],{"intervention":5773,"totalTrials":235,"cells":5774},"Sotatercept",{"EARLY_PHASE1":5775,"PHASE1":5777,"PHASE2":5779,"PHASE3":5809,"PHASE4":5811,"NA":5813},{"trials":5776,"activeCount":100},[],{"trials":5778,"activeCount":100},[],{"trials":5780,"activeCount":100},[5781,5789,5801],{"nctId":5782,"briefTitle":5783,"status":106,"phases":5784,"primaryCompletion":3393,"completion":3393,"start":5785,"enrollment":12,"conditions":5786,"interventions":5788},"NCT01999582","A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis",[90],"2013-11-30",[1454,5787],"Kidney Failure, Chronic",[5773,5773],{"nctId":5790,"briefTitle":5791,"status":171,"phases":5792,"primaryCompletion":5793,"completion":5794,"start":5795,"enrollment":186,"conditions":5796,"interventions":5799},"NCT01571635","Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.",[90],"2015-07-02","2022-05-24","2012-10-10",[5797,5798],"Beta Thalassemia Major","Beta Thalassemia Intermedia",[5800],"SOTATERCEPT",{"nctId":5802,"briefTitle":5803,"status":106,"phases":5804,"primaryCompletion":5805,"completion":5805,"start":5806,"enrollment":12,"conditions":5807,"interventions":5808},"NCT01146574","A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.",[90],"2016-03-07","2010-06-30",[1454],[5773],{"trials":5810,"activeCount":100},[],{"trials":5812,"activeCount":100},[],{"trials":5814,"activeCount":100},[],{"intervention":651,"totalTrials":235,"cells":5816},{"EARLY_PHASE1":5817,"PHASE1":5819,"PHASE2":5829,"PHASE3":5835,"PHASE4":5837,"NA":5839},{"trials":5818,"activeCount":100},[],{"trials":5820,"activeCount":100},[5821,5825],{"nctId":5185,"briefTitle":5186,"status":171,"phases":5822,"primaryCompletion":5188,"completion":5189,"start":5190,"enrollment":877,"conditions":5823,"interventions":5824},[89],[5192],[5194,651,2700],{"nctId":642,"briefTitle":643,"status":171,"phases":5826,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":5827,"interventions":5828},[89],[32],[650,128,651],{"trials":5830,"activeCount":100},[5831],{"nctId":1382,"briefTitle":1383,"status":171,"phases":5832,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":5833,"interventions":5834},[90],[1389],[1391,226],{"trials":5836,"activeCount":100},[],{"trials":5838,"activeCount":100},[],{"trials":5840,"activeCount":100},[],{"intervention":729,"totalTrials":235,"cells":5842},{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5861,"PHASE4":5863,"NA":5865},{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[5849,5853,5857],{"nctId":3105,"briefTitle":3106,"status":106,"phases":5850,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":5851,"interventions":5852},[89,90],[727],[638,729,662],{"nctId":719,"briefTitle":720,"status":106,"phases":5854,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":5855,"interventions":5856},[89,90],[660,727],[189,115,128,729,167],{"nctId":2910,"briefTitle":2911,"status":106,"phases":5858,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":5859,"interventions":5860},[89,90],[24,124,125],[159,189,638,729,56,2917,2700,144],{"trials":5862,"activeCount":100},[],{"trials":5864,"activeCount":100},[],{"trials":5866,"activeCount":100},[],{"intervention":5868,"totalTrials":190,"cells":5869},"MRZ",{"EARLY_PHASE1":5870,"PHASE1":5872,"PHASE2":5884,"PHASE3":5895,"PHASE4":5897,"NA":5899},{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":100},[5874],{"nctId":5875,"briefTitle":5876,"status":106,"phases":5877,"primaryCompletion":5878,"completion":5878,"start":5879,"enrollment":4162,"conditions":5880,"interventions":5882},"NCT02903069","Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer",[89],"2021-01-25","2016-08-17",[5108,5881],"Malignant Glioma",[5868,5883],"TMZ",{"trials":5885,"activeCount":100},[5886],{"nctId":5887,"briefTitle":5888,"status":106,"phases":5889,"primaryCompletion":3420,"completion":3420,"start":5890,"enrollment":5891,"conditions":5892,"interventions":5893},"NCT02330562","Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab",[89,90],"2015-04-15",121,[5881,5108],[5868,5894],"BEV",{"trials":5896,"activeCount":100},[],{"trials":5898,"activeCount":100},[],{"trials":5900,"activeCount":100},[],{"intervention":5902,"totalTrials":190,"cells":5903},"Nanoparticle Paclitaxel",{"EARLY_PHASE1":5904,"PHASE1":5906,"PHASE2":5908,"PHASE3":5927,"PHASE4":5929,"NA":5931},{"trials":5905,"activeCount":100},[],{"trials":5907,"activeCount":100},[],{"trials":5909,"activeCount":100},[5910,5918],{"nctId":5911,"briefTitle":5912,"status":106,"phases":5913,"primaryCompletion":545,"completion":545,"start":4973,"enrollment":5914,"conditions":5915,"interventions":5917},"NCT00124943","Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis",[89,90],112,[5916],"Coronary Restenosis",[5902],{"nctId":5919,"briefTitle":5920,"status":171,"phases":5921,"primaryCompletion":545,"completion":5922,"start":5923,"enrollment":963,"conditions":5924,"interventions":5926},"NCT00518284","Prevention of Restenosis Following Revascularization",[90],"2009-09","2008-01",[5925],"Vascular Disease, Peripheral",[5902],{"trials":5928,"activeCount":100},[],{"trials":5930,"activeCount":100},[],{"trials":5932,"activeCount":100},[],{"intervention":5934,"totalTrials":190,"cells":5935},"ABI-008",{"EARLY_PHASE1":5936,"PHASE1":5938,"PHASE2":5940,"PHASE3":5956,"PHASE4":5958,"NA":5960},{"trials":5937,"activeCount":100},[],{"trials":5939,"activeCount":100},[],{"trials":5941,"activeCount":100},[5942,5950],{"nctId":5943,"briefTitle":5944,"status":106,"phases":5945,"primaryCompletion":5946,"completion":5946,"start":1042,"enrollment":1698,"conditions":5947,"interventions":5949},"NCT00477529","ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer",[89,90],"2011-06-02",[5948],"Hormone Refractory Prostate Cancer",[5934],{"nctId":5951,"briefTitle":5952,"status":171,"phases":5953,"primaryCompletion":467,"completion":467,"start":3590,"enrollment":317,"conditions":5954,"interventions":5955},"NCT00531271","ABI-008 Trial in Patients With Metastatic Breast Cancer",[89,90],[2485],[5934],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[],{"trials":5961,"activeCount":100},[],{"intervention":5963,"totalTrials":190,"cells":5964},"FK228",{"EARLY_PHASE1":5965,"PHASE1":5967,"PHASE2":5969,"PHASE3":5987,"PHASE4":5989,"NA":5991},{"trials":5966,"activeCount":100},[],{"trials":5968,"activeCount":100},[],{"trials":5970,"activeCount":100},[5971,5979],{"nctId":5972,"briefTitle":5973,"status":106,"phases":5974,"primaryCompletion":2360,"completion":2360,"start":5975,"enrollment":190,"conditions":5976,"interventions":5978},"NCT00106301","Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228",[90],"2004-04-01",[5977,1018],"Carcinoma, Renal Cell",[5963],{"nctId":5980,"briefTitle":5981,"status":106,"phases":5982,"primaryCompletion":5983,"completion":5983,"start":5984,"enrollment":1821,"conditions":5985,"interventions":5986},"NCT00106613","A Research Study for Patients With Metastatic Renal Cell Carcinoma",[90],"2004-08-01","2003-05-01",[5977,3745],[5963],{"trials":5988,"activeCount":100},[],{"trials":5990,"activeCount":100},[],{"trials":5992,"activeCount":100},[],{"intervention":2459,"totalTrials":190,"cells":5994},{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":6009,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":5996,"activeCount":100},[],{"trials":5998,"activeCount":100},[5999],{"nctId":6000,"briefTitle":6001,"status":171,"phases":6002,"primaryCompletion":6003,"completion":6004,"start":6005,"enrollment":3110,"conditions":6006,"interventions":6007},"NCT04036461","A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma",[89],"2024-07-08","2024-08-19","2019-08-26",[16],[6008,2459],"CC-99712",{"trials":6010,"activeCount":100},[6011],{"nctId":2451,"briefTitle":2452,"status":171,"phases":6012,"primaryCompletion":2454,"completion":2454,"start":2455,"enrollment":175,"conditions":6013,"interventions":6014},[89,90],[16],[2458,56,2459],{"trials":6016,"activeCount":100},[],{"trials":6018,"activeCount":100},[],{"trials":6020,"activeCount":100},[],{"intervention":6022,"totalTrials":190,"cells":6023},"CC-930",{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6028,"PHASE3":6047,"PHASE4":6049,"NA":6051},{"trials":6025,"activeCount":100},[],{"trials":6027,"activeCount":100},[],{"trials":6029,"activeCount":100},[6030,6039],{"nctId":6031,"briefTitle":6032,"status":171,"phases":6033,"primaryCompletion":6034,"completion":6034,"start":6035,"enrollment":3034,"conditions":6036,"interventions":6038},"NCT01466725","A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus",[90],"2012-07-30","2011-11-01",[6037],"Discoid Lupus",[6022],{"nctId":6040,"briefTitle":6041,"status":171,"phases":6042,"primaryCompletion":6043,"completion":6044,"start":1586,"enrollment":1197,"conditions":6045,"interventions":6046},"NCT01203943","A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)",[90],"2012-01-31","2012-08-24",[5373,5353,5374,1947,5377],[6022,6022,6022],{"trials":6048,"activeCount":100},[],{"trials":6050,"activeCount":100},[],{"trials":6052,"activeCount":100},[],{"intervention":289,"totalTrials":190,"cells":6054},{"EARLY_PHASE1":6055,"PHASE1":6057,"PHASE2":6063,"PHASE3":6073,"PHASE4":6075,"NA":6077},{"trials":6056,"activeCount":100},[],{"trials":6058,"activeCount":100},[6059],{"nctId":281,"briefTitle":282,"status":106,"phases":6060,"primaryCompletion":284,"completion":285,"start":286,"enrollment":20,"conditions":6061,"interventions":6062},[89],[16],[289,226,241],{"trials":6064,"activeCount":100},[6065],{"nctId":6066,"briefTitle":6067,"status":106,"phases":6068,"primaryCompletion":3859,"completion":6069,"start":6070,"enrollment":3012,"conditions":6071,"interventions":6072},"NCT01323751","Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma",[89,90],"2016-12-03","2011-07",[16],[289],{"trials":6074,"activeCount":100},[],{"trials":6076,"activeCount":100},[],{"trials":6078,"activeCount":100},[],{"intervention":3566,"totalTrials":190,"cells":6080},{"EARLY_PHASE1":6081,"PHASE1":6083,"PHASE2":6085,"PHASE3":6103,"PHASE4":6105,"NA":6107},{"trials":6082,"activeCount":100},[],{"trials":6084,"activeCount":100},[],{"trials":6086,"activeCount":100},[6087,6099],{"nctId":6088,"briefTitle":6089,"status":171,"phases":6090,"start":6091,"conditions":6092,"interventions":6095},"NCT00040391","A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan\u002F5FU\u002FLeucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer",[90],"2002-06",[6093,6094],"Colorectal Neoplasms","Diarrhea",[6096,6097,3566,6098],"Investigational drug","Irinotecan","Leucovorin",{"nctId":3555,"briefTitle":3556,"status":106,"phases":6100,"primaryCompletion":3558,"completion":3559,"start":3560,"enrollment":3561,"conditions":6101,"interventions":6102},[90],[3563],[3565,2701,432,3566],{"trials":6104,"activeCount":100},[],{"trials":6106,"activeCount":100},[],{"trials":6108,"activeCount":100},[],{"intervention":6110,"totalTrials":146,"cells":6111},"VTX-2337 plus radiotherapy",{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6113,"activeCount":100},[],{"trials":6115,"activeCount":100},[],{"trials":6117,"activeCount":100},[6118],{"nctId":6119,"briefTitle":6120,"status":171,"phases":6121,"primaryCompletion":6122,"completion":6123,"start":6070,"enrollment":190,"conditions":6124,"interventions":6126},"NCT01289210","VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas",[89,90],"2011-11","2012-10",[6125],"Low Grade B Cell Lymphoma",[6110],{"trials":6128,"activeCount":100},[],{"trials":6130,"activeCount":100},[],{"trials":6132,"activeCount":100},[],{"intervention":6134,"totalTrials":146,"cells":6135},"CC-1088",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6140,"PHASE3":6151,"PHASE4":6153,"NA":6155},{"trials":6137,"activeCount":100},[],{"trials":6139,"activeCount":100},[],{"trials":6141,"activeCount":100},[6142],{"nctId":6143,"briefTitle":6144,"status":106,"phases":6145,"primaryCompletion":6146,"completion":6147,"start":6148,"enrollment":877,"conditions":6149,"interventions":6150},"NCT00045786","Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes",[90],"2001-12","2003-11","2001-10",[34],[6134],{"trials":6152,"activeCount":100},[],{"trials":6154,"activeCount":100},[],{"trials":6156,"activeCount":100},[],{"intervention":5894,"totalTrials":146,"cells":6158},{"EARLY_PHASE1":6159,"PHASE1":6161,"PHASE2":6163,"PHASE3":6169,"PHASE4":6171,"NA":6173},{"trials":6160,"activeCount":100},[],{"trials":6162,"activeCount":100},[],{"trials":6164,"activeCount":100},[6165],{"nctId":5887,"briefTitle":5888,"status":106,"phases":6166,"primaryCompletion":3420,"completion":3420,"start":5890,"enrollment":5891,"conditions":6167,"interventions":6168},[89,90],[5881,5108],[5868,5894],{"trials":6170,"activeCount":100},[],{"trials":6172,"activeCount":100},[],{"trials":6174,"activeCount":100},[],{"intervention":3545,"totalTrials":146,"cells":6176},{"EARLY_PHASE1":6177,"PHASE1":6179,"PHASE2":6181,"PHASE3":6187,"PHASE4":6189,"NA":6191},{"trials":6178,"activeCount":100},[],{"trials":6180,"activeCount":100},[],{"trials":6182,"activeCount":100},[6183],{"nctId":3539,"briefTitle":3540,"status":106,"phases":6184,"primaryCompletion":507,"completion":507,"start":3542,"enrollment":823,"conditions":6185,"interventions":6186},[90],[2773],[2745,2701,3545],{"trials":6188,"activeCount":100},[],{"trials":6190,"activeCount":100},[],{"trials":6192,"activeCount":100},[],{"intervention":6194,"totalTrials":146,"cells":6195},"CC-220 0.3 mg Daily",{"EARLY_PHASE1":6196,"PHASE1":6198,"PHASE2":6200,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6197,"activeCount":100},[],{"trials":6199,"activeCount":100},[],{"trials":6201,"activeCount":100},[6202],{"nctId":6203,"briefTitle":6204,"status":423,"phases":6205,"primaryCompletion":6206,"completion":6206,"start":6207,"enrollment":100,"conditions":6208,"interventions":6210},"NCT02192489","A Phase 2 Study With CC-220 in Skin Sarcoidosis",[90],"2017-06-30","2014-11-01",[6209],"Sarcoidosis",[6194,6211],"CC-220 0.6mg Daily",{"trials":6213,"activeCount":100},[],{"trials":6215,"activeCount":100},[],{"trials":6217,"activeCount":100},[],{"intervention":6211,"totalTrials":146,"cells":6219},{"EARLY_PHASE1":6220,"PHASE1":6222,"PHASE2":6224,"PHASE3":6230,"PHASE4":6232,"NA":6234},{"trials":6221,"activeCount":100},[],{"trials":6223,"activeCount":100},[],{"trials":6225,"activeCount":100},[6226],{"nctId":6203,"briefTitle":6204,"status":423,"phases":6227,"primaryCompletion":6206,"completion":6206,"start":6207,"enrollment":100,"conditions":6228,"interventions":6229},[90],[6209],[6194,6211],{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[],{"trials":6235,"activeCount":100},[],{"intervention":6237,"totalTrials":146,"cells":6238},"dexmethylphenidate",{"EARLY_PHASE1":6239,"PHASE1":6241,"PHASE2":6243,"PHASE3":6254,"PHASE4":6256,"NA":6258},{"trials":6240,"activeCount":100},[],{"trials":6242,"activeCount":100},[],{"trials":6244,"activeCount":100},[6245],{"nctId":6246,"briefTitle":6247,"status":106,"phases":6248,"completion":6249,"start":6091,"enrollment":6250,"conditions":6251,"interventions":6253},"NCT00047476","D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients",[90],"2004-03",160,[6252,32],"Fatigue",[6237],{"trials":6255,"activeCount":100},[],{"trials":6257,"activeCount":100},[],{"trials":6259,"activeCount":100},[],{"intervention":1299,"totalTrials":146,"cells":6261},{"EARLY_PHASE1":6262,"PHASE1":6264,"PHASE2":6266,"PHASE3":6272,"PHASE4":6274,"NA":6276},{"trials":6263,"activeCount":100},[],{"trials":6265,"activeCount":100},[],{"trials":6267,"activeCount":100},[6268],{"nctId":1291,"briefTitle":1292,"status":171,"phases":6269,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":25,"conditions":6270,"interventions":6271},[89,90],[1297],[115,1299],{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[],{"trials":6277,"activeCount":100},[],{"intervention":6279,"totalTrials":146,"cells":6280},"nab-paclitaxel IV",{"EARLY_PHASE1":6281,"PHASE1":6283,"PHASE2":6285,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6282,"activeCount":100},[],{"trials":6284,"activeCount":100},[],{"trials":6286,"activeCount":100},[6287],{"nctId":6288,"briefTitle":6289,"status":106,"phases":6290,"primaryCompletion":6291,"completion":6292,"start":6293,"enrollment":6294,"conditions":6295,"interventions":6296},"NCT02250326","Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second\u002FThird-line Treatment for Advanced Non-small Cell Lung Cancer",[90],"2017-07-17","2023-08-17","2015-01-07",240,[3512],[6279,3516,6297],"Duravalumab",{"trials":6299,"activeCount":100},[],{"trials":6301,"activeCount":100},[],{"trials":6303,"activeCount":100},[],{"intervention":6297,"totalTrials":146,"cells":6305},{"EARLY_PHASE1":6306,"PHASE1":6308,"PHASE2":6310,"PHASE3":6316,"PHASE4":6318,"NA":6320},{"trials":6307,"activeCount":100},[],{"trials":6309,"activeCount":100},[],{"trials":6311,"activeCount":100},[6312],{"nctId":6288,"briefTitle":6289,"status":106,"phases":6313,"primaryCompletion":6291,"completion":6292,"start":6293,"enrollment":6294,"conditions":6314,"interventions":6315},[90],[3512],[6279,3516,6297],{"trials":6317,"activeCount":100},[],{"trials":6319,"activeCount":100},[],{"trials":6321,"activeCount":100},[],{"intervention":6323,"totalTrials":146,"cells":6324},"Fulvestrant",{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6329,"PHASE3":6339,"PHASE4":6341,"NA":6343},{"trials":6326,"activeCount":100},[],{"trials":6328,"activeCount":100},[],{"trials":6330,"activeCount":100},[6331],{"nctId":6332,"briefTitle":6333,"status":171,"phases":6334,"primaryCompletion":6335,"completion":2750,"start":6336,"enrollment":17,"conditions":6337,"interventions":6338},"NCT02374099","Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant",[90],"2016-12-13","2015-03-13",[2696],[3516,6323],{"trials":6340,"activeCount":100},[],{"trials":6342,"activeCount":100},[],{"trials":6344,"activeCount":100},[],{"intervention":2440,"totalTrials":146,"cells":6346},{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6351,"PHASE3":6357,"PHASE4":6359,"NA":6361},{"trials":6348,"activeCount":100},[],{"trials":6350,"activeCount":100},[],{"trials":6352,"activeCount":100},[6353],{"nctId":2432,"briefTitle":2433,"status":106,"phases":6354,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":2437,"conditions":6355,"interventions":6356},[90],[16],[113,2440,2441],{"trials":6358,"activeCount":100},[],{"trials":6360,"activeCount":100},[],{"trials":6362,"activeCount":100},[],{"intervention":2441,"totalTrials":146,"cells":6364},{"EARLY_PHASE1":6365,"PHASE1":6367,"PHASE2":6369,"PHASE3":6375,"PHASE4":6377,"NA":6379},{"trials":6366,"activeCount":100},[],{"trials":6368,"activeCount":100},[],{"trials":6370,"activeCount":100},[6371],{"nctId":2432,"briefTitle":2433,"status":106,"phases":6372,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":2437,"conditions":6373,"interventions":6374},[90],[16],[113,2440,2441],{"trials":6376,"activeCount":100},[],{"trials":6378,"activeCount":100},[],{"trials":6380,"activeCount":100},[],{"intervention":6382,"totalTrials":146,"cells":6383},"JCAR015",{"EARLY_PHASE1":6384,"PHASE1":6386,"PHASE2":6388,"PHASE3":6399,"PHASE4":6401,"NA":6403},{"trials":6385,"activeCount":100},[],{"trials":6387,"activeCount":100},[],{"trials":6389,"activeCount":100},[6390],{"nctId":6391,"briefTitle":6392,"status":423,"phases":6393,"primaryCompletion":6394,"completion":6395,"start":6396,"enrollment":100,"conditions":6397,"interventions":6398},"NCT02973191","A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia",[89,90],"2019-06-25","2021-01-24","2016-12-20",[177],[6382],{"trials":6400,"activeCount":100},[],{"trials":6402,"activeCount":100},[],{"trials":6404,"activeCount":100},[],{"intervention":6406,"totalTrials":146,"cells":6407},"CDC-501",{"EARLY_PHASE1":6408,"PHASE1":6410,"PHASE2":6412,"PHASE3":6423,"PHASE4":6425,"NA":6427},{"trials":6409,"activeCount":100},[],{"trials":6411,"activeCount":100},[],{"trials":6413,"activeCount":100},[6414],{"nctId":6415,"briefTitle":6416,"status":106,"phases":6417,"primaryCompletion":6418,"completion":6419,"start":6420,"enrollment":1698,"conditions":6421,"interventions":6422},"NCT00044018","CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma",[90],"2004-12-01","2007-02-15","2002-04-01",[16],[6406],{"trials":6424,"activeCount":100},[],{"trials":6426,"activeCount":100},[],{"trials":6428,"activeCount":100},[],{"intervention":5655,"totalTrials":146,"cells":6430},{"EARLY_PHASE1":6431,"PHASE1":6433,"PHASE2":6435,"PHASE3":6441,"PHASE4":6443,"NA":6445},{"trials":6432,"activeCount":100},[],{"trials":6434,"activeCount":100},[],{"trials":6436,"activeCount":100},[6437],{"nctId":5649,"briefTitle":5650,"status":106,"phases":6438,"primaryCompletion":3662,"completion":1921,"start":1186,"enrollment":5652,"conditions":6439,"interventions":6440},[90],[2773],[5655,2487,5656,5657,5658],{"trials":6442,"activeCount":100},[],{"trials":6444,"activeCount":100},[],{"trials":6446,"activeCount":100},[],{"intervention":5656,"totalTrials":146,"cells":6448},{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6453,"PHASE3":6459,"PHASE4":6461,"NA":6463},{"trials":6450,"activeCount":100},[],{"trials":6452,"activeCount":100},[],{"trials":6454,"activeCount":100},[6455],{"nctId":5649,"briefTitle":5650,"status":106,"phases":6456,"primaryCompletion":3662,"completion":1921,"start":1186,"enrollment":5652,"conditions":6457,"interventions":6458},[90],[2773],[5655,2487,5656,5657,5658],{"trials":6460,"activeCount":100},[],{"trials":6462,"activeCount":100},[],{"trials":6464,"activeCount":100},[],{"intervention":5658,"totalTrials":146,"cells":6466},{"EARLY_PHASE1":6467,"PHASE1":6469,"PHASE2":6471,"PHASE3":6477,"PHASE4":6479,"NA":6481},{"trials":6468,"activeCount":100},[],{"trials":6470,"activeCount":100},[],{"trials":6472,"activeCount":100},[6473],{"nctId":5649,"briefTitle":5650,"status":106,"phases":6474,"primaryCompletion":3662,"completion":1921,"start":1186,"enrollment":5652,"conditions":6475,"interventions":6476},[90],[2773],[5655,2487,5656,5657,5658],{"trials":6478,"activeCount":100},[],{"trials":6480,"activeCount":100},[],{"trials":6482,"activeCount":100},[],{"intervention":1319,"totalTrials":146,"cells":6484},{"EARLY_PHASE1":6485,"PHASE1":6487,"PHASE2":6489,"PHASE3":6495,"PHASE4":6497,"NA":6499},{"trials":6486,"activeCount":100},[],{"trials":6488,"activeCount":100},[],{"trials":6490,"activeCount":100},[6491],{"nctId":1309,"briefTitle":1310,"status":106,"phases":6492,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":6493,"interventions":6494},[90],[1250,1317],[115,1319],{"trials":6496,"activeCount":100},[],{"trials":6498,"activeCount":100},[],{"trials":6500,"activeCount":100},[],{"intervention":5761,"totalTrials":146,"cells":6502},{"EARLY_PHASE1":6503,"PHASE1":6505,"PHASE2":6507,"PHASE3":6513,"PHASE4":6515,"NA":6517},{"trials":6504,"activeCount":100},[],{"trials":6506,"activeCount":100},[],{"trials":6508,"activeCount":100},[6509],{"nctId":5750,"briefTitle":5751,"status":106,"phases":6510,"primaryCompletion":5753,"completion":5753,"start":5754,"enrollment":5755,"conditions":6511,"interventions":6512},[90],[5757,5758,5759],[5761,3565],{"trials":6514,"activeCount":100},[],{"trials":6516,"activeCount":100},[],{"trials":6518,"activeCount":100},[],{"intervention":179,"totalTrials":146,"cells":6520},{"EARLY_PHASE1":6521,"PHASE1":6523,"PHASE2":6525,"PHASE3":6531,"PHASE4":6533,"NA":6535},{"trials":6522,"activeCount":100},[],{"trials":6524,"activeCount":100},[],{"trials":6526,"activeCount":100},[6527],{"nctId":169,"briefTitle":170,"status":171,"phases":6528,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":6529,"interventions":6530},[89,90],[177,24],[159,179,114,96],{"trials":6532,"activeCount":100},[],{"trials":6534,"activeCount":100},[],{"trials":6536,"activeCount":100},[],{"intervention":6538,"totalTrials":146,"cells":6539},"ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone",{"EARLY_PHASE1":6540,"PHASE1":6542,"PHASE2":6544,"PHASE3":6555,"PHASE4":6557,"NA":6559},{"trials":6541,"activeCount":100},[],{"trials":6543,"activeCount":100},[],{"trials":6545,"activeCount":100},[6546],{"nctId":6547,"briefTitle":6548,"status":171,"phases":6549,"primaryCompletion":6550,"completion":6550,"start":6551,"enrollment":6552,"conditions":6553,"interventions":6554},"NCT01997840","ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma",[89,90],"2024-02-29","2014-03-01",103,[16],[6538],{"trials":6556,"activeCount":100},[],{"trials":6558,"activeCount":100},[],{"trials":6560,"activeCount":100},[],{"intervention":6562,"totalTrials":146,"cells":6563},"Pomalidomide and Dexamethasone",{"EARLY_PHASE1":6564,"PHASE1":6566,"PHASE2":6568,"PHASE3":6578,"PHASE4":6580,"NA":6582},{"trials":6565,"activeCount":100},[],{"trials":6567,"activeCount":100},[],{"trials":6569,"activeCount":100},[6570],{"nctId":6571,"briefTitle":6572,"status":106,"phases":6573,"primaryCompletion":6574,"completion":1016,"start":6575,"enrollment":3386,"conditions":6576,"interventions":6577},"NCT02045017","Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency",[90],"2017-01-27","2014-02-28",[16],[6562],{"trials":6579,"activeCount":100},[],{"trials":6581,"activeCount":100},[],{"trials":6583,"activeCount":100},[],{"intervention":2917,"totalTrials":146,"cells":6585},{"EARLY_PHASE1":6586,"PHASE1":6588,"PHASE2":6590,"PHASE3":6596,"PHASE4":6598,"NA":6600},{"trials":6587,"activeCount":100},[],{"trials":6589,"activeCount":100},[],{"trials":6591,"activeCount":100},[6592],{"nctId":2910,"briefTitle":2911,"status":106,"phases":6593,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":407,"conditions":6594,"interventions":6595},[89,90],[24,124,125],[159,189,638,729,56,2917,2700,144],{"trials":6597,"activeCount":100},[],{"trials":6599,"activeCount":100},[],{"trials":6601,"activeCount":100},[],{"intervention":6603,"totalTrials":146,"cells":6604},"Paclitaxel Nanoparticle Albumin Bound",{"EARLY_PHASE1":6605,"PHASE1":6607,"PHASE2":6609,"PHASE3":6621,"PHASE4":6623,"NA":6625},{"trials":6606,"activeCount":100},[],{"trials":6608,"activeCount":100},[],{"trials":6610,"activeCount":100},[6611],{"nctId":6612,"briefTitle":6613,"status":106,"phases":6614,"primaryCompletion":6615,"completion":6615,"start":6616,"enrollment":4171,"conditions":6617,"interventions":6620},"NCT00093223","A Safety Study of ABI-007 for In-Stent Restenosis",[90],"2007-12-01","2001-09-01",[6618,6619],"Angina Pectoris","Coronary Artery Disease",[6603,6603,6603],{"trials":6622,"activeCount":100},[],{"trials":6624,"activeCount":100},[],{"trials":6626,"activeCount":100},[],{"intervention":6628,"totalTrials":146,"cells":6629},"MRZ 0.5 mg\u002Fm^2",{"EARLY_PHASE1":6630,"PHASE1":6632,"PHASE2":6634,"PHASE3":6643,"PHASE4":6645,"NA":6647},{"trials":6631,"activeCount":100},[],{"trials":6633,"activeCount":100},[],{"trials":6635,"activeCount":100},[6636],{"nctId":6637,"briefTitle":6638,"status":106,"phases":6639,"primaryCompletion":377,"completion":6640,"start":546,"enrollment":296,"conditions":6641,"interventions":6642},"NCT00461045","Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed\u002FRefractory Multiple Myeloma",[90],"2014-10",[16],[6628],{"trials":6644,"activeCount":100},[],{"trials":6646,"activeCount":100},[],{"trials":6648,"activeCount":100},[],{"intervention":3708,"totalTrials":146,"cells":6650},{"EARLY_PHASE1":6651,"PHASE1":6653,"PHASE2":6655,"PHASE3":6661,"PHASE4":6663,"NA":6665},{"trials":6652,"activeCount":100},[],{"trials":6654,"activeCount":100},[],{"trials":6656,"activeCount":100},[6657],{"nctId":3701,"briefTitle":3702,"status":171,"phases":6658,"completion":3704,"start":3705,"enrollment":669,"conditions":6659,"interventions":6660},[89,90],[3684],[372,3708],{"trials":6662,"activeCount":100},[],{"trials":6664,"activeCount":100},[],{"trials":6666,"activeCount":100},[],{"intervention":1362,"totalTrials":146,"cells":6668},{"EARLY_PHASE1":6669,"PHASE1":6671,"PHASE2":6673,"PHASE3":6679,"PHASE4":6681,"NA":6683},{"trials":6670,"activeCount":100},[],{"trials":6672,"activeCount":100},[],{"trials":6674,"activeCount":100},[6675],{"nctId":1353,"briefTitle":1354,"status":106,"phases":6676,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":684,"conditions":6677,"interventions":6678},[89,90],[1360],[115,1362],{"trials":6680,"activeCount":100},[],{"trials":6682,"activeCount":100},[],{"trials":6684,"activeCount":100},[],{"intervention":6686,"totalTrials":146,"cells":6687},"ABI-007 (Abraxane) and Carboplatin",{"EARLY_PHASE1":6688,"PHASE1":6690,"PHASE2":6692,"PHASE3":6703,"PHASE4":6705,"NA":6707},{"trials":6689,"activeCount":100},[],{"trials":6691,"activeCount":100},[],{"trials":6693,"activeCount":100},[6694],{"nctId":6695,"briefTitle":6696,"status":106,"phases":6697,"primaryCompletion":3632,"completion":3632,"start":6698,"enrollment":6699,"conditions":6700,"interventions":6702},"NCT00274443","An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin",[90],"2005-03-01",250,[6701],"Non-Small Cell Lung Cancer (NSCLC)",[6686],{"trials":6704,"activeCount":100},[],{"trials":6706,"activeCount":100},[],{"trials":6708,"activeCount":100},[],{"intervention":2756,"totalTrials":146,"cells":6710},{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6715,"PHASE3":6721,"PHASE4":6723,"NA":6725},{"trials":6712,"activeCount":100},[],{"trials":6714,"activeCount":100},[],{"trials":6716,"activeCount":100},[6717],{"nctId":2747,"briefTitle":2748,"status":106,"phases":6718,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":6719,"interventions":6720},[90],[2697],[2699,431,2756,2757],{"trials":6722,"activeCount":100},[],{"trials":6724,"activeCount":100},[],{"trials":6726,"activeCount":100},[],{"intervention":2757,"totalTrials":146,"cells":6728},{"EARLY_PHASE1":6729,"PHASE1":6731,"PHASE2":6733,"PHASE3":6739,"PHASE4":6741,"NA":6743},{"trials":6730,"activeCount":100},[],{"trials":6732,"activeCount":100},[],{"trials":6734,"activeCount":100},[6735],{"nctId":2747,"briefTitle":2748,"status":106,"phases":6736,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":6737,"interventions":6738},[90],[2697],[2699,431,2756,2757],{"trials":6740,"activeCount":100},[],{"trials":6742,"activeCount":100},[],{"trials":6744,"activeCount":100},[],{"intervention":6746,"totalTrials":146,"cells":6747},"vinorelbine",{"EARLY_PHASE1":6748,"PHASE1":6750,"PHASE2":6752,"PHASE3":6764,"PHASE4":6766,"NA":6768},{"trials":6749,"activeCount":100},[],{"trials":6751,"activeCount":100},[],{"trials":6753,"activeCount":100},[6754],{"nctId":6755,"briefTitle":6756,"status":171,"phases":6757,"primaryCompletion":6758,"completion":6758,"start":1304,"enrollment":25,"conditions":6759,"interventions":6761},"NCT00140140","A Phase I\u002FII Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer",[89,90],"2008-02",[6760],"Stage IV (Metastatic) Breast Cancer",[2487,6746,6762,6763],"Trastuzumab","G-CSF",{"trials":6765,"activeCount":100},[],{"trials":6767,"activeCount":100},[],{"trials":6769,"activeCount":100},[],{"intervention":6762,"totalTrials":146,"cells":6771},{"EARLY_PHASE1":6772,"PHASE1":6774,"PHASE2":6776,"PHASE3":6782,"PHASE4":6784,"NA":6786},{"trials":6773,"activeCount":100},[],{"trials":6775,"activeCount":100},[],{"trials":6777,"activeCount":100},[6778],{"nctId":6755,"briefTitle":6756,"status":171,"phases":6779,"primaryCompletion":6758,"completion":6758,"start":1304,"enrollment":25,"conditions":6780,"interventions":6781},[89,90],[6760],[2487,6746,6762,6763],{"trials":6783,"activeCount":100},[],{"trials":6785,"activeCount":100},[],{"trials":6787,"activeCount":100},[],{"intervention":6763,"totalTrials":146,"cells":6789},{"EARLY_PHASE1":6790,"PHASE1":6792,"PHASE2":6794,"PHASE3":6800,"PHASE4":6802,"NA":6804},{"trials":6791,"activeCount":100},[],{"trials":6793,"activeCount":100},[],{"trials":6795,"activeCount":100},[6796],{"nctId":6755,"briefTitle":6756,"status":171,"phases":6797,"primaryCompletion":6758,"completion":6758,"start":1304,"enrollment":25,"conditions":6798,"interventions":6799},[89,90],[6760],[2487,6746,6762,6763],{"trials":6801,"activeCount":100},[],{"trials":6803,"activeCount":100},[],{"trials":6805,"activeCount":100},[],{"intervention":6807,"totalTrials":146,"cells":6808},"CC5013",{"EARLY_PHASE1":6809,"PHASE1":6811,"PHASE2":6813,"PHASE3":6822,"PHASE4":6824,"NA":6826},{"trials":6810,"activeCount":100},[],{"trials":6812,"activeCount":100},[],{"trials":6814,"activeCount":100},[6815],{"nctId":6816,"briefTitle":6817,"status":171,"phases":6818,"completion":6819,"start":2733,"enrollment":684,"conditions":6820,"interventions":6821},"NCT00179738","A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.",[90],"2007-04",[1082],[6807],{"trials":6823,"activeCount":100},[],{"trials":6825,"activeCount":100},[],{"trials":6827,"activeCount":100},[],{"intervention":6096,"totalTrials":146,"cells":6829},{"EARLY_PHASE1":6830,"PHASE1":6832,"PHASE2":6834,"PHASE3":6840,"PHASE4":6842,"NA":6844},{"trials":6831,"activeCount":100},[],{"trials":6833,"activeCount":100},[],{"trials":6835,"activeCount":100},[6836],{"nctId":6088,"briefTitle":6089,"status":171,"phases":6837,"start":6091,"conditions":6838,"interventions":6839},[90],[6093,6094],[6096,6097,3566,6098],{"trials":6841,"activeCount":100},[],{"trials":6843,"activeCount":100},[],{"trials":6845,"activeCount":100},[],{"intervention":6097,"totalTrials":146,"cells":6847},{"EARLY_PHASE1":6848,"PHASE1":6850,"PHASE2":6852,"PHASE3":6858,"PHASE4":6860,"NA":6862},{"trials":6849,"activeCount":100},[],{"trials":6851,"activeCount":100},[],{"trials":6853,"activeCount":100},[6854],{"nctId":6088,"briefTitle":6089,"status":171,"phases":6855,"start":6091,"conditions":6856,"interventions":6857},[90],[6093,6094],[6096,6097,3566,6098],{"trials":6859,"activeCount":100},[],{"trials":6861,"activeCount":100},[],{"trials":6863,"activeCount":100},[],{"intervention":6098,"totalTrials":146,"cells":6865},{"EARLY_PHASE1":6866,"PHASE1":6868,"PHASE2":6870,"PHASE3":6876,"PHASE4":6878,"NA":6880},{"trials":6867,"activeCount":100},[],{"trials":6869,"activeCount":100},[],{"trials":6871,"activeCount":100},[6872],{"nctId":6088,"briefTitle":6089,"status":171,"phases":6873,"start":6091,"conditions":6874,"interventions":6875},[90],[6093,6094],[6096,6097,3566,6098],{"trials":6877,"activeCount":100},[],{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[],{"intervention":6883,"totalTrials":146,"cells":6884},"Pembrolizumab",{"EARLY_PHASE1":6885,"PHASE1":6887,"PHASE2":6889,"PHASE3":6898,"PHASE4":6900,"NA":6902},{"trials":6886,"activeCount":100},[],{"trials":6888,"activeCount":100},[],{"trials":6890,"activeCount":100},[6891],{"nctId":6892,"briefTitle":6893,"status":106,"phases":6894,"primaryCompletion":4285,"completion":6895,"start":3947,"enrollment":3407,"conditions":6896,"interventions":6897},"NCT02546986","Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer",[90],"2025-07-07",[3512],[3516,6883],{"trials":6899,"activeCount":100},[],{"trials":6901,"activeCount":100},[],{"trials":6903,"activeCount":100},[],{"intervention":6905,"totalTrials":146,"cells":6906},"RPC4046",{"EARLY_PHASE1":6907,"PHASE1":6909,"PHASE2":6911,"PHASE3":6922,"PHASE4":6924,"NA":6926},{"trials":6908,"activeCount":100},[],{"trials":6910,"activeCount":100},[],{"trials":6912,"activeCount":100},[6913],{"nctId":6914,"briefTitle":6915,"status":106,"phases":6916,"primaryCompletion":6917,"completion":6918,"start":6919,"enrollment":3407,"conditions":6920,"interventions":6921},"NCT02098473","Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis",[90],"2016-02-17","2017-01-30","2014-08-31",[4043],[6905],{"trials":6923,"activeCount":100},[],{"trials":6925,"activeCount":100},[],{"trials":6927,"activeCount":100},[],{"intervention":320,"totalTrials":306,"cells":6929},{"EARLY_PHASE1":6930,"PHASE1":6932,"PHASE2":6953,"PHASE3":6955,"PHASE4":6957,"NA":6959},{"trials":6931,"activeCount":100},[],{"trials":6933,"activeCount":100},[6934,6938,6945,6949],{"nctId":5196,"briefTitle":5197,"status":106,"phases":6935,"primaryCompletion":5199,"completion":5199,"start":5200,"enrollment":146,"conditions":6936,"interventions":6937},[89],[3635],[320,5203,5204],{"nctId":6939,"briefTitle":6940,"status":106,"phases":6941,"primaryCompletion":393,"completion":6942,"start":2425,"enrollment":623,"conditions":6943,"interventions":6944},"NCT02551185","ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",[89],"2019-10-04",[4139],[320],{"nctId":5223,"briefTitle":5224,"status":171,"phases":6946,"primaryCompletion":5226,"completion":5226,"start":5227,"enrollment":1399,"conditions":6947,"interventions":6948},[89],[5229],[320,2700],{"nctId":312,"briefTitle":313,"status":171,"phases":6950,"primaryCompletion":315,"completion":315,"start":316,"enrollment":317,"conditions":6951,"interventions":6952},[89],[16],[320,257,241],{"trials":6954,"activeCount":100},[],{"trials":6956,"activeCount":100},[],{"trials":6958,"activeCount":100},[],{"trials":6960,"activeCount":100},[],{"intervention":2051,"totalTrials":235,"cells":6962},{"EARLY_PHASE1":6963,"PHASE1":6965,"PHASE2":6989,"PHASE3":6991,"PHASE4":6993,"NA":6995},{"trials":6964,"activeCount":100},[],{"trials":6966,"activeCount":100},[6967,6971,6979],{"nctId":2043,"briefTitle":2044,"status":171,"phases":6968,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":600,"conditions":6969,"interventions":6970},[89],[27],[2051,2052,46,2053],{"nctId":6972,"briefTitle":6973,"status":106,"phases":6974,"primaryCompletion":6975,"completion":6975,"start":6976,"enrollment":862,"conditions":6977,"interventions":6978},"NCT04297124","A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects",[89],"2021-06-04","2020-03-11",[29],[2051],{"nctId":6980,"briefTitle":6981,"status":171,"phases":6982,"primaryCompletion":6983,"completion":6984,"start":6985,"enrollment":6986,"conditions":6987,"interventions":6988},"NCT02848001","A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes",[89],"2023-04-11","2024-04-11","2016-11-14",101,[27,22],[2051],{"trials":6990,"activeCount":100},[],{"trials":6992,"activeCount":100},[],{"trials":6994,"activeCount":100},[],{"trials":6996,"activeCount":100},[],{"intervention":2052,"totalTrials":235,"cells":6998},{"EARLY_PHASE1":6999,"PHASE1":7001,"PHASE2":7019,"PHASE3":7021,"PHASE4":7023,"NA":7025},{"trials":7000,"activeCount":100},[],{"trials":7002,"activeCount":100},[7003,7007,7011],{"nctId":2043,"briefTitle":2044,"status":171,"phases":7004,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":600,"conditions":7005,"interventions":7006},[89],[27],[2051,2052,46,2053],{"nctId":2065,"briefTitle":2066,"status":171,"phases":7008,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":146,"conditions":7009,"interventions":7010},[89],[1401],[1020,2052,46,2052,1020],{"nctId":7012,"briefTitle":7013,"status":106,"phases":7014,"primaryCompletion":7015,"completion":7015,"start":7016,"enrollment":963,"conditions":7017,"interventions":7018},"NCT04887857","A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)",[89],"2024-01-08","2021-12-01",[27],[3516,2052],{"trials":7020,"activeCount":100},[],{"trials":7022,"activeCount":100},[],{"trials":7024,"activeCount":100},[],{"trials":7026,"activeCount":100},[],{"intervention":7028,"totalTrials":235,"cells":7029},"CC-90010",{"EARLY_PHASE1":7030,"PHASE1":7032,"PHASE2":7060,"PHASE3":7062,"PHASE4":7064,"NA":7066},{"trials":7031,"activeCount":100},[],{"trials":7033,"activeCount":100},[7034,7042,7051],{"nctId":7035,"briefTitle":7036,"status":171,"phases":7037,"primaryCompletion":315,"completion":315,"start":7038,"enrollment":623,"conditions":7039,"interventions":7041},"NCT04047303","CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive\u002FRecurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma",[89],"2020-01-02",[7040,5108],"Astrocytoma",[7028],{"nctId":7043,"briefTitle":7044,"status":171,"phases":7045,"primaryCompletion":7046,"completion":7046,"start":7047,"enrollment":7048,"conditions":7049,"interventions":7050},"NCT03220347","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed\u002FRefractory Non-Hodgkin's Lymphomas",[89],"2024-09-06","2017-07-24",139,[24,32],[7028],{"nctId":7052,"briefTitle":7053,"status":171,"phases":7054,"primaryCompletion":7055,"completion":7055,"start":7056,"enrollment":1286,"conditions":7057,"interventions":7058},"NCT04324840","A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma",[89],"2024-07-09","2020-07-10",[5108],[7028,7059],"Temozolomide",{"trials":7061,"activeCount":100},[],{"trials":7063,"activeCount":100},[],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[],{"intervention":1892,"totalTrials":235,"cells":7069},{"EARLY_PHASE1":7070,"PHASE1":7072,"PHASE2":7086,"PHASE3":7088,"PHASE4":7090,"NA":7092},{"trials":7071,"activeCount":100},[],{"trials":7073,"activeCount":100},[7074,7078,7082],{"nctId":2318,"briefTitle":2319,"status":106,"phases":7075,"primaryCompletion":2321,"completion":2321,"start":2322,"enrollment":296,"conditions":7076,"interventions":7077},[89],[2324,2325],[826,1892],{"nctId":5691,"briefTitle":5692,"status":106,"phases":7079,"primaryCompletion":5694,"completion":5694,"start":5695,"enrollment":2333,"conditions":7080,"interventions":7081},[89],[19],[639,1892],{"nctId":1884,"briefTitle":1885,"status":106,"phases":7083,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":823,"conditions":7084,"interventions":7085},[89],[1890,1226],[257,1892,1893,1894],{"trials":7087,"activeCount":100},[],{"trials":7089,"activeCount":100},[],{"trials":7091,"activeCount":100},[],{"trials":7093,"activeCount":100},[],{"intervention":3431,"totalTrials":235,"cells":7095},{"EARLY_PHASE1":7096,"PHASE1":7098,"PHASE2":7112,"PHASE3":7114,"PHASE4":7116,"NA":7118},{"trials":7097,"activeCount":100},[],{"trials":7099,"activeCount":100},[7100,7104,7108],{"nctId":5337,"briefTitle":5338,"status":106,"phases":7101,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":7102,"interventions":7103},[89],[5342],[5305,3863,3428,5344,3431,3430,3429,5345],{"nctId":3417,"briefTitle":3418,"status":106,"phases":7105,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":7106,"interventions":7107},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"nctId":4088,"briefTitle":4089,"status":106,"phases":7109,"primaryCompletion":4091,"completion":4092,"start":4093,"enrollment":9,"conditions":7110,"interventions":7111},[89],[19],[3479,3429,3431,3430],{"trials":7113,"activeCount":100},[],{"trials":7115,"activeCount":100},[],{"trials":7117,"activeCount":100},[],{"trials":7119,"activeCount":100},[],{"intervention":3430,"totalTrials":235,"cells":7121},{"EARLY_PHASE1":7122,"PHASE1":7124,"PHASE2":7138,"PHASE3":7140,"PHASE4":7142,"NA":7144},{"trials":7123,"activeCount":100},[],{"trials":7125,"activeCount":100},[7126,7130,7134],{"nctId":5337,"briefTitle":5338,"status":106,"phases":7127,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":7128,"interventions":7129},[89],[5342],[5305,3863,3428,5344,3431,3430,3429,5345],{"nctId":3417,"briefTitle":3418,"status":106,"phases":7131,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":7132,"interventions":7133},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"nctId":4088,"briefTitle":4089,"status":106,"phases":7135,"primaryCompletion":4091,"completion":4092,"start":4093,"enrollment":9,"conditions":7136,"interventions":7137},[89],[19],[3479,3429,3431,3430],{"trials":7139,"activeCount":100},[],{"trials":7141,"activeCount":100},[],{"trials":7143,"activeCount":100},[],{"trials":7145,"activeCount":100},[],{"intervention":3429,"totalTrials":235,"cells":7147},{"EARLY_PHASE1":7148,"PHASE1":7150,"PHASE2":7164,"PHASE3":7166,"PHASE4":7168,"NA":7170},{"trials":7149,"activeCount":100},[],{"trials":7151,"activeCount":100},[7152,7156,7160],{"nctId":5337,"briefTitle":5338,"status":106,"phases":7153,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":7154,"interventions":7155},[89],[5342],[5305,3863,3428,5344,3431,3430,3429,5345],{"nctId":3417,"briefTitle":3418,"status":106,"phases":7157,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":7158,"interventions":7159},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"nctId":4088,"briefTitle":4089,"status":106,"phases":7161,"primaryCompletion":4091,"completion":4092,"start":4093,"enrollment":9,"conditions":7162,"interventions":7163},[89],[19],[3479,3429,3431,3430],{"trials":7165,"activeCount":100},[],{"trials":7167,"activeCount":100},[],{"trials":7169,"activeCount":100},[],{"trials":7171,"activeCount":100},[],{"intervention":4264,"totalTrials":190,"cells":7173},{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7192,"PHASE3":7194,"PHASE4":7196,"NA":7198},{"trials":7175,"activeCount":100},[],{"trials":7177,"activeCount":100},[7178,7182],{"nctId":4256,"briefTitle":4257,"status":106,"phases":7179,"primaryCompletion":4259,"completion":4259,"start":4260,"enrollment":4261,"conditions":7180,"interventions":7181},[89],[29],[4264,4265,4266,4249,4267],{"nctId":7183,"briefTitle":7184,"status":106,"phases":7185,"primaryCompletion":7186,"completion":7186,"start":7187,"enrollment":7188,"conditions":7189,"interventions":7190},"NCT04978298","Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants",[89],"2023-02-26","2021-07-19",128,[19],[7191,4264,3410],"Rasigiline",{"trials":7193,"activeCount":100},[],{"trials":7195,"activeCount":100},[],{"trials":7197,"activeCount":100},[],{"trials":7199,"activeCount":100},[],{"intervention":7201,"totalTrials":190,"cells":7202},"CC-90006",{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7223,"PHASE3":7225,"PHASE4":7227,"NA":7229},{"trials":7204,"activeCount":100},[],{"trials":7206,"activeCount":100},[7207,7215],{"nctId":7208,"briefTitle":7209,"status":106,"phases":7210,"primaryCompletion":7211,"completion":7211,"start":7212,"enrollment":684,"conditions":7213,"interventions":7214},"NCT02934269","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects",[89],"2017-08-15","2016-11-21",[19],[7201],{"nctId":7216,"briefTitle":7217,"status":106,"phases":7218,"primaryCompletion":7219,"completion":7219,"start":3890,"enrollment":254,"conditions":7220,"interventions":7222},"NCT03337022","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis",[89],"2019-04-26",[7221],"Psoriasis",[7201],{"trials":7224,"activeCount":100},[],{"trials":7226,"activeCount":100},[],{"trials":7228,"activeCount":100},[],{"trials":7230,"activeCount":100},[],{"intervention":3863,"totalTrials":190,"cells":7232},{"EARLY_PHASE1":7233,"PHASE1":7235,"PHASE2":7245,"PHASE3":7247,"PHASE4":7249,"NA":7251},{"trials":7234,"activeCount":100},[],{"trials":7236,"activeCount":100},[7237,7241],{"nctId":3856,"briefTitle":3857,"status":106,"phases":7238,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":877,"conditions":7239,"interventions":7240},[89],[19],[3839,3863],{"nctId":5337,"briefTitle":5338,"status":106,"phases":7242,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":7243,"interventions":7244},[89],[5342],[5305,3863,3428,5344,3431,3430,3429,5345],{"trials":7246,"activeCount":100},[],{"trials":7248,"activeCount":100},[],{"trials":7250,"activeCount":100},[],{"trials":7252,"activeCount":100},[],{"intervention":7254,"totalTrials":190,"cells":7255},"CC-97489",{"EARLY_PHASE1":7256,"PHASE1":7258,"PHASE2":7278,"PHASE3":7280,"PHASE4":7282,"NA":7284},{"trials":7257,"activeCount":100},[],{"trials":7259,"activeCount":100},[7260,7270],{"nctId":7261,"briefTitle":7262,"status":106,"phases":7263,"primaryCompletion":7264,"completion":7264,"start":7265,"enrollment":823,"conditions":7266,"interventions":7267},"NCT05065541","Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants",[89],"2024-01-29","2021-09-24",[19],[7254,7268,7269],"[18F]T-401","[11C]MK-3168",{"nctId":7271,"briefTitle":7272,"status":171,"phases":7273,"primaryCompletion":7274,"completion":7274,"start":3421,"enrollment":7275,"conditions":7276,"interventions":7277},"NCT05099822","Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants",[89],"2022-07-11",84,[19],[7254],{"trials":7279,"activeCount":100},[],{"trials":7281,"activeCount":100},[],{"trials":7283,"activeCount":100},[],{"trials":7285,"activeCount":100},[],{"intervention":1893,"totalTrials":190,"cells":7287},{"EARLY_PHASE1":7288,"PHASE1":7290,"PHASE2":7300,"PHASE3":7302,"PHASE4":7304,"NA":7306},{"trials":7289,"activeCount":100},[],{"trials":7291,"activeCount":100},[7292,7296],{"nctId":3381,"briefTitle":3382,"status":106,"phases":7293,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":3386,"conditions":7294,"interventions":7295},[89],[29],[638,1107,1893,1108],{"nctId":1884,"briefTitle":1885,"status":106,"phases":7297,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":823,"conditions":7298,"interventions":7299},[89],[1890,1226],[257,1892,1893,1894],{"trials":7301,"activeCount":100},[],{"trials":7303,"activeCount":100},[],{"trials":7305,"activeCount":100},[],{"trials":7307,"activeCount":100},[],{"intervention":673,"totalTrials":190,"cells":7309},{"EARLY_PHASE1":7310,"PHASE1":7312,"PHASE2":7326,"PHASE3":7328,"PHASE4":7330,"NA":7332},{"trials":7311,"activeCount":100},[],{"trials":7313,"activeCount":100},[7314,7318],{"nctId":664,"briefTitle":665,"status":106,"phases":7315,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":7316,"interventions":7317},[89],[671],[673,128],{"nctId":7319,"briefTitle":7320,"status":171,"phases":7321,"primaryCompletion":7322,"completion":7322,"start":7323,"enrollment":1197,"conditions":7324,"interventions":7325},"NCT02641002","A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)",[89],"2018-07-18","2016-03-01",[27,22],[673],{"trials":7327,"activeCount":100},[],{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"trials":7333,"activeCount":100},[],{"intervention":3428,"totalTrials":190,"cells":7335},{"EARLY_PHASE1":7336,"PHASE1":7338,"PHASE2":7348,"PHASE3":7350,"PHASE4":7352,"NA":7354},{"trials":7337,"activeCount":100},[],{"trials":7339,"activeCount":100},[7340,7344],{"nctId":5337,"briefTitle":5338,"status":106,"phases":7341,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":7342,"interventions":7343},[89],[5342],[5305,3863,3428,5344,3431,3430,3429,5345],{"nctId":3417,"briefTitle":3418,"status":106,"phases":7345,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":7346,"interventions":7347},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"trials":7349,"activeCount":100},[],{"trials":7351,"activeCount":100},[],{"trials":7353,"activeCount":100},[],{"trials":7355,"activeCount":100},[],{"intervention":1702,"totalTrials":190,"cells":7357},{"EARLY_PHASE1":7358,"PHASE1":7360,"PHASE2":7370,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7359,"activeCount":100},[],{"trials":7361,"activeCount":100},[7362,7366],{"nctId":1693,"briefTitle":1694,"status":106,"phases":7363,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":1698,"conditions":7364,"interventions":7365},[89],[1700],[71,1702],{"nctId":3146,"briefTitle":3147,"status":106,"phases":7367,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":9,"conditions":7368,"interventions":7369},[89],[29],[1702,81],{"trials":7371,"activeCount":100},[],{"trials":7373,"activeCount":100},[],{"trials":7375,"activeCount":100},[],{"trials":7377,"activeCount":100},[],{"intervention":4265,"totalTrials":146,"cells":7379},{"EARLY_PHASE1":7380,"PHASE1":7382,"PHASE2":7388,"PHASE3":7390,"PHASE4":7392,"NA":7394},{"trials":7381,"activeCount":100},[],{"trials":7383,"activeCount":100},[7384],{"nctId":4256,"briefTitle":4257,"status":106,"phases":7385,"primaryCompletion":4259,"completion":4259,"start":4260,"enrollment":4261,"conditions":7386,"interventions":7387},[89],[29],[4264,4265,4266,4249,4267],{"trials":7389,"activeCount":100},[],{"trials":7391,"activeCount":100},[],{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[],{"intervention":4266,"totalTrials":146,"cells":7397},{"EARLY_PHASE1":7398,"PHASE1":7400,"PHASE2":7406,"PHASE3":7408,"PHASE4":7410,"NA":7412},{"trials":7399,"activeCount":100},[],{"trials":7401,"activeCount":100},[7402],{"nctId":4256,"briefTitle":4257,"status":106,"phases":7403,"primaryCompletion":4259,"completion":4259,"start":4260,"enrollment":4261,"conditions":7404,"interventions":7405},[89],[29],[4264,4265,4266,4249,4267],{"trials":7407,"activeCount":100},[],{"trials":7409,"activeCount":100},[],{"trials":7411,"activeCount":100},[],{"trials":7413,"activeCount":100},[],{"intervention":5194,"totalTrials":146,"cells":7415},{"EARLY_PHASE1":7416,"PHASE1":7418,"PHASE2":7424,"PHASE3":7426,"PHASE4":7428,"NA":7430},{"trials":7417,"activeCount":100},[],{"trials":7419,"activeCount":100},[7420],{"nctId":5185,"briefTitle":5186,"status":171,"phases":7421,"primaryCompletion":5188,"completion":5189,"start":5190,"enrollment":877,"conditions":7422,"interventions":7423},[89],[5192],[5194,651,2700],{"trials":7425,"activeCount":100},[],{"trials":7427,"activeCount":100},[],{"trials":7429,"activeCount":100},[],{"trials":7431,"activeCount":100},[],{"intervention":7433,"totalTrials":146,"cells":7434},"BMS-986369",{"EARLY_PHASE1":7435,"PHASE1":7437,"PHASE2":7447,"PHASE3":7449,"PHASE4":7451,"NA":7453},{"trials":7436,"activeCount":100},[],{"trials":7438,"activeCount":100},[7439],{"nctId":7440,"briefTitle":7441,"status":106,"phases":7442,"primaryCompletion":7443,"completion":7443,"start":7444,"enrollment":4079,"conditions":7445,"interventions":7446},"NCT06535399","Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment",[89],"2025-11-12","2024-08-15",[2855,19],[7433],{"trials":7448,"activeCount":100},[],{"trials":7450,"activeCount":100},[],{"trials":7452,"activeCount":100},[],{"trials":7454,"activeCount":100},[],{"intervention":3627,"totalTrials":146,"cells":7456},{"EARLY_PHASE1":7457,"PHASE1":7459,"PHASE2":7465,"PHASE3":7467,"PHASE4":7469,"NA":7471},{"trials":7458,"activeCount":100},[],{"trials":7460,"activeCount":100},[7461],{"nctId":3622,"briefTitle":3623,"status":171,"phases":7462,"completion":498,"start":517,"enrollment":684,"conditions":7463,"interventions":7464},[89],[3606],[372,3627],{"trials":7466,"activeCount":100},[],{"trials":7468,"activeCount":100},[],{"trials":7470,"activeCount":100},[],{"trials":7472,"activeCount":100},[],{"intervention":7191,"totalTrials":146,"cells":7474},{"EARLY_PHASE1":7475,"PHASE1":7477,"PHASE2":7483,"PHASE3":7485,"PHASE4":7487,"NA":7489},{"trials":7476,"activeCount":100},[],{"trials":7478,"activeCount":100},[7479],{"nctId":7183,"briefTitle":7184,"status":106,"phases":7480,"primaryCompletion":7186,"completion":7186,"start":7187,"enrollment":7188,"conditions":7481,"interventions":7482},[89],[19],[7191,4264,3410],{"trials":7484,"activeCount":100},[],{"trials":7486,"activeCount":100},[],{"trials":7488,"activeCount":100},[],{"trials":7490,"activeCount":100},[],{"intervention":2053,"totalTrials":146,"cells":7492},{"EARLY_PHASE1":7493,"PHASE1":7495,"PHASE2":7501,"PHASE3":7503,"PHASE4":7505,"NA":7507},{"trials":7494,"activeCount":100},[],{"trials":7496,"activeCount":100},[7497],{"nctId":2043,"briefTitle":2044,"status":171,"phases":7498,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":600,"conditions":7499,"interventions":7500},[89],[27],[2051,2052,46,2053],{"trials":7502,"activeCount":100},[],{"trials":7504,"activeCount":100},[],{"trials":7506,"activeCount":100},[],{"trials":7508,"activeCount":100},[],{"intervention":1838,"totalTrials":146,"cells":7510},{"EARLY_PHASE1":7511,"PHASE1":7513,"PHASE2":7519,"PHASE3":7521,"PHASE4":7523,"NA":7525},{"trials":7512,"activeCount":100},[],{"trials":7514,"activeCount":100},[7515],{"nctId":1828,"briefTitle":1829,"status":106,"phases":7516,"primaryCompletion":1831,"completion":607,"start":1832,"enrollment":20,"conditions":7517,"interventions":7518},[89],[1834,1835,16],[579,1837,1838],{"trials":7520,"activeCount":100},[],{"trials":7522,"activeCount":100},[],{"trials":7524,"activeCount":100},[],{"trials":7526,"activeCount":100},[],{"intervention":7528,"totalTrials":146,"cells":7529},"[14C]-BMS-986368",{"EARLY_PHASE1":7530,"PHASE1":7532,"PHASE2":7542,"PHASE3":7544,"PHASE4":7546,"NA":7548},{"trials":7531,"activeCount":100},[],{"trials":7533,"activeCount":100},[7534],{"nctId":7535,"briefTitle":7536,"status":106,"phases":7537,"primaryCompletion":7538,"completion":7538,"start":7539,"enrollment":862,"conditions":7540,"interventions":7541},"NCT06227975","A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants",[89],"2024-04-03","2024-02-02",[19],[7528],{"trials":7543,"activeCount":100},[],{"trials":7545,"activeCount":100},[],{"trials":7547,"activeCount":100},[],{"trials":7549,"activeCount":100},[],{"intervention":7551,"totalTrials":146,"cells":7552},"CC-92252",{"EARLY_PHASE1":7553,"PHASE1":7555,"PHASE2":7564,"PHASE3":7566,"PHASE4":7568,"NA":7570},{"trials":7554,"activeCount":100},[],{"trials":7556,"activeCount":100},[7557],{"nctId":7558,"briefTitle":7559,"status":171,"phases":7560,"primaryCompletion":7561,"completion":7561,"start":4260,"enrollment":2386,"conditions":7562,"interventions":7563},"NCT03971825","A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis",[89],"2021-08-05",[19,7221],[7551],{"trials":7565,"activeCount":100},[],{"trials":7567,"activeCount":100},[],{"trials":7569,"activeCount":100},[],{"trials":7571,"activeCount":100},[],{"intervention":5204,"totalTrials":146,"cells":7573},{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7582,"PHASE3":7584,"PHASE4":7586,"NA":7588},{"trials":7575,"activeCount":100},[],{"trials":7577,"activeCount":100},[7578],{"nctId":5196,"briefTitle":5197,"status":106,"phases":7579,"primaryCompletion":5199,"completion":5199,"start":5200,"enrollment":146,"conditions":7580,"interventions":7581},[89],[3635],[320,5203,5204],{"trials":7583,"activeCount":100},[],{"trials":7585,"activeCount":100},[],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"intervention":7591,"totalTrials":146,"cells":7592},"CC-90003",{"EARLY_PHASE1":7593,"PHASE1":7595,"PHASE2":7605,"PHASE3":7607,"PHASE4":7609,"NA":7611},{"trials":7594,"activeCount":100},[],{"trials":7596,"activeCount":100},[7597],{"nctId":7598,"briefTitle":7599,"status":171,"phases":7600,"primaryCompletion":7601,"completion":7601,"start":7602,"enrollment":2375,"conditions":7603,"interventions":7604},"NCT02313012","Safety and PK Study of CC-90003 in Relapsed\u002FRefractory Solid Tumors",[89],"2016-05-03","2015-01-05",[3745],[7591],{"trials":7606,"activeCount":100},[],{"trials":7608,"activeCount":100},[],{"trials":7610,"activeCount":100},[],{"trials":7612,"activeCount":100},[],{"intervention":4362,"totalTrials":146,"cells":7614},{"EARLY_PHASE1":7615,"PHASE1":7617,"PHASE2":7623,"PHASE3":7625,"PHASE4":7627,"NA":7629},{"trials":7616,"activeCount":100},[],{"trials":7618,"activeCount":100},[7619],{"nctId":4354,"briefTitle":4355,"status":106,"phases":7620,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":30,"conditions":7621,"interventions":7622},[89],[4360],[4362,2715,4363,4364,4347],{"trials":7624,"activeCount":100},[],{"trials":7626,"activeCount":100},[],{"trials":7628,"activeCount":100},[],{"trials":7630,"activeCount":100},[],{"intervention":4364,"totalTrials":146,"cells":7632},{"EARLY_PHASE1":7633,"PHASE1":7635,"PHASE2":7641,"PHASE3":7643,"PHASE4":7645,"NA":7647},{"trials":7634,"activeCount":100},[],{"trials":7636,"activeCount":100},[7637],{"nctId":4354,"briefTitle":4355,"status":106,"phases":7638,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":30,"conditions":7639,"interventions":7640},[89],[4360],[4362,2715,4363,4364,4347],{"trials":7642,"activeCount":100},[],{"trials":7644,"activeCount":100},[],{"trials":7646,"activeCount":100},[],{"trials":7648,"activeCount":100},[],{"intervention":650,"totalTrials":146,"cells":7650},{"EARLY_PHASE1":7651,"PHASE1":7653,"PHASE2":7659,"PHASE3":7661,"PHASE4":7663,"NA":7665},{"trials":7652,"activeCount":100},[],{"trials":7654,"activeCount":100},[7655],{"nctId":642,"briefTitle":643,"status":171,"phases":7656,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":7657,"interventions":7658},[89],[32],[650,128,651],{"trials":7660,"activeCount":100},[],{"trials":7662,"activeCount":100},[],{"trials":7664,"activeCount":100},[],{"trials":7666,"activeCount":100},[],{"intervention":7668,"totalTrials":146,"cells":7669},"Thalidomide Celgene™",{"EARLY_PHASE1":7670,"PHASE1":7672,"PHASE2":7681,"PHASE3":7683,"PHASE4":7685,"NA":7687},{"trials":7671,"activeCount":100},[],{"trials":7673,"activeCount":100},[7674],{"nctId":7675,"briefTitle":7676,"status":106,"phases":7677,"primaryCompletion":1195,"completion":1195,"start":7678,"enrollment":1953,"conditions":7679,"interventions":7680},"NCT01937442","Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma",[89],"2013-11-07",[16],[7668],{"trials":7682,"activeCount":100},[],{"trials":7684,"activeCount":100},[],{"trials":7686,"activeCount":100},[],{"trials":7688,"activeCount":100},[],{"intervention":268,"totalTrials":146,"cells":7690},{"EARLY_PHASE1":7691,"PHASE1":7693,"PHASE2":7699,"PHASE3":7701,"PHASE4":7703,"NA":7705},{"trials":7692,"activeCount":100},[],{"trials":7694,"activeCount":100},[7695],{"nctId":260,"briefTitle":261,"status":106,"phases":7696,"primaryCompletion":263,"completion":263,"start":264,"enrollment":10,"conditions":7697,"interventions":7698},[89],[266],[268,269,241],{"trials":7700,"activeCount":100},[],{"trials":7702,"activeCount":100},[],{"trials":7704,"activeCount":100},[],{"trials":7706,"activeCount":100},[],{"intervention":269,"totalTrials":146,"cells":7708},{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7717,"PHASE3":7719,"PHASE4":7721,"NA":7723},{"trials":7710,"activeCount":100},[],{"trials":7712,"activeCount":100},[7713],{"nctId":260,"briefTitle":261,"status":106,"phases":7714,"primaryCompletion":263,"completion":263,"start":264,"enrollment":10,"conditions":7715,"interventions":7716},[89],[266],[268,269,241],{"trials":7718,"activeCount":100},[],{"trials":7720,"activeCount":100},[],{"trials":7722,"activeCount":100},[],{"trials":7724,"activeCount":100},[],{"intervention":7726,"totalTrials":146,"cells":7727},"CC-91633",{"EARLY_PHASE1":7728,"PHASE1":7730,"PHASE2":7740,"PHASE3":7742,"PHASE4":7744,"NA":7746},{"trials":7729,"activeCount":100},[],{"trials":7731,"activeCount":100},[7732],{"nctId":7733,"briefTitle":7734,"status":171,"phases":7735,"primaryCompletion":7736,"completion":7736,"start":7737,"enrollment":440,"conditions":7738,"interventions":7739},"NCT04951778","Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes",[89],"2025-07-30","2021-12-02",[27,22],[7726],{"trials":7741,"activeCount":100},[],{"trials":7743,"activeCount":100},[],{"trials":7745,"activeCount":100},[],{"trials":7747,"activeCount":100},[],{"intervention":5490,"totalTrials":146,"cells":7749},{"EARLY_PHASE1":7750,"PHASE1":7752,"PHASE2":7758,"PHASE3":7760,"PHASE4":7762,"NA":7764},{"trials":7751,"activeCount":100},[],{"trials":7753,"activeCount":100},[7754],{"nctId":5483,"briefTitle":5484,"status":106,"phases":7755,"primaryCompletion":5486,"completion":5486,"start":5487,"enrollment":9,"conditions":7756,"interventions":7757},[89],[19],[640,5490],{"trials":7759,"activeCount":100},[],{"trials":7761,"activeCount":100},[],{"trials":7763,"activeCount":100},[],{"trials":7765,"activeCount":100},[],{"intervention":7767,"totalTrials":146,"cells":7768},"AVL-292",{"EARLY_PHASE1":7769,"PHASE1":7771,"PHASE2":7783,"PHASE3":7785,"PHASE4":7787,"NA":7789},{"trials":7770,"activeCount":100},[],{"trials":7772,"activeCount":100},[7773],{"nctId":7774,"briefTitle":7775,"status":106,"phases":7776,"primaryCompletion":7777,"completion":7777,"start":7778,"enrollment":3060,"conditions":7779,"interventions":7782},"NCT01351935","Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia",[89],"2015-06-26","2011-07-18",[7780,1179,7781],"B Cell Non-Hodgkin's Lymphoma","Waldenstrom Macroglobulinemia",[7767],{"trials":7784,"activeCount":100},[],{"trials":7786,"activeCount":100},[],{"trials":7788,"activeCount":100},[],{"trials":7790,"activeCount":100},[],{"intervention":7792,"totalTrials":146,"cells":7793},"4 mg Oral POM + 40 mg Oral DEX",{"EARLY_PHASE1":7794,"PHASE1":7796,"PHASE2":7806,"PHASE3":7808,"PHASE4":7810,"NA":7812},{"trials":7795,"activeCount":100},[],{"trials":7797,"activeCount":100},[7798],{"nctId":7799,"briefTitle":7800,"status":106,"phases":7801,"primaryCompletion":7802,"completion":7802,"start":4810,"enrollment":527,"conditions":7803,"interventions":7804},"NCT01575925","Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)",[89],"2018-08-07",[16,1737],[7792,7805],"2 mg Oral POM + 40 mg Oral DEX",{"trials":7807,"activeCount":100},[],{"trials":7809,"activeCount":100},[],{"trials":7811,"activeCount":100},[],{"trials":7813,"activeCount":100},[],{"intervention":7805,"totalTrials":146,"cells":7815},{"EARLY_PHASE1":7816,"PHASE1":7818,"PHASE2":7824,"PHASE3":7826,"PHASE4":7828,"NA":7830},{"trials":7817,"activeCount":100},[],{"trials":7819,"activeCount":100},[7820],{"nctId":7799,"briefTitle":7800,"status":106,"phases":7821,"primaryCompletion":7802,"completion":7802,"start":4810,"enrollment":527,"conditions":7822,"interventions":7823},[89],[16,1737],[7792,7805],{"trials":7825,"activeCount":100},[],{"trials":7827,"activeCount":100},[],{"trials":7829,"activeCount":100},[],{"trials":7831,"activeCount":100},[],{"intervention":1862,"totalTrials":146,"cells":7833},{"EARLY_PHASE1":7834,"PHASE1":7836,"PHASE2":7842,"PHASE3":7844,"PHASE4":7846,"NA":7848},{"trials":7835,"activeCount":100},[],{"trials":7837,"activeCount":100},[7838],{"nctId":1853,"briefTitle":1854,"status":106,"phases":7839,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1858,"conditions":7840,"interventions":7841},[89],[1860],[257,257,1862],{"trials":7843,"activeCount":100},[],{"trials":7845,"activeCount":100},[],{"trials":7847,"activeCount":100},[],{"trials":7849,"activeCount":100},[],{"intervention":7851,"totalTrials":146,"cells":7852},"CC-92328",{"EARLY_PHASE1":7853,"PHASE1":7855,"PHASE2":7864,"PHASE3":7866,"PHASE4":7868,"NA":7870},{"trials":7854,"activeCount":100},[],{"trials":7856,"activeCount":100},[7857],{"nctId":7858,"briefTitle":7859,"status":171,"phases":7860,"primaryCompletion":3829,"completion":3829,"start":7861,"enrollment":330,"conditions":7862,"interventions":7863},"NCT04975399","Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and\u002For Refractory Multiple Myeloma",[89],"2021-10-05",[16],[7851],{"trials":7865,"activeCount":100},[],{"trials":7867,"activeCount":100},[],{"trials":7869,"activeCount":100},[],{"trials":7871,"activeCount":100},[],{"intervention":4082,"totalTrials":146,"cells":7873},{"EARLY_PHASE1":7874,"PHASE1":7876,"PHASE2":7882,"PHASE3":7884,"PHASE4":7886,"NA":7888},{"trials":7875,"activeCount":100},[],{"trials":7877,"activeCount":100},[7878],{"nctId":4073,"briefTitle":4074,"status":106,"phases":7879,"primaryCompletion":4076,"completion":4077,"start":4078,"enrollment":4079,"conditions":7880,"interventions":7881},[89],[19],[3479,4082],{"trials":7883,"activeCount":100},[],{"trials":7885,"activeCount":100},[],{"trials":7887,"activeCount":100},[],{"trials":7889,"activeCount":100},[],{"intervention":7891,"totalTrials":146,"cells":7892},"CC-11006",{"EARLY_PHASE1":7893,"PHASE1":7895,"PHASE2":7904,"PHASE3":7906,"PHASE4":7908,"NA":7910},{"trials":7894,"activeCount":100},[],{"trials":7896,"activeCount":100},[7897],{"nctId":7898,"briefTitle":7899,"status":171,"phases":7900,"primaryCompletion":507,"completion":467,"start":7901,"enrollment":254,"conditions":7902,"interventions":7903},"NCT00458159","A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes",[89],"2007-05-01",[34],[7891],{"trials":7905,"activeCount":100},[],{"trials":7907,"activeCount":100},[],{"trials":7909,"activeCount":100},[],{"trials":7911,"activeCount":100},[],{"intervention":7268,"totalTrials":146,"cells":7913},{"EARLY_PHASE1":7914,"PHASE1":7916,"PHASE2":7922,"PHASE3":7924,"PHASE4":7926,"NA":7928},{"trials":7915,"activeCount":100},[],{"trials":7917,"activeCount":100},[7918],{"nctId":7261,"briefTitle":7262,"status":106,"phases":7919,"primaryCompletion":7264,"completion":7264,"start":7265,"enrollment":823,"conditions":7920,"interventions":7921},[89],[19],[7254,7268,7269],{"trials":7923,"activeCount":100},[],{"trials":7925,"activeCount":100},[],{"trials":7927,"activeCount":100},[],{"trials":7929,"activeCount":100},[],{"intervention":7269,"totalTrials":146,"cells":7931},{"EARLY_PHASE1":7932,"PHASE1":7934,"PHASE2":7940,"PHASE3":7942,"PHASE4":7944,"NA":7946},{"trials":7933,"activeCount":100},[],{"trials":7935,"activeCount":100},[7936],{"nctId":7261,"briefTitle":7262,"status":106,"phases":7937,"primaryCompletion":7264,"completion":7264,"start":7265,"enrollment":823,"conditions":7938,"interventions":7939},[89],[19],[7254,7268,7269],{"trials":7941,"activeCount":100},[],{"trials":7943,"activeCount":100},[],{"trials":7945,"activeCount":100},[],{"trials":7947,"activeCount":100},[],{"intervention":7949,"totalTrials":146,"cells":7950},"Cyclosporine",{"EARLY_PHASE1":7951,"PHASE1":7953,"PHASE2":7962,"PHASE3":7964,"PHASE4":7966,"NA":7968},{"trials":7952,"activeCount":100},[],{"trials":7954,"activeCount":100},[7955],{"nctId":7956,"briefTitle":7957,"status":106,"phases":7958,"primaryCompletion":7959,"completion":3149,"start":6942,"enrollment":684,"conditions":7960,"interventions":7961},"NCT04149678","Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites",[89],"2019-11-13",[19],[3410,7949],{"trials":7963,"activeCount":100},[],{"trials":7965,"activeCount":100},[],{"trials":7967,"activeCount":100},[],{"trials":7969,"activeCount":100},[],{"intervention":7971,"totalTrials":146,"cells":7972},"ABI-010",{"EARLY_PHASE1":7973,"PHASE1":7975,"PHASE2":7984,"PHASE3":7986,"PHASE4":7988,"NA":7990},{"trials":7974,"activeCount":100},[],{"trials":7976,"activeCount":100},[7977],{"nctId":7978,"briefTitle":7979,"status":423,"phases":7980,"primaryCompletion":7981,"completion":770,"start":1900,"enrollment":100,"conditions":7982,"interventions":7983},"NCT00820768","A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies",[89],"2013-04-01",[5460],[7971],{"trials":7985,"activeCount":100},[],{"trials":7987,"activeCount":100},[],{"trials":7989,"activeCount":100},[],{"trials":7991,"activeCount":100},[],{"intervention":7993,"totalTrials":146,"cells":7994},"ACY-1215 in combination with pomalidomide and dexamethasone",{"EARLY_PHASE1":7995,"PHASE1":7997,"PHASE2":8008,"PHASE3":8010,"PHASE4":8012,"NA":8014},{"trials":7996,"activeCount":100},[],{"trials":7998,"activeCount":100},[7999],{"nctId":8000,"briefTitle":8001,"status":106,"phases":8002,"primaryCompletion":8003,"completion":8004,"start":8005,"enrollment":25,"conditions":8006,"interventions":8007},"NCT02189343","Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma",[89],"2018-04-18","2018-04-30","2014-09-15",[16],[7993],{"trials":8009,"activeCount":100},[],{"trials":8011,"activeCount":100},[],{"trials":8013,"activeCount":100},[],{"trials":8015,"activeCount":100},[],{"intervention":8017,"totalTrials":146,"cells":8018},"[14C]-CC-92480",{"EARLY_PHASE1":8019,"PHASE1":8021,"PHASE2":8030,"PHASE3":8032,"PHASE4":8034,"NA":8036},{"trials":8020,"activeCount":100},[],{"trials":8022,"activeCount":100},[8023],{"nctId":8024,"briefTitle":8025,"status":106,"phases":8026,"primaryCompletion":4077,"completion":4077,"start":8027,"enrollment":862,"conditions":8028,"interventions":8029},"NCT04560738","A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants",[89],"2020-10-15",[19],[8017],{"trials":8031,"activeCount":100},[],{"trials":8033,"activeCount":100},[],{"trials":8035,"activeCount":100},[],{"trials":8037,"activeCount":100},[],{"intervention":8039,"totalTrials":146,"cells":8040},"CC-96673",{"EARLY_PHASE1":8041,"PHASE1":8043,"PHASE2":8053,"PHASE3":8055,"PHASE4":8057,"NA":8059},{"trials":8042,"activeCount":100},[],{"trials":8044,"activeCount":100},[8045],{"nctId":8046,"briefTitle":8047,"status":171,"phases":8048,"primaryCompletion":8049,"completion":8049,"start":8050,"enrollment":805,"conditions":8051,"interventions":8052},"NCT04860466","A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma",[89],"2024-07-31","2022-01-20",[24],[8039],{"trials":8054,"activeCount":100},[],{"trials":8056,"activeCount":100},[],{"trials":8058,"activeCount":100},[],{"trials":8060,"activeCount":100},[],{"intervention":5564,"totalTrials":146,"cells":8062},{"EARLY_PHASE1":8063,"PHASE1":8065,"PHASE2":8071,"PHASE3":8073,"PHASE4":8075,"NA":8077},{"trials":8064,"activeCount":100},[],{"trials":8066,"activeCount":100},[8067],{"nctId":5558,"briefTitle":5559,"status":106,"phases":8068,"primaryCompletion":2903,"completion":2903,"start":5561,"enrollment":1197,"conditions":8069,"interventions":8070},[89],[19],[5564,3425],{"trials":8072,"activeCount":100},[],{"trials":8074,"activeCount":100},[],{"trials":8076,"activeCount":100},[],{"trials":8078,"activeCount":100},[],{"intervention":8080,"totalTrials":146,"cells":8081},"CC-96191",{"EARLY_PHASE1":8082,"PHASE1":8084,"PHASE2":8095,"PHASE3":8097,"PHASE4":8099,"NA":8101},{"trials":8083,"activeCount":100},[],{"trials":8085,"activeCount":100},[8086],{"nctId":8087,"briefTitle":8088,"status":171,"phases":8089,"primaryCompletion":8090,"completion":8090,"start":8091,"enrollment":8092,"conditions":8093,"interventions":8094},"NCT04789655","Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2025-04-14","2021-06-16",45,[1401],[8080],{"trials":8096,"activeCount":100},[],{"trials":8098,"activeCount":100},[],{"trials":8100,"activeCount":100},[],{"trials":8102,"activeCount":100},[],{"intervention":5124,"totalTrials":146,"cells":8104},{"EARLY_PHASE1":8105,"PHASE1":8107,"PHASE2":8113,"PHASE3":8115,"PHASE4":8117,"NA":8119},{"trials":8106,"activeCount":100},[],{"trials":8108,"activeCount":100},[8109],{"nctId":5116,"briefTitle":5117,"status":171,"phases":8110,"primaryCompletion":5119,"completion":5119,"start":5120,"enrollment":30,"conditions":8111,"interventions":8112},[89],[5122],[638,5124],{"trials":8114,"activeCount":100},[],{"trials":8116,"activeCount":100},[],{"trials":8118,"activeCount":100},[],{"trials":8120,"activeCount":100},[],{"intervention":3396,"totalTrials":146,"cells":8122},{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8131,"PHASE3":8133,"PHASE4":8135,"NA":8137},{"trials":8124,"activeCount":100},[],{"trials":8126,"activeCount":100},[8127],{"nctId":3390,"briefTitle":3391,"status":171,"phases":8128,"primaryCompletion":2172,"completion":2172,"start":3393,"enrollment":3099,"conditions":8129,"interventions":8130},[89],[24,32],[1020,3396,1107],{"trials":8132,"activeCount":100},[],{"trials":8134,"activeCount":100},[],{"trials":8136,"activeCount":100},[],{"trials":8138,"activeCount":100},[],{"intervention":8140,"totalTrials":146,"cells":8141},"CC-115",{"EARLY_PHASE1":8142,"PHASE1":8144,"PHASE2":8157,"PHASE3":8159,"PHASE4":8161,"NA":8163},{"trials":8143,"activeCount":100},[],{"trials":8145,"activeCount":100},[8146],{"nctId":8147,"briefTitle":8148,"status":106,"phases":8149,"primaryCompletion":8150,"completion":8150,"start":8151,"enrollment":8152,"conditions":8153,"interventions":8156},"NCT01353625","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",[89],"2021-03-12","2011-04-25",118,[5717,8154,1082,8155,1179,3745],"Squamous Cell Carcinoma of Head and Neck","Ewing's Osteosarcoma",[8140],{"trials":8158,"activeCount":100},[],{"trials":8160,"activeCount":100},[],{"trials":8162,"activeCount":100},[],{"trials":8164,"activeCount":100},[],{"intervention":2994,"totalTrials":146,"cells":8166},{"EARLY_PHASE1":8167,"PHASE1":8169,"PHASE2":8175,"PHASE3":8177,"PHASE4":8179,"NA":8181},{"trials":8168,"activeCount":100},[],{"trials":8170,"activeCount":100},[8171],{"nctId":2987,"briefTitle":2988,"status":106,"phases":8172,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":823,"conditions":8173,"interventions":8174},[89],[1700],[2980,1107,2994],{"trials":8176,"activeCount":100},[],{"trials":8178,"activeCount":100},[],{"trials":8180,"activeCount":100},[],{"trials":8182,"activeCount":100},[],{"intervention":1683,"totalTrials":146,"cells":8184},{"EARLY_PHASE1":8185,"PHASE1":8187,"PHASE2":8193,"PHASE3":8195,"PHASE4":8197,"NA":8199},{"trials":8186,"activeCount":100},[],{"trials":8188,"activeCount":100},[8189],{"nctId":1675,"briefTitle":1676,"status":106,"phases":8190,"primaryCompletion":1678,"completion":1679,"start":1680,"enrollment":9,"conditions":8191,"interventions":8192},[89],[19],[71,1683,1684,1685],{"trials":8194,"activeCount":100},[],{"trials":8196,"activeCount":100},[],{"trials":8198,"activeCount":100},[],{"trials":8200,"activeCount":100},[],{"intervention":1684,"totalTrials":146,"cells":8202},{"EARLY_PHASE1":8203,"PHASE1":8205,"PHASE2":8211,"PHASE3":8213,"PHASE4":8215,"NA":8217},{"trials":8204,"activeCount":100},[],{"trials":8206,"activeCount":100},[8207],{"nctId":1675,"briefTitle":1676,"status":106,"phases":8208,"primaryCompletion":1678,"completion":1679,"start":1680,"enrollment":9,"conditions":8209,"interventions":8210},[89],[19],[71,1683,1684,1685],{"trials":8212,"activeCount":100},[],{"trials":8214,"activeCount":100},[],{"trials":8216,"activeCount":100},[],{"trials":8218,"activeCount":100},[],{"intervention":1685,"totalTrials":146,"cells":8220},{"EARLY_PHASE1":8221,"PHASE1":8223,"PHASE2":8229,"PHASE3":8231,"PHASE4":8233,"NA":8235},{"trials":8222,"activeCount":100},[],{"trials":8224,"activeCount":100},[8225],{"nctId":1675,"briefTitle":1676,"status":106,"phases":8226,"primaryCompletion":1678,"completion":1679,"start":1680,"enrollment":9,"conditions":8227,"interventions":8228},[89],[19],[71,1683,1684,1685],{"trials":8230,"activeCount":100},[],{"trials":8232,"activeCount":100},[],{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[],{"intervention":8238,"totalTrials":146,"cells":8239},"CC-223, erlotinib",{"EARLY_PHASE1":8240,"PHASE1":8242,"PHASE2":8253,"PHASE3":8255,"PHASE4":8257,"NA":8259},{"trials":8241,"activeCount":100},[],{"trials":8243,"activeCount":100},[8244],{"nctId":8245,"briefTitle":8246,"status":106,"phases":8247,"primaryCompletion":8248,"completion":8248,"start":8249,"enrollment":4171,"conditions":8250,"interventions":8251},"NCT01545947","Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",[89],"2014-12-11","2012-05-01",[3512,3606],[8238,8252,8252],"CC-223, oral azacitidine",{"trials":8254,"activeCount":100},[],{"trials":8256,"activeCount":100},[],{"trials":8258,"activeCount":100},[],{"trials":8260,"activeCount":100},[],{"intervention":8252,"totalTrials":146,"cells":8262},{"EARLY_PHASE1":8263,"PHASE1":8265,"PHASE2":8271,"PHASE3":8273,"PHASE4":8275,"NA":8277},{"trials":8264,"activeCount":100},[],{"trials":8266,"activeCount":100},[8267],{"nctId":8245,"briefTitle":8246,"status":106,"phases":8268,"primaryCompletion":8248,"completion":8248,"start":8249,"enrollment":4171,"conditions":8269,"interventions":8270},[89],[3512,3606],[8238,8252,8252],{"trials":8272,"activeCount":100},[],{"trials":8274,"activeCount":100},[],{"trials":8276,"activeCount":100},[],{"trials":8278,"activeCount":100},[],{"intervention":8280,"totalTrials":146,"cells":8281},"[14C]CC-90001",{"EARLY_PHASE1":8282,"PHASE1":8284,"PHASE2":8293,"PHASE3":8295,"PHASE4":8297,"NA":8299},{"trials":8283,"activeCount":100},[],{"trials":8285,"activeCount":100},[8286],{"nctId":8287,"briefTitle":8288,"status":106,"phases":8289,"primaryCompletion":8290,"completion":8290,"start":697,"enrollment":862,"conditions":8291,"interventions":8292},"NCT04655898","Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects",[89],"2021-03-11",[29],[8280],{"trials":8294,"activeCount":100},[],{"trials":8296,"activeCount":100},[],{"trials":8298,"activeCount":100},[],{"trials":8300,"activeCount":100},[],{"intervention":8302,"totalTrials":146,"cells":8303},"NPI-0052 (marizomib) + vorinostat",{"EARLY_PHASE1":8304,"PHASE1":8306,"PHASE2":8316,"PHASE3":8318,"PHASE4":8320,"NA":8322},{"trials":8305,"activeCount":100},[],{"trials":8307,"activeCount":100},[8308],{"nctId":8309,"briefTitle":8310,"status":106,"phases":8311,"primaryCompletion":8312,"completion":8312,"start":8313,"enrollment":600,"conditions":8314,"interventions":8315},"NCT00667082","NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",[89],"2010-01","2008-03",[3606,2343,3744,660,16],[8302],{"trials":8317,"activeCount":100},[],{"trials":8319,"activeCount":100},[],{"trials":8321,"activeCount":100},[],{"trials":8323,"activeCount":100},[],{"intervention":5344,"totalTrials":146,"cells":8325},{"EARLY_PHASE1":8326,"PHASE1":8328,"PHASE2":8334,"PHASE3":8336,"PHASE4":8338,"NA":8340},{"trials":8327,"activeCount":100},[],{"trials":8329,"activeCount":100},[8330],{"nctId":5337,"briefTitle":5338,"status":106,"phases":8331,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":8332,"interventions":8333},[89],[5342],[5305,3863,3428,5344,3431,3430,3429,5345],{"trials":8335,"activeCount":100},[],{"trials":8337,"activeCount":100},[],{"trials":8339,"activeCount":100},[],{"trials":8341,"activeCount":100},[],{"intervention":5345,"totalTrials":146,"cells":8343},{"EARLY_PHASE1":8344,"PHASE1":8346,"PHASE2":8352,"PHASE3":8354,"PHASE4":8356,"NA":8358},{"trials":8345,"activeCount":100},[],{"trials":8347,"activeCount":100},[8348],{"nctId":5337,"briefTitle":5338,"status":106,"phases":8349,"primaryCompletion":5340,"completion":5340,"start":875,"enrollment":440,"conditions":8350,"interventions":8351},[89],[5342],[5305,3863,3428,5344,3431,3430,3429,5345],{"trials":8353,"activeCount":100},[],{"trials":8355,"activeCount":100},[],{"trials":8357,"activeCount":100},[],{"trials":8359,"activeCount":100},[],{"intervention":3411,"totalTrials":146,"cells":8361},{"EARLY_PHASE1":8362,"PHASE1":8364,"PHASE2":8370,"PHASE3":8372,"PHASE4":8374,"NA":8376},{"trials":8363,"activeCount":100},[],{"trials":8365,"activeCount":100},[8366],{"nctId":3402,"briefTitle":3403,"status":106,"phases":8367,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":8368,"interventions":8369},[89],[29],[3410,3411,1107,1108],{"trials":8371,"activeCount":100},[],{"trials":8373,"activeCount":100},[],{"trials":8375,"activeCount":100},[],{"trials":8377,"activeCount":100},[],{"intervention":6008,"totalTrials":146,"cells":8379},{"EARLY_PHASE1":8380,"PHASE1":8382,"PHASE2":8388,"PHASE3":8390,"PHASE4":8392,"NA":8394},{"trials":8381,"activeCount":100},[],{"trials":8383,"activeCount":100},[8384],{"nctId":6000,"briefTitle":6001,"status":171,"phases":8385,"primaryCompletion":6003,"completion":6004,"start":6005,"enrollment":3110,"conditions":8386,"interventions":8387},[89],[16],[6008,2459],{"trials":8389,"activeCount":100},[],{"trials":8391,"activeCount":100},[],{"trials":8393,"activeCount":100},[],{"trials":8395,"activeCount":100},[],{"intervention":8397,"totalTrials":146,"cells":8398},"Vidaza",{"EARLY_PHASE1":8399,"PHASE1":8401,"PHASE2":8420,"PHASE3":8422,"PHASE4":8424,"NA":8426},{"trials":8400,"activeCount":100},[],{"trials":8402,"activeCount":100},[8403],{"nctId":8404,"briefTitle":8405,"status":106,"phases":8406,"primaryCompletion":8407,"completion":8408,"start":8409,"enrollment":8410,"conditions":8411,"interventions":8419},"NCT02223052","Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies",[89],"2018-06-11","2018-12-18","2014-10-27",89,[8412,1557,8413,660,16,1269,8414,22,32,3744,2773,2485,3606,4149,1297,5717,8415,8416,8417,8418],"Hematological Neoplasms","Hodgkin's Lymphoma","Leukemia","Osteosarcoma","Sarcoma","Thyroid Cancer","Genitourinary",[3516,8397],{"trials":8421,"activeCount":100},[],{"trials":8423,"activeCount":100},[],{"trials":8425,"activeCount":100},[],{"trials":8427,"activeCount":100},[],{"intervention":8429,"totalTrials":146,"cells":8430},"CC-95775",{"EARLY_PHASE1":8431,"PHASE1":8433,"PHASE2":8443,"PHASE3":8445,"PHASE4":8447,"NA":8449},{"trials":8432,"activeCount":100},[],{"trials":8434,"activeCount":100},[8435],{"nctId":8436,"briefTitle":8437,"status":106,"phases":8438,"primaryCompletion":8439,"completion":8439,"start":8440,"enrollment":9,"conditions":8441,"interventions":8442},"NCT04089527","Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed\u002FRefractory Non-Hodgkin Lymphoma",[89],"2021-10-25","2019-10-24",[24],[8429],{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[],{"trials":8448,"activeCount":100},[],{"trials":8450,"activeCount":100},[],{"intervention":7059,"totalTrials":146,"cells":8452},{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8461,"PHASE3":8463,"PHASE4":8465,"NA":8467},{"trials":8454,"activeCount":100},[],{"trials":8456,"activeCount":100},[8457],{"nctId":7052,"briefTitle":7053,"status":171,"phases":8458,"primaryCompletion":7055,"completion":7055,"start":7056,"enrollment":1286,"conditions":8459,"interventions":8460},[89],[5108],[7028,7059],{"trials":8462,"activeCount":100},[],{"trials":8464,"activeCount":100},[],{"trials":8466,"activeCount":100},[],{"trials":8468,"activeCount":100},[],{"intervention":5883,"totalTrials":146,"cells":8470},{"EARLY_PHASE1":8471,"PHASE1":8473,"PHASE2":8479,"PHASE3":8481,"PHASE4":8483,"NA":8485},{"trials":8472,"activeCount":100},[],{"trials":8474,"activeCount":100},[8475],{"nctId":5875,"briefTitle":5876,"status":106,"phases":8476,"primaryCompletion":5878,"completion":5878,"start":5879,"enrollment":4162,"conditions":8477,"interventions":8478},[89],[5108,5881],[5868,5883],{"trials":8480,"activeCount":100},[],{"trials":8482,"activeCount":100},[],{"trials":8484,"activeCount":100},[],{"trials":8486,"activeCount":100},[],{"intervention":4275,"totalTrials":146,"cells":8488},{"EARLY_PHASE1":8489,"PHASE1":8491,"PHASE2":8497,"PHASE3":8499,"PHASE4":8501,"NA":8503},{"trials":8490,"activeCount":100},[],{"trials":8492,"activeCount":100},[8493],{"nctId":4269,"briefTitle":4270,"status":106,"phases":8494,"primaryCompletion":2693,"completion":2693,"start":4272,"enrollment":1413,"conditions":8495,"interventions":8496},[89],[19],[4267,4275,4249],{"trials":8498,"activeCount":100},[],{"trials":8500,"activeCount":100},[],{"trials":8502,"activeCount":100},[],{"trials":8504,"activeCount":100},[],{"intervention":1894,"totalTrials":146,"cells":8506},{"EARLY_PHASE1":8507,"PHASE1":8509,"PHASE2":8515,"PHASE3":8517,"PHASE4":8519,"NA":8521},{"trials":8508,"activeCount":100},[],{"trials":8510,"activeCount":100},[8511],{"nctId":1884,"briefTitle":1885,"status":106,"phases":8512,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":823,"conditions":8513,"interventions":8514},[89],[1890,1226],[257,1892,1893,1894],{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[],{"trials":8522,"activeCount":100},[],{"intervention":3480,"totalTrials":146,"cells":8524},{"EARLY_PHASE1":8525,"PHASE1":8527,"PHASE2":8533,"PHASE3":8535,"PHASE4":8537,"NA":8539},{"trials":8526,"activeCount":100},[],{"trials":8528,"activeCount":100},[8529],{"nctId":3471,"briefTitle":3472,"status":106,"phases":8530,"primaryCompletion":3474,"completion":3475,"start":3476,"enrollment":823,"conditions":8531,"interventions":8532},[89],[19],[3479,1108,3480],{"trials":8534,"activeCount":100},[],{"trials":8536,"activeCount":100},[],{"trials":8538,"activeCount":100},[],{"trials":8540,"activeCount":100},[],{"intervention":8542,"totalTrials":146,"cells":8543},"CC-401",{"EARLY_PHASE1":8544,"PHASE1":8546,"PHASE2":8557,"PHASE3":8559,"PHASE4":8561,"NA":8563},{"trials":8545,"activeCount":100},[],{"trials":8547,"activeCount":100},[8548],{"nctId":8549,"briefTitle":8550,"status":171,"phases":8551,"completion":8552,"start":8553,"enrollment":379,"conditions":8554,"interventions":8556},"NCT00126893","Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia",[89],"2006-09","2005-10",[8555],"Myeloid Leukemia",[8542],{"trials":8558,"activeCount":100},[],{"trials":8560,"activeCount":100},[],{"trials":8562,"activeCount":100},[],{"trials":8564,"activeCount":100},[],{"intervention":1228,"totalTrials":146,"cells":8566},{"EARLY_PHASE1":8567,"PHASE1":8569,"PHASE2":8575,"PHASE3":8577,"PHASE4":8579,"NA":8581},{"trials":8568,"activeCount":100},[],{"trials":8570,"activeCount":100},[8571],{"nctId":1220,"briefTitle":1221,"status":106,"phases":8572,"primaryCompletion":1223,"completion":1223,"start":329,"enrollment":1224,"conditions":8573,"interventions":8574},[89],[1226],[115,1228,1229,1230],{"trials":8576,"activeCount":100},[],{"trials":8578,"activeCount":100},[],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"intervention":1229,"totalTrials":146,"cells":8584},{"EARLY_PHASE1":8585,"PHASE1":8587,"PHASE2":8593,"PHASE3":8595,"PHASE4":8597,"NA":8599},{"trials":8586,"activeCount":100},[],{"trials":8588,"activeCount":100},[8589],{"nctId":1220,"briefTitle":1221,"status":106,"phases":8590,"primaryCompletion":1223,"completion":1223,"start":329,"enrollment":1224,"conditions":8591,"interventions":8592},[89],[1226],[115,1228,1229,1230],{"trials":8594,"activeCount":100},[],{"trials":8596,"activeCount":100},[],{"trials":8598,"activeCount":100},[],{"trials":8600,"activeCount":100},[],{"intervention":1230,"totalTrials":146,"cells":8602},{"EARLY_PHASE1":8603,"PHASE1":8605,"PHASE2":8611,"PHASE3":8613,"PHASE4":8615,"NA":8617},{"trials":8604,"activeCount":100},[],{"trials":8606,"activeCount":100},[8607],{"nctId":1220,"briefTitle":1221,"status":106,"phases":8608,"primaryCompletion":1223,"completion":1223,"start":329,"enrollment":1224,"conditions":8609,"interventions":8610},[89],[1226],[115,1228,1229,1230],{"trials":8612,"activeCount":100},[],{"trials":8614,"activeCount":100},[],{"trials":8616,"activeCount":100},[],{"trials":8618,"activeCount":100},[],{"intervention":8620,"totalTrials":146,"cells":8621},"Cendakimab",{"EARLY_PHASE1":8622,"PHASE1":8624,"PHASE2":8635,"PHASE3":8637,"PHASE4":8639,"NA":8641},{"trials":8623,"activeCount":100},[],{"trials":8625,"activeCount":100},[8626],{"nctId":8627,"briefTitle":8628,"status":106,"phases":8629,"primaryCompletion":8630,"completion":8630,"start":8631,"enrollment":25,"conditions":8632,"interventions":8633},"NCT05175352","A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab",[89],"2024-10-11","2022-06-07",[4043],[8620,8634],"CYP substrates",{"trials":8636,"activeCount":100},[],{"trials":8638,"activeCount":100},[],{"trials":8640,"activeCount":100},[],{"trials":8642,"activeCount":100},[],{"intervention":8634,"totalTrials":146,"cells":8644},{"EARLY_PHASE1":8645,"PHASE1":8647,"PHASE2":8653,"PHASE3":8655,"PHASE4":8657,"NA":8659},{"trials":8646,"activeCount":100},[],{"trials":8648,"activeCount":100},[8649],{"nctId":8627,"briefTitle":8628,"status":106,"phases":8650,"primaryCompletion":8630,"completion":8630,"start":8631,"enrollment":25,"conditions":8651,"interventions":8652},[89],[4043],[8620,8634],{"trials":8654,"activeCount":100},[],{"trials":8656,"activeCount":100},[],{"trials":8658,"activeCount":100},[],{"trials":8660,"activeCount":100},[],{"intervention":3426,"totalTrials":146,"cells":8662},{"EARLY_PHASE1":8663,"PHASE1":8665,"PHASE2":8671,"PHASE3":8673,"PHASE4":8675,"NA":8677},{"trials":8664,"activeCount":100},[],{"trials":8666,"activeCount":100},[8667],{"nctId":3417,"briefTitle":3418,"status":106,"phases":8668,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":8669,"interventions":8670},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"trials":8672,"activeCount":100},[],{"trials":8674,"activeCount":100},[],{"trials":8676,"activeCount":100},[],{"trials":8678,"activeCount":100},[],{"intervention":3427,"totalTrials":146,"cells":8680},{"EARLY_PHASE1":8681,"PHASE1":8683,"PHASE2":8689,"PHASE3":8691,"PHASE4":8693,"NA":8695},{"trials":8682,"activeCount":100},[],{"trials":8684,"activeCount":100},[8685],{"nctId":3417,"briefTitle":3418,"status":106,"phases":8686,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":3422,"conditions":8687,"interventions":8688},[89],[29],[3425,3426,3427,1107,1108,3428,3429,3430,3431],{"trials":8690,"activeCount":100},[],{"trials":8692,"activeCount":100},[],{"trials":8694,"activeCount":100},[],{"trials":8696,"activeCount":100},[],{"intervention":8698,"totalTrials":146,"cells":8699},"NPI-0052",{"EARLY_PHASE1":8700,"PHASE1":8702,"PHASE2":8713,"PHASE3":8715,"PHASE4":8717,"NA":8719},{"trials":8701,"activeCount":100},[],{"trials":8703,"activeCount":100},[8704],{"nctId":8705,"briefTitle":8706,"status":106,"phases":8707,"primaryCompletion":8708,"completion":8708,"start":8709,"enrollment":1387,"conditions":8710,"interventions":8712},"NCT00396864","Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma",[89],"2010-03","2006-05",[2377,8711],"Lymphomas",[8698],{"trials":8714,"activeCount":100},[],{"trials":8716,"activeCount":100},[],{"trials":8718,"activeCount":100},[],{"trials":8720,"activeCount":100},[],{"intervention":8722,"totalTrials":146,"cells":8723},"CC-8490",{"EARLY_PHASE1":8724,"PHASE1":8726,"PHASE2":8735,"PHASE3":8737,"PHASE4":8739,"NA":8741},{"trials":8725,"activeCount":100},[],{"trials":8727,"activeCount":100},[8728],{"nctId":8729,"briefTitle":8730,"status":106,"phases":8731,"completion":1377,"start":3713,"enrollment":379,"conditions":8732,"interventions":8734},"NCT00074646","Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent\u002FRefractory High-Grade Gliomas",[89],[5108,8733],"Malignant Gliomas",[8722],{"trials":8736,"activeCount":100},[],{"trials":8738,"activeCount":100},[],{"trials":8740,"activeCount":100},[],{"trials":8742,"activeCount":100},[],{"intervention":5431,"totalTrials":146,"cells":8744},{"EARLY_PHASE1":8745,"PHASE1":8747,"PHASE2":8753,"PHASE3":8755,"PHASE4":8757,"NA":8759},{"trials":8746,"activeCount":100},[],{"trials":8748,"activeCount":100},[8749],{"nctId":5422,"briefTitle":5423,"status":106,"phases":8750,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":684,"conditions":8751,"interventions":8752},[89],[27],[5430,5431,5432,5433],{"trials":8754,"activeCount":100},[],{"trials":8756,"activeCount":100},[],{"trials":8758,"activeCount":100},[],{"trials":8760,"activeCount":100},[],{"intervention":5432,"totalTrials":146,"cells":8762},{"EARLY_PHASE1":8763,"PHASE1":8765,"PHASE2":8771,"PHASE3":8773,"PHASE4":8775,"NA":8777},{"trials":8764,"activeCount":100},[],{"trials":8766,"activeCount":100},[8767],{"nctId":5422,"briefTitle":5423,"status":106,"phases":8768,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":684,"conditions":8769,"interventions":8770},[89],[27],[5430,5431,5432,5433],{"trials":8772,"activeCount":100},[],{"trials":8774,"activeCount":100},[],{"trials":8776,"activeCount":100},[],{"trials":8778,"activeCount":100},[],{"intervention":5433,"totalTrials":146,"cells":8780},{"EARLY_PHASE1":8781,"PHASE1":8783,"PHASE2":8789,"PHASE3":8791,"PHASE4":8793,"NA":8795},{"trials":8782,"activeCount":100},[],{"trials":8784,"activeCount":100},[8785],{"nctId":5422,"briefTitle":5423,"status":106,"phases":8786,"primaryCompletion":5425,"completion":5426,"start":5427,"enrollment":684,"conditions":8787,"interventions":8788},[89],[27],[5430,5431,5432,5433],{"trials":8790,"activeCount":100},[],{"trials":8792,"activeCount":100},[],{"trials":8794,"activeCount":100},[],{"trials":8796,"activeCount":100},[],{"intervention":8798,"totalTrials":146,"cells":8799},"ABI-011",{"EARLY_PHASE1":8800,"PHASE1":8802,"PHASE2":8811,"PHASE3":8813,"PHASE4":8815,"NA":8817},{"trials":8801,"activeCount":100},[],{"trials":8803,"activeCount":100},[8804],{"nctId":8805,"briefTitle":8806,"status":171,"phases":8807,"primaryCompletion":8808,"completion":8808,"start":1555,"enrollment":669,"conditions":8809,"interventions":8810},"NCT01163071","A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas",[89],"2011-09-23",[4139],[8798],{"trials":8812,"activeCount":100},[],{"trials":8814,"activeCount":100},[],{"trials":8816,"activeCount":100},[],{"trials":8818,"activeCount":100},[],{"intervention":8820,"totalTrials":146,"cells":8821},"CC-94676",{"EARLY_PHASE1":8822,"PHASE1":8824,"PHASE2":8835,"PHASE3":8837,"PHASE4":8839,"NA":8841},{"trials":8823,"activeCount":100},[],{"trials":8825,"activeCount":100},[8826],{"nctId":8827,"briefTitle":8828,"status":106,"phases":8829,"primaryCompletion":8830,"completion":8830,"start":4006,"enrollment":2386,"conditions":8831,"interventions":8832},"NCT04428788","Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer",[89],"2025-10-28",[1018],[8820,8833,8834],"CC1083611","CC1083610",{"trials":8836,"activeCount":100},[],{"trials":8838,"activeCount":100},[],{"trials":8840,"activeCount":100},[],{"trials":8842,"activeCount":100},[],{"intervention":8833,"totalTrials":146,"cells":8844},{"EARLY_PHASE1":8845,"PHASE1":8847,"PHASE2":8853,"PHASE3":8855,"PHASE4":8857,"NA":8859},{"trials":8846,"activeCount":100},[],{"trials":8848,"activeCount":100},[8849],{"nctId":8827,"briefTitle":8828,"status":106,"phases":8850,"primaryCompletion":8830,"completion":8830,"start":4006,"enrollment":2386,"conditions":8851,"interventions":8852},[89],[1018],[8820,8833,8834],{"trials":8854,"activeCount":100},[],{"trials":8856,"activeCount":100},[],{"trials":8858,"activeCount":100},[],{"trials":8860,"activeCount":100},[],{"intervention":8834,"totalTrials":146,"cells":8862},{"EARLY_PHASE1":8863,"PHASE1":8865,"PHASE2":8871,"PHASE3":8873,"PHASE4":8875,"NA":8877},{"trials":8864,"activeCount":100},[],{"trials":8866,"activeCount":100},[8867],{"nctId":8827,"briefTitle":8828,"status":106,"phases":8868,"primaryCompletion":8830,"completion":8830,"start":4006,"enrollment":2386,"conditions":8869,"interventions":8870},[89],[1018],[8820,8833,8834],{"trials":8872,"activeCount":100},[],{"trials":8874,"activeCount":100},[],{"trials":8876,"activeCount":100},[],{"trials":8878,"activeCount":100},[],{"intervention":2892,"totalTrials":146,"cells":8880},{"EARLY_PHASE1":8881,"PHASE1":8883,"PHASE2":8889,"PHASE3":8891,"PHASE4":8893,"NA":8895},{"trials":8882,"activeCount":100},[],{"trials":8884,"activeCount":100},[8885],{"nctId":2886,"briefTitle":2887,"status":106,"phases":8886,"primaryCompletion":2889,"completion":2889,"start":1887,"enrollment":339,"conditions":8887,"interventions":8888},[89],[1226],[2892,2893,2894,2895,2896,56,56,56],{"trials":8890,"activeCount":100},[],{"trials":8892,"activeCount":100},[],{"trials":8894,"activeCount":100},[],{"trials":8896,"activeCount":100},[],{"intervention":2893,"totalTrials":146,"cells":8898},{"EARLY_PHASE1":8899,"PHASE1":8901,"PHASE2":8907,"PHASE3":8909,"PHASE4":8911,"NA":8913},{"trials":8900,"activeCount":100},[],{"trials":8902,"activeCount":100},[8903],{"nctId":2886,"briefTitle":2887,"status":106,"phases":8904,"primaryCompletion":2889,"completion":2889,"start":1887,"enrollment":339,"conditions":8905,"interventions":8906},[89],[1226],[2892,2893,2894,2895,2896,56,56,56],{"trials":8908,"activeCount":100},[],{"trials":8910,"activeCount":100},[],{"trials":8912,"activeCount":100},[],{"trials":8914,"activeCount":100},[],{"intervention":2894,"totalTrials":146,"cells":8916},{"EARLY_PHASE1":8917,"PHASE1":8919,"PHASE2":8925,"PHASE3":8927,"PHASE4":8929,"NA":8931},{"trials":8918,"activeCount":100},[],{"trials":8920,"activeCount":100},[8921],{"nctId":2886,"briefTitle":2887,"status":106,"phases":8922,"primaryCompletion":2889,"completion":2889,"start":1887,"enrollment":339,"conditions":8923,"interventions":8924},[89],[1226],[2892,2893,2894,2895,2896,56,56,56],{"trials":8926,"activeCount":100},[],{"trials":8928,"activeCount":100},[],{"trials":8930,"activeCount":100},[],{"trials":8932,"activeCount":100},[],{"intervention":2895,"totalTrials":146,"cells":8934},{"EARLY_PHASE1":8935,"PHASE1":8937,"PHASE2":8943,"PHASE3":8945,"PHASE4":8947,"NA":8949},{"trials":8936,"activeCount":100},[],{"trials":8938,"activeCount":100},[8939],{"nctId":2886,"briefTitle":2887,"status":106,"phases":8940,"primaryCompletion":2889,"completion":2889,"start":1887,"enrollment":339,"conditions":8941,"interventions":8942},[89],[1226],[2892,2893,2894,2895,2896,56,56,56],{"trials":8944,"activeCount":100},[],{"trials":8946,"activeCount":100},[],{"trials":8948,"activeCount":100},[],{"trials":8950,"activeCount":100},[],{"intervention":2896,"totalTrials":146,"cells":8952},{"EARLY_PHASE1":8953,"PHASE1":8955,"PHASE2":8961,"PHASE3":8963,"PHASE4":8965,"NA":8967},{"trials":8954,"activeCount":100},[],{"trials":8956,"activeCount":100},[8957],{"nctId":2886,"briefTitle":2887,"status":106,"phases":8958,"primaryCompletion":2889,"completion":2889,"start":1887,"enrollment":339,"conditions":8959,"interventions":8960},[89],[1226],[2892,2893,2894,2895,2896,56,56,56],{"trials":8962,"activeCount":100},[],{"trials":8964,"activeCount":100},[],{"trials":8966,"activeCount":100},[],{"trials":8968,"activeCount":100},[],{"intervention":703,"totalTrials":146,"cells":8970},{"EARLY_PHASE1":8971,"PHASE1":8973,"PHASE2":8979,"PHASE3":8981,"PHASE4":8983,"NA":8985},{"trials":8972,"activeCount":100},[],{"trials":8974,"activeCount":100},[8975],{"nctId":693,"briefTitle":694,"status":106,"phases":8976,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":8977,"interventions":8978},[89],[701],[703,128,704,130,131],{"trials":8980,"activeCount":100},[],{"trials":8982,"activeCount":100},[],{"trials":8984,"activeCount":100},[],{"trials":8986,"activeCount":100},[],{"intervention":704,"totalTrials":146,"cells":8988},{"EARLY_PHASE1":8989,"PHASE1":8991,"PHASE2":8997,"PHASE3":8999,"PHASE4":9001,"NA":9003},{"trials":8990,"activeCount":100},[],{"trials":8992,"activeCount":100},[8993],{"nctId":693,"briefTitle":694,"status":106,"phases":8994,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":8995,"interventions":8996},[89],[701],[703,128,704,130,131],{"trials":8998,"activeCount":100},[],{"trials":9000,"activeCount":100},[],{"trials":9002,"activeCount":100},[],{"trials":9004,"activeCount":100},[],{"intervention":9006,"totalTrials":146,"cells":9007},"CC-90005",{"EARLY_PHASE1":9008,"PHASE1":9010,"PHASE2":9021,"PHASE3":9023,"PHASE4":9025,"NA":9027},{"trials":9009,"activeCount":100},[],{"trials":9011,"activeCount":100},[9012],{"nctId":9013,"briefTitle":9014,"status":171,"phases":9015,"primaryCompletion":9016,"completion":9016,"start":9017,"enrollment":9,"conditions":9018,"interventions":9020},"NCT02502188","Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis",[89],"2015-11-02","2015-07-17",[9019,19],"Parapsoriasis",[9006],{"trials":9022,"activeCount":100},[],{"trials":9024,"activeCount":100},[],{"trials":9026,"activeCount":100},[],{"trials":9028,"activeCount":100},[],{"intervention":9030,"totalTrials":146,"cells":9031},"ABI-009",{"EARLY_PHASE1":9032,"PHASE1":9034,"PHASE2":9044,"PHASE3":9046,"PHASE4":9048,"NA":9050},{"trials":9033,"activeCount":100},[],{"trials":9035,"activeCount":100},[9036],{"nctId":9037,"briefTitle":9038,"status":106,"phases":9039,"primaryCompletion":9040,"completion":9040,"start":6615,"enrollment":9041,"conditions":9042,"interventions":9043},"NCT00635284","ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies",[89],"2011-06-01",27,[2081],[9030],{"trials":9045,"activeCount":100},[],{"trials":9047,"activeCount":100},[],{"trials":9049,"activeCount":100},[],{"trials":9051,"activeCount":100},[],{"intervention":9053,"totalTrials":146,"cells":9054},"CC-93269",{"EARLY_PHASE1":9055,"PHASE1":9057,"PHASE2":9068,"PHASE3":9070,"PHASE4":9072,"NA":9074},{"trials":9056,"activeCount":100},[],{"trials":9058,"activeCount":100},[9059],{"nctId":9060,"briefTitle":9061,"status":171,"phases":9062,"primaryCompletion":9063,"completion":9063,"start":9064,"enrollment":9065,"conditions":9066,"interventions":9067},"NCT03486067","Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma",[89],"2025-03-18","2018-04-03",183,[16],[9053],{"trials":9069,"activeCount":100},[],{"trials":9071,"activeCount":100},[],{"trials":9073,"activeCount":100},[],{"trials":9075,"activeCount":100},[],{"intervention":3801,"totalTrials":146,"cells":9077},{"EARLY_PHASE1":9078,"PHASE1":9080,"PHASE2":9086,"PHASE3":9088,"PHASE4":9090,"NA":9092},{"trials":9079,"activeCount":100},[],{"trials":9081,"activeCount":100},[9082],{"nctId":3790,"briefTitle":3791,"status":106,"phases":9083,"primaryCompletion":3793,"completion":3794,"start":3795,"enrollment":3796,"conditions":9084,"interventions":9085},[89],[2265,3798,3799],[3801,127,127],{"trials":9087,"activeCount":100},[],{"trials":9089,"activeCount":100},[],{"trials":9091,"activeCount":100},[],{"trials":9093,"activeCount":100},[],{"intervention":9095,"totalTrials":146,"cells":9096},"50 mg AVL-292",{"EARLY_PHASE1":9097,"PHASE1":9099,"PHASE2":9112,"PHASE3":9114,"PHASE4":9116,"NA":9118},{"trials":9098,"activeCount":100},[],{"trials":9100,"activeCount":100},[9101],{"nctId":9102,"briefTitle":9103,"status":106,"phases":9104,"primaryCompletion":9105,"completion":9105,"start":9106,"enrollment":1413,"conditions":9107,"interventions":9108},"NCT01692184","Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292",[89],"2012-10-08","2012-08-01",[1226],[9095,9109,9110,9111],"100 mg AVL-292","200 mg AVL-292","350 mg AVL-292",{"trials":9113,"activeCount":100},[],{"trials":9115,"activeCount":100},[],{"trials":9117,"activeCount":100},[],{"trials":9119,"activeCount":100},[],{"intervention":9109,"totalTrials":146,"cells":9121},{"EARLY_PHASE1":9122,"PHASE1":9124,"PHASE2":9130,"PHASE3":9132,"PHASE4":9134,"NA":9136},{"trials":9123,"activeCount":100},[],{"trials":9125,"activeCount":100},[9126],{"nctId":9102,"briefTitle":9103,"status":106,"phases":9127,"primaryCompletion":9105,"completion":9105,"start":9106,"enrollment":1413,"conditions":9128,"interventions":9129},[89],[1226],[9095,9109,9110,9111],{"trials":9131,"activeCount":100},[],{"trials":9133,"activeCount":100},[],{"trials":9135,"activeCount":100},[],{"trials":9137,"activeCount":100},[],{"intervention":9110,"totalTrials":146,"cells":9139},{"EARLY_PHASE1":9140,"PHASE1":9142,"PHASE2":9148,"PHASE3":9150,"PHASE4":9152,"NA":9154},{"trials":9141,"activeCount":100},[],{"trials":9143,"activeCount":100},[9144],{"nctId":9102,"briefTitle":9103,"status":106,"phases":9145,"primaryCompletion":9105,"completion":9105,"start":9106,"enrollment":1413,"conditions":9146,"interventions":9147},[89],[1226],[9095,9109,9110,9111],{"trials":9149,"activeCount":100},[],{"trials":9151,"activeCount":100},[],{"trials":9153,"activeCount":100},[],{"trials":9155,"activeCount":100},[],{"intervention":9111,"totalTrials":146,"cells":9157},{"EARLY_PHASE1":9158,"PHASE1":9160,"PHASE2":9166,"PHASE3":9168,"PHASE4":9170,"NA":9172},{"trials":9159,"activeCount":100},[],{"trials":9161,"activeCount":100},[9162],{"nctId":9102,"briefTitle":9103,"status":106,"phases":9163,"primaryCompletion":9105,"completion":9105,"start":9106,"enrollment":1413,"conditions":9164,"interventions":9165},[89],[1226],[9095,9109,9110,9111],{"trials":9167,"activeCount":100},[],{"trials":9169,"activeCount":100},[],{"trials":9171,"activeCount":100},[],{"trials":9173,"activeCount":100},[],{"intervention":3410,"totalTrials":877,"cells":9175},{"EARLY_PHASE1":9176,"PHASE1":9178,"PHASE2":9226,"PHASE3":9238,"PHASE4":9301,"NA":9303},{"trials":9177,"activeCount":100},[],{"trials":9179,"activeCount":100},[9180,9184,9188,9192,9200,9204,9213,9217],{"nctId":4256,"briefTitle":4257,"status":106,"phases":9181,"primaryCompletion":4259,"completion":4259,"start":4260,"enrollment":4261,"conditions":9182,"interventions":9183},[89],[29],[4264,4265,4266,4249,4267],{"nctId":7183,"briefTitle":7184,"status":106,"phases":9185,"primaryCompletion":7186,"completion":7186,"start":7187,"enrollment":7188,"conditions":9186,"interventions":9187},[89],[19],[7191,4264,3410],{"nctId":7956,"briefTitle":7957,"status":106,"phases":9189,"primaryCompletion":7959,"completion":3149,"start":6942,"enrollment":684,"conditions":9190,"interventions":9191},[89],[19],[3410,7949],{"nctId":9193,"briefTitle":9194,"status":106,"phases":9195,"primaryCompletion":9196,"completion":2455,"start":9197,"enrollment":440,"conditions":9198,"interventions":9199},"NCT04528290","A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects",[89],"2021-05-19","2020-10-07",[19],[3410,3410],{"nctId":3402,"briefTitle":3403,"status":106,"phases":9201,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":9202,"interventions":9203},[89],[29],[3410,3411,1107,1108],{"nctId":9205,"briefTitle":9206,"status":106,"phases":9207,"primaryCompletion":9208,"completion":9209,"start":9210,"enrollment":9,"conditions":9211,"interventions":9212},"NCT04211558","A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects",[89],"2020-09-26","2020-10-09","2020-08-12",[29],[3410],{"nctId":4269,"briefTitle":4270,"status":106,"phases":9214,"primaryCompletion":2693,"completion":2693,"start":4272,"enrollment":1413,"conditions":9215,"interventions":9216},[89],[19],[4267,4275,4249],{"nctId":9218,"briefTitle":9219,"status":106,"phases":9220,"primaryCompletion":9221,"completion":9221,"start":9222,"enrollment":330,"conditions":9223,"interventions":9225},"NCT04639115","A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod",[89],"2022-04-06","2020-12-18",[9224,2813],"Liver Diseases",[3410],{"trials":9227,"activeCount":100},[9228],{"nctId":9229,"briefTitle":9230,"status":106,"phases":9231,"primaryCompletion":9232,"completion":9233,"start":9234,"enrollment":9235,"conditions":9236,"interventions":9237},"NCT01647516","Efficacy and Safety Study of Ozanimod in Ulcerative Colitis",[90],"2015-03-10","2019-08-30","2012-12-26",199,[3962],[3410],{"trials":9239,"activeCount":100},[9240,9249,9258,9267,9271,9280,9289,9297],{"nctId":9241,"briefTitle":9242,"status":171,"phases":9243,"primaryCompletion":9244,"completion":9244,"start":9245,"enrollment":9246,"conditions":9247,"interventions":9248},"NCT03467958","An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease",[91],"2024-10-31","2018-08-24",854,[3853],[3410],{"nctId":9250,"briefTitle":9251,"status":106,"phases":9252,"primaryCompletion":9253,"completion":724,"start":9254,"enrollment":9255,"conditions":9256,"interventions":9257},"NCT01628393","Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients",[90,91],"2014-04-13","2012-09-18",258,[4289],[3410],{"nctId":9259,"briefTitle":9260,"status":171,"phases":9261,"primaryCompletion":9262,"completion":9262,"start":9263,"enrollment":9264,"conditions":9265,"interventions":9266},"NCT03464097","A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease",[91],"2024-10-03","2018-06-27",550,[3853],[3410],{"nctId":4410,"briefTitle":4411,"status":106,"phases":9268,"primaryCompletion":4413,"completion":4413,"start":4414,"enrollment":4415,"conditions":9269,"interventions":9270},[91],[3930],[3410,4292],{"nctId":9272,"briefTitle":9273,"status":171,"phases":9274,"primaryCompletion":9275,"completion":9275,"start":9276,"enrollment":9277,"conditions":9278,"interventions":9279},"NCT03440372","Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease",[91],"2024-10-01","2018-02-27",625,[3853],[3410],{"nctId":9281,"briefTitle":9282,"status":106,"phases":9283,"primaryCompletion":9284,"completion":9284,"start":9285,"enrollment":9286,"conditions":9287,"interventions":9288},"NCT03915769","To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis",[91],"2025-09-30","2019-06-03",198,[3874],[3410],{"nctId":9290,"briefTitle":9291,"status":106,"phases":9292,"primaryCompletion":5103,"completion":5103,"start":9293,"enrollment":9294,"conditions":9295,"interventions":9296},"NCT03440385","Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease",[91],"2018-03-07",606,[3853],[3410],{"nctId":4281,"briefTitle":4282,"status":106,"phases":9298,"primaryCompletion":4284,"completion":4285,"start":4286,"enrollment":4287,"conditions":9299,"interventions":9300},[91],[4289],[3410,4291,4292,4293],{"trials":9302,"activeCount":100},[],{"trials":9304,"activeCount":100},[9305],{"nctId":9306,"briefTitle":9307,"status":106,"phases":9308,"primaryCompletion":9309,"completion":9309,"start":9310,"enrollment":9311,"conditions":9312,"interventions":9313},"NCT03665610","Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites",[],"2019-01-10","2018-09-10",212,[19],[4267],{"intervention":2487,"totalTrials":1399,"cells":9315},{"EARLY_PHASE1":9316,"PHASE1":9318,"PHASE2":9336,"PHASE3":9403,"PHASE4":9416,"NA":9418},{"trials":9317,"activeCount":100},[],{"trials":9319,"activeCount":100},[9320,9324,9332],{"nctId":3500,"briefTitle":3501,"status":106,"phases":9321,"primaryCompletion":3503,"completion":3503,"start":3504,"enrollment":3505,"conditions":9322,"interventions":9323},[89],[3507,3508,3509,3510,3511,3512,3513,3514],[3516,2701,2487],{"nctId":9325,"briefTitle":9326,"status":106,"phases":9327,"start":9328,"enrollment":623,"conditions":9329,"interventions":9331},"NCT00046423","A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies",[89],"2000-04",[32,9330],"Metastases, Neoplasm",[2487],{"nctId":3531,"briefTitle":3532,"status":171,"phases":9333,"primaryCompletion":1921,"completion":1921,"start":2741,"enrollment":963,"conditions":9334,"interventions":9335},[89],[3510,3511,3509],[2487,2701],{"trials":9337,"activeCount":100},[9338,9347,9353,9360,9364,9371,9378,9382,9391,9395,9399],{"nctId":9339,"briefTitle":9340,"status":106,"phases":9341,"primaryCompletion":9342,"completion":9343,"start":9344,"enrollment":3872,"conditions":9345,"interventions":9346},"NCT02103062","Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer",[90],"2014-11-10","2015-01-09","2014-05-05",[6093],[2487],{"nctId":9348,"briefTitle":9349,"status":106,"phases":9350,"completion":1060,"start":3713,"enrollment":3099,"conditions":9351,"interventions":9352},"NCT00073723","Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer",[89,90],[3606],[2487],{"nctId":9354,"briefTitle":9355,"status":171,"phases":9356,"primaryCompletion":3590,"completion":3590,"start":506,"enrollment":805,"conditions":9357,"interventions":9359},"NCT00249002","Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis",[90],[9358],"Hemodialysis Graft Dysfunction",[2487],{"nctId":2479,"briefTitle":2480,"status":106,"phases":9361,"primaryCompletion":1412,"completion":2482,"start":506,"enrollment":2483,"conditions":9362,"interventions":9363},[90],[2485],[2487,1084],{"nctId":9365,"briefTitle":9366,"status":106,"phases":9367,"primaryCompletion":1285,"start":9368,"enrollment":3099,"conditions":9369,"interventions":9370},"NCT00093119","Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma",[90],"2003-07",[3744,2363],[2487],{"nctId":9372,"briefTitle":9373,"status":106,"phases":9374,"start":9375,"enrollment":3407,"conditions":9376,"interventions":9377},"NCT00046514","ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer",[90],"2001-06",[2696,9330],[2487],{"nctId":5649,"briefTitle":5650,"status":106,"phases":9379,"primaryCompletion":3662,"completion":1921,"start":1186,"enrollment":5652,"conditions":9380,"interventions":9381},[90],[2773],[5655,2487,5656,5657,5658],{"nctId":9383,"briefTitle":9384,"status":171,"phases":9385,"primaryCompletion":9386,"completion":9387,"start":1921,"enrollment":9388,"conditions":9389,"interventions":9390},"NCT00456846","First Line Therapy for Patients With Metastatic Breast Cancer",[90],"2012-12-11","2013-05-31",123,[2485],[2487],{"nctId":5660,"briefTitle":5661,"status":106,"phases":9392,"primaryCompletion":1295,"completion":5663,"start":5664,"enrollment":12,"conditions":9393,"interventions":9394},[90],[2485],[2487,5657],{"nctId":5668,"briefTitle":5669,"status":171,"phases":9396,"primaryCompletion":1206,"completion":1555,"start":469,"enrollment":5671,"conditions":9397,"interventions":9398},[90],[2696,3745],[2487,4363],{"nctId":6755,"briefTitle":6756,"status":171,"phases":9400,"primaryCompletion":6758,"completion":6758,"start":1304,"enrollment":25,"conditions":9401,"interventions":9402},[89,90],[6760],[2487,6746,6762,6763],{"trials":9404,"activeCount":100},[9405,9412],{"nctId":9406,"briefTitle":9407,"status":106,"phases":9408,"start":9375,"enrollment":9409,"conditions":9410,"interventions":9411},"NCT00046527","Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer",[91],460,[2696,9330],[2487],{"nctId":4807,"briefTitle":4808,"status":106,"phases":9413,"primaryCompletion":4810,"completion":4811,"start":4812,"enrollment":4813,"conditions":9414,"interventions":9415},[91],[3635],[2487,4796],{"trials":9417,"activeCount":100},[],{"trials":9419,"activeCount":100},[9420],{"nctId":9421,"briefTitle":9422,"status":106,"phases":9423,"primaryCompletion":9424,"completion":9424,"start":9425,"enrollment":684,"conditions":9426,"interventions":9427},"NCT02021500","A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.",[],"2015-04-16","2014-01-02",[2343],[2487],{"intervention":2715,"totalTrials":35,"cells":9429},{"EARLY_PHASE1":9430,"PHASE1":9432,"PHASE2":9446,"PHASE3":9488,"PHASE4":9498,"NA":9504},{"trials":9431,"activeCount":100},[],{"trials":9433,"activeCount":100},[9434,9438,9442],{"nctId":4354,"briefTitle":4355,"status":106,"phases":9435,"primaryCompletion":4357,"completion":4357,"start":4358,"enrollment":30,"conditions":9436,"interventions":9437},[89],[4360],[4362,2715,4363,4364,4347],{"nctId":2690,"briefTitle":2691,"status":106,"phases":9439,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":277,"conditions":9440,"interventions":9441},[89],[2696,2697],[2699,2700,431,2701],{"nctId":2707,"briefTitle":2708,"status":171,"phases":9443,"primaryCompletion":2710,"completion":2710,"start":2711,"enrollment":146,"conditions":9444,"interventions":9445},[89],[2697,2713],[2715,431],{"trials":9447,"activeCount":100},[9448,9452,9456,9484],{"nctId":2719,"briefTitle":2720,"status":106,"phases":9449,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":2725,"conditions":9450,"interventions":9451},[90],[2697],[2715,431],{"nctId":3547,"briefTitle":3548,"status":106,"phases":9453,"primaryCompletion":3550,"completion":3550,"start":3551,"enrollment":684,"conditions":9454,"interventions":9455},[90],[3512],[2699,2701],{"nctId":9457,"briefTitle":9458,"status":106,"phases":9459,"primaryCompletion":9460,"completion":2149,"start":9461,"enrollment":2753,"conditions":9462,"interventions":9483},"NCT01962103","Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent\u002F Refractory Solid Tumors",[89,90],"2017-12-05","2013-12-04",[9463,9464,9465,9466,9467,9468,9469,9470,3744,3635,9471,9472,9473,9474,9475,9476,9477,2377,9478,9479,9480,9481,9482],"Neuroblastoma","Rhabdomyosarcoma","Ewing's Sarcoma","Ewing's Tumor","Sarcoma, Ewing's","Sarcomas, Epitheliod","Sarcoma, Soft Tissue","Sarcoma, Spindle Cell","Clinical Oncology","Oncology, Medical","Pediatrics, Osteosarcoma","Osteogenic Sarcoma","Osteosarcoma Tumor","Sarcoma, Osteogenic","Tumors","Neoplasia","Neoplasm","Histiocytoma","Fibrosarcoma","Dermatofibrosarcoma",[2715,2715],{"nctId":2747,"briefTitle":2748,"status":106,"phases":9485,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":9486,"interventions":9487},[90],[2697],[2699,431,2756,2757],{"trials":9489,"activeCount":100},[9490,9494],{"nctId":2765,"briefTitle":2766,"status":106,"phases":9491,"primaryCompletion":2768,"completion":2768,"start":2769,"enrollment":2770,"conditions":9492,"interventions":9493},[90,91],[2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2485],[2699,2701,431],{"nctId":2802,"briefTitle":2803,"status":106,"phases":9495,"primaryCompletion":2805,"completion":2805,"start":2806,"enrollment":2807,"conditions":9496,"interventions":9497},[91],[2697,2809,2810,32,2811,2812,2813,2814,431,2815],[2699,431],{"trials":9499,"activeCount":100},[9500],{"nctId":3599,"briefTitle":3600,"status":106,"phases":9501,"primaryCompletion":3602,"completion":3602,"start":3603,"enrollment":3604,"conditions":9502,"interventions":9503},[92],[3606,3607,3608,3609,3610,3611],[2715,2701],{"trials":9505,"activeCount":100},[9506],{"nctId":9507,"briefTitle":9508,"status":106,"phases":9509,"primaryCompletion":9510,"completion":9511,"start":9512,"enrollment":9513,"conditions":9514,"interventions":9515},"NCT02555696","Abraxane in Treatment of Metastatic Breast Cancer",[],"2016-02-28","2016-12-31","2012-05-31",203,[2485],[2715],{"intervention":3516,"totalTrials":2311,"cells":9517},{"EARLY_PHASE1":9518,"PHASE1":9520,"PHASE2":9534,"PHASE3":9575,"PHASE4":9577,"NA":9579},{"trials":9519,"activeCount":100},[],{"trials":9521,"activeCount":100},[9522,9526,9530],{"nctId":3500,"briefTitle":3501,"status":106,"phases":9523,"primaryCompletion":3503,"completion":3503,"start":3504,"enrollment":3505,"conditions":9524,"interventions":9525},[89],[3507,3508,3509,3510,3511,3512,3513,3514],[3516,2701,2487],{"nctId":8404,"briefTitle":8405,"status":106,"phases":9527,"primaryCompletion":8407,"completion":8408,"start":8409,"enrollment":8410,"conditions":9528,"interventions":9529},[89],[8412,1557,8413,660,16,1269,8414,22,32,3744,2773,2485,3606,4149,1297,5717,8415,8416,8417,8418],[3516,8397],{"nctId":7012,"briefTitle":7013,"status":106,"phases":9531,"primaryCompletion":7015,"completion":7015,"start":7016,"enrollment":963,"conditions":9532,"interventions":9533},[89],[27],[3516,2052],{"trials":9535,"activeCount":100},[9536,9545,9549,9553,9562,9566],{"nctId":9537,"briefTitle":9538,"status":106,"phases":9539,"primaryCompletion":9540,"completion":9540,"start":9541,"enrollment":379,"conditions":9542,"interventions":9544},"NCT02269943","Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma",[90],"2017-04-20","2015-02-13",[9543],"Nasopharyngeal Neoplasms",[3516],{"nctId":6288,"briefTitle":6289,"status":106,"phases":9546,"primaryCompletion":6291,"completion":6292,"start":6293,"enrollment":6294,"conditions":9547,"interventions":9548},[90],[3512],[6279,3516,6297],{"nctId":6332,"briefTitle":6333,"status":171,"phases":9550,"primaryCompletion":6335,"completion":2750,"start":6336,"enrollment":17,"conditions":9551,"interventions":9552},[90],[2696],[3516,6323],{"nctId":9554,"briefTitle":9555,"status":106,"phases":9556,"primaryCompletion":8090,"completion":8090,"start":9557,"enrollment":3034,"conditions":9558,"interventions":9561},"NCT02494258","A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders",[90],"2015-10-22",[9559,32,9560],"Hematologic Neoplasm","Hematologic Malignancies",[3516],{"nctId":6892,"briefTitle":6893,"status":106,"phases":9563,"primaryCompletion":4285,"completion":6895,"start":3947,"enrollment":3407,"conditions":9564,"interventions":9565},[90],[3512],[3516,6883],{"nctId":9567,"briefTitle":9568,"status":106,"phases":9569,"primaryCompletion":9570,"completion":9571,"start":9572,"enrollment":1224,"conditions":9573,"interventions":9574},"NCT01835587","Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).",[89,90],"2016-11-13","2017-05-26","2013-10-25",[27,22],[3516],{"trials":9576,"activeCount":100},[],{"trials":9578,"activeCount":100},[],{"trials":9580,"activeCount":100},[9581],{"nctId":9582,"briefTitle":9583,"status":2028,"phases":9584,"conditions":9585,"interventions":9586},"NCT03723135","Expanded Access for CC-486",[],[3799],[3516],{"intervention":473,"totalTrials":3034,"cells":9588},{"EARLY_PHASE1":9589,"PHASE1":9591,"PHASE2":9593,"PHASE3":9603,"PHASE4":9628,"NA":9630},{"trials":9590,"activeCount":100},[],{"trials":9592,"activeCount":100},[],{"trials":9594,"activeCount":100},[9595],{"nctId":9596,"briefTitle":9597,"status":106,"phases":9598,"enrollment":3099,"conditions":9599,"interventions":9602},"NCT00002127","A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome",[90],[9600,9601],"HIV Infections","HIV Wasting Syndrome",[473],{"trials":9604,"activeCount":100},[9605,9609,9618],{"nctId":464,"briefTitle":465,"status":106,"phases":9606,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":9607,"interventions":9608},[91],[16],[473,241],{"nctId":9610,"briefTitle":9611,"status":106,"phases":9612,"primaryCompletion":9613,"completion":9614,"start":9615,"enrollment":200,"conditions":9616,"interventions":9617},"NCT00657488","Thalidomide 100 mg\u002FDay Versus Thalidomide 400 mg\u002FDay in Relapse Refractory Multiple Myeloma",[90,91],"2005-10-01","2006-04-01","2001-12-01",[16],[473],{"nctId":9619,"briefTitle":9620,"status":106,"phases":9621,"completion":9622,"start":9623,"enrollment":9624,"conditions":9625,"interventions":9626},"NCT00050843","A Study to Access the Safety\u002FEfficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes",[91],"2004-02","2001-08",220,[22],[9627],"thalidomide",{"trials":9629,"activeCount":100},[],{"trials":9631,"activeCount":100},[9632],{"nctId":9633,"briefTitle":9634,"status":106,"phases":9635,"conditions":9636,"interventions":9637},"NCT00002157","Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome",[93],[9600,9601],[473],{"intervention":2829,"totalTrials":306,"cells":9639},{"EARLY_PHASE1":9640,"PHASE1":9642,"PHASE2":9650,"PHASE3":9660,"PHASE4":9666,"NA":9668},{"trials":9641,"activeCount":100},[],{"trials":9643,"activeCount":100},[9644],{"nctId":9645,"briefTitle":9646,"status":106,"phases":9647,"start":3672,"enrollment":1821,"conditions":9648,"interventions":9649},"NCT00107094","Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer",[89],[2773],[2829],{"trials":9651,"activeCount":100},[9652],{"nctId":9653,"briefTitle":9654,"status":423,"phases":9655,"primaryCompletion":9656,"completion":9656,"start":9656,"enrollment":100,"conditions":9657,"interventions":9659},"NCT01933061","Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma",[90],"2014-01",[9658],"Metastatic Melanoma",[2829,2829],{"trials":9661,"activeCount":100},[9662],{"nctId":3570,"briefTitle":3571,"status":106,"phases":9663,"primaryCompletion":3573,"completion":3574,"start":3575,"enrollment":3576,"conditions":9664,"interventions":9665},[91],[3578],[2829,2701,2829,2829,2701],{"trials":9667,"activeCount":100},[],{"trials":9669,"activeCount":100},[9670],{"nctId":2822,"briefTitle":2823,"status":106,"phases":9671,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":1565,"conditions":9672,"interventions":9673},[],[2743],[2829,431],{"intervention":9675,"totalTrials":306,"cells":9676},"Revlimid",{"EARLY_PHASE1":9677,"PHASE1":9679,"PHASE2":9681,"PHASE3":9683,"PHASE4":9685,"NA":9687},{"trials":9678,"activeCount":100},[],{"trials":9680,"activeCount":100},[],{"trials":9682,"activeCount":100},[],{"trials":9684,"activeCount":100},[],{"trials":9686,"activeCount":100},[],{"trials":9688,"activeCount":100},[9689,9698,9706,9715],{"nctId":9690,"briefTitle":9691,"status":106,"phases":9692,"primaryCompletion":9693,"completion":9693,"start":9694,"enrollment":9695,"conditions":9696,"interventions":9697},"NCT03106324","A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant",[],"2026-01-14","2017-03-31",911,[16],[9675],{"nctId":9699,"briefTitle":9700,"status":171,"phases":9701,"primaryCompletion":2841,"completion":2840,"start":9702,"enrollment":9703,"conditions":9704,"interventions":9705},"NCT01947309","Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)",[],"2013-11",176,[16],[9675],{"nctId":9707,"briefTitle":9708,"status":106,"phases":9709,"primaryCompletion":9710,"completion":9710,"start":9711,"enrollment":9712,"conditions":9713,"interventions":9714},"NCT03098589","Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)",[],"2020-09-18","2017-05-30",1149,[660],[9675],{"nctId":9716,"briefTitle":9717,"status":106,"phases":9718,"primaryCompletion":9719,"completion":9720,"start":1586,"enrollment":3407,"conditions":9721,"interventions":9722},"NCT01752075","A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan",[],"2013-07-12","2013-07-19",[16],[9675],{"intervention":9724,"totalTrials":190,"cells":9725},"Marizomib",{"EARLY_PHASE1":9726,"PHASE1":9728,"PHASE2":9734,"PHASE3":9736,"PHASE4":9738,"NA":9740},{"trials":9727,"activeCount":100},[],{"trials":9729,"activeCount":100},[9730],{"nctId":1828,"briefTitle":1829,"status":106,"phases":9731,"primaryCompletion":1831,"completion":607,"start":1832,"enrollment":20,"conditions":9732,"interventions":9733},[89],[1834,1835,16],[579,1837,1838],{"trials":9735,"activeCount":100},[],{"trials":9737,"activeCount":100},[],{"trials":9739,"activeCount":100},[],{"trials":9741,"activeCount":100},[9742],{"nctId":9743,"briefTitle":9744,"status":3340,"phases":9745,"conditions":9746,"interventions":9747},"NCT04644107","Expanded Access for Marizomib",[],[5460],[9724],{"intervention":9749,"totalTrials":190,"cells":9750},"CC-4047",{"EARLY_PHASE1":9751,"PHASE1":9753,"PHASE2":9755,"PHASE3":9764,"PHASE4":9766,"NA":9768},{"trials":9752,"activeCount":100},[],{"trials":9754,"activeCount":100},[],{"trials":9756,"activeCount":100},[9757],{"nctId":9758,"briefTitle":9759,"status":106,"phases":9760,"completion":2733,"start":9761,"enrollment":379,"conditions":9762,"interventions":9763},"NCT00072722","Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)",[90],"2003-09",[1082],[9749],{"trials":9765,"activeCount":100},[],{"trials":9767,"activeCount":100},[],{"trials":9769,"activeCount":100},[9770],{"nctId":9771,"briefTitle":9772,"status":3340,"phases":9773,"conditions":9774,"interventions":9775},"NCT03723096","Expanded Access for CC-4047",[],[16],[9749],{"intervention":9777,"totalTrials":190,"cells":9778},"ACE-011",{"EARLY_PHASE1":9779,"PHASE1":9781,"PHASE2":9783,"PHASE3":9792,"PHASE4":9794,"NA":9796},{"trials":9780,"activeCount":100},[],{"trials":9782,"activeCount":100},[],{"trials":9784,"activeCount":100},[9785],{"nctId":9786,"briefTitle":9787,"status":106,"phases":9788,"primaryCompletion":9789,"completion":9789,"start":822,"enrollment":1821,"conditions":9790,"interventions":9791},"NCT00747123","A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma",[90],"2009-08-01",[16],[9777],{"trials":9793,"activeCount":100},[],{"trials":9795,"activeCount":100},[],{"trials":9797,"activeCount":100},[9798],{"nctId":9799,"briefTitle":9800,"status":3340,"phases":9801,"conditions":9802,"interventions":9803},"NCT03724227","Expanded Access for ACE-011",[],[34],[9777],{"intervention":612,"totalTrials":190,"cells":9805},{"EARLY_PHASE1":9806,"PHASE1":9808,"PHASE2":9810,"PHASE3":9812,"PHASE4":9814,"NA":9816},{"trials":9807,"activeCount":100},[],{"trials":9809,"activeCount":100},[],{"trials":9811,"activeCount":100},[],{"trials":9813,"activeCount":100},[],{"trials":9815,"activeCount":100},[],{"trials":9817,"activeCount":100},[9818,9822],{"nctId":604,"briefTitle":605,"status":106,"phases":9819,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":9820,"interventions":9821},[],[16],[612,241],{"nctId":9823,"briefTitle":9824,"status":106,"phases":9825,"primaryCompletion":9826,"completion":9826,"start":3946,"enrollment":1197,"conditions":9827,"interventions":9828},"NCT04036448","A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory\u002FRelapsed Mantle Cell Lymphoma in Korea",[],"2023-08-15",[22,1317,125],[612],{"intervention":9830,"totalTrials":146,"cells":9831},"CC-2001",{"EARLY_PHASE1":9832,"PHASE1":9834,"PHASE2":9836,"PHASE3":9838,"PHASE4":9840,"NA":9842},{"trials":9833,"activeCount":100},[],{"trials":9835,"activeCount":100},[],{"trials":9837,"activeCount":100},[],{"trials":9839,"activeCount":100},[],{"trials":9841,"activeCount":100},[],{"trials":9843,"activeCount":100},[9844],{"nctId":9845,"briefTitle":9846,"status":3340,"phases":9847,"conditions":9848,"interventions":9851},"NCT03723083","Expanded Access for CC-2001",[],[9849,9850],"Dermatologic","Other",[9830],{"intervention":9853,"totalTrials":146,"cells":9854},"POMALYST®",{"EARLY_PHASE1":9855,"PHASE1":9857,"PHASE2":9859,"PHASE3":9861,"PHASE4":9863,"NA":9865},{"trials":9856,"activeCount":100},[],{"trials":9858,"activeCount":100},[],{"trials":9860,"activeCount":100},[],{"trials":9862,"activeCount":100},[],{"trials":9864,"activeCount":100},[],{"trials":9866,"activeCount":100},[9867],{"nctId":9868,"briefTitle":9869,"status":106,"phases":9870,"primaryCompletion":9871,"completion":9871,"start":9872,"enrollment":9873,"conditions":9874,"interventions":9875},"NCT03288974","Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea",[],"2023-11-16","2017-12-28",397,[16],[9853],{"intervention":9877,"totalTrials":146,"cells":9878},"IMNOVID",{"EARLY_PHASE1":9879,"PHASE1":9881,"PHASE2":9883,"PHASE3":9885,"PHASE4":9887,"NA":9889},{"trials":9880,"activeCount":100},[],{"trials":9882,"activeCount":100},[],{"trials":9884,"activeCount":100},[],{"trials":9886,"activeCount":100},[],{"trials":9888,"activeCount":100},[],{"trials":9890,"activeCount":100},[9891],{"nctId":9892,"briefTitle":9893,"status":106,"phases":9894,"primaryCompletion":9895,"completion":9895,"start":9896,"enrollment":9897,"conditions":9898,"interventions":9899},"NCT02164955","A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.",[],"2022-10-10","2014-06-26",775,[16],[9877],{"intervention":9901,"totalTrials":146,"cells":9902},"Nonconforming idecabtagene vicleucel",{"EARLY_PHASE1":9903,"PHASE1":9905,"PHASE2":9907,"PHASE3":9909,"PHASE4":9911,"NA":9913},{"trials":9904,"activeCount":100},[],{"trials":9906,"activeCount":100},[],{"trials":9908,"activeCount":100},[],{"trials":9910,"activeCount":100},[],{"trials":9912,"activeCount":100},[],{"trials":9914,"activeCount":100},[9915],{"nctId":9916,"briefTitle":9917,"status":9918,"phases":9919,"conditions":9920,"interventions":9921},"NCT04771078","Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release","AVAILABLE",[],[16],[9901],{"intervention":9923,"totalTrials":146,"cells":9924},"Glucocorticoid",{"EARLY_PHASE1":9925,"PHASE1":9927,"PHASE2":9929,"PHASE3":9931,"PHASE4":9933,"NA":9935},{"trials":9926,"activeCount":100},[],{"trials":9928,"activeCount":100},[],{"trials":9930,"activeCount":100},[],{"trials":9932,"activeCount":100},[],{"trials":9934,"activeCount":100},[],{"trials":9936,"activeCount":100},[9937],{"nctId":9938,"briefTitle":9939,"status":106,"phases":9940,"primaryCompletion":9941,"completion":9941,"start":9942,"enrollment":862,"conditions":9943,"interventions":9945},"NCT03324503","A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis",[93],"2019-11-15","2017-12-08",[9944],"Sarcoidosis, Pulmonary",[9923],{"intervention":9947,"totalTrials":146,"cells":9948},"Oral Fedratinib",{"EARLY_PHASE1":9949,"PHASE1":9951,"PHASE2":9953,"PHASE3":9955,"PHASE4":9957,"NA":9959},{"trials":9950,"activeCount":100},[],{"trials":9952,"activeCount":100},[],{"trials":9954,"activeCount":100},[],{"trials":9956,"activeCount":100},[],{"trials":9958,"activeCount":100},[],{"trials":9960,"activeCount":100},[9961],{"nctId":9962,"briefTitle":9963,"status":9918,"phases":9964,"conditions":9965,"interventions":9966},"NCT03723148","Individual Patient Compassionate Use of Fedratinib",[],[1047],[9947],{"intervention":9968,"totalTrials":146,"cells":9969},"Istodax",{"EARLY_PHASE1":9970,"PHASE1":9972,"PHASE2":9974,"PHASE3":9976,"PHASE4":9978,"NA":9980},{"trials":9971,"activeCount":100},[],{"trials":9973,"activeCount":100},[],{"trials":9975,"activeCount":100},[],{"trials":9977,"activeCount":100},[],{"trials":9979,"activeCount":100},[],{"trials":9981,"activeCount":100},[9982],{"nctId":9983,"briefTitle":9984,"status":106,"phases":9985,"primaryCompletion":5449,"completion":5449,"start":9986,"enrollment":547,"conditions":9987,"interventions":9989},"NCT03742921","ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma",[],"2019-02-04",[9988],"Lymphoma, T-Cell, Peripheral",[9968],{"intervention":9991,"totalTrials":146,"cells":9992},"Safety and efficacy assessments",{"EARLY_PHASE1":9993,"PHASE1":9995,"PHASE2":9997,"PHASE3":9999,"PHASE4":10001,"NA":10003},{"trials":9994,"activeCount":100},[],{"trials":9996,"activeCount":100},[],{"trials":9998,"activeCount":100},[],{"trials":10000,"activeCount":100},[],{"trials":10002,"activeCount":100},[],{"trials":10004,"activeCount":100},[10005],{"nctId":10006,"briefTitle":10007,"status":106,"phases":10008,"primaryCompletion":10009,"completion":10009,"start":10010,"enrollment":12,"conditions":10011,"interventions":10012},"NCT02786511","Longterm Follow-up of Subjects Treated With bb2121",[],"2019-10-11","2016-04-28",[16],[9991],{"intervention":10014,"totalTrials":146,"cells":10015},"Vidaza®",{"EARLY_PHASE1":10016,"PHASE1":10018,"PHASE2":10020,"PHASE3":10022,"PHASE4":10024,"NA":10026},{"trials":10017,"activeCount":100},[],{"trials":10019,"activeCount":100},[],{"trials":10021,"activeCount":100},[],{"trials":10023,"activeCount":100},[],{"trials":10025,"activeCount":100},[],{"trials":10027,"activeCount":100},[10028],{"nctId":10029,"briefTitle":10030,"status":106,"phases":10031,"primaryCompletion":10032,"completion":10032,"start":10033,"enrollment":10034,"conditions":10035,"interventions":10036},"NCT02137629","Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea",[],"2016-05-19","2010-12-27",511,[34],[10014],{"intervention":10038,"totalTrials":146,"cells":10039},"Second-line Multiple Myeloma treatments",{"EARLY_PHASE1":10040,"PHASE1":10042,"PHASE2":10044,"PHASE3":10046,"PHASE4":10048,"NA":10050},{"trials":10041,"activeCount":100},[],{"trials":10043,"activeCount":100},[],{"trials":10045,"activeCount":100},[],{"trials":10047,"activeCount":100},[],{"trials":10049,"activeCount":100},[],{"trials":10051,"activeCount":100},[10052],{"nctId":10053,"briefTitle":10054,"status":171,"phases":10055,"primaryCompletion":10056,"completion":10056,"start":1295,"enrollment":10057,"conditions":10058,"interventions":10059},"NCT01081028","Connect® MM- The Multiple Myeloma Disease Registry",[],"2024-12-31",3011,[16],[10038]]